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iABSTRACT
The omega-3 polyunsaturated fatty acids (n-3 PUFAs) are a unique class of fatty
acids that cannot be manufactured by the body, and must be acquired via dietary
sources. In the UK, as well as in other Western nations, these ‘essential’ fatty acids
are consumed in quantities that fall below government guidelines. This thesis
examined the relationship between n-3 PUFAs and cognitive function and mood in
healthy children (8-10 years) and adults (18-35 years), with a view to evaluate their
efficacy for cognitive and mood enhancement in these populations. A second aim
was to evaluate the effects of n-3 PUFAs on cerebral hemodynamics, a novel line of
enquiry.
Chapters 2 and 4 describe novel intervention studies that assessed the effects of n-
3 PUFA supplements on cognitive function and mood in healthy children and adults,
respectively. In Chapter 3, the relationship between peripheral PUFA
concentrations, a correlate of dietary PUFA intake, and cognitive and function and
mood was examined for the first time in healthy adults. Chapter 5 describes a pilot
trial in which Near Infrared Spectroscopy (NIRS) imaging technique was applied to
investigate the cerebral hemodynamic effects of n-3 PUFA supplements. The
results of this study were explored in more detail in Chapter 6, with the additional
inclusion of parallel cognitive measures.
Most notably, the behavioural data from the intervention studies described herein do
not support the use of n-3 PUFA supplements for cognitive and mood enhancement
in healthy children and adults not consuming appreciable amounts of oily fish.
However, the results do suggest that supplementation with dietary n-3 PUFAs has
an impact on peripheral fatty acid status and cerebral hemodynamics in healthy
adults. Taken together, these findings suggest that, in healthy, cognitively intact
individuals, short-term use of n-3 PUFA supplements has a minimal effect on
behaviour; the impact of long-term n-3 PUFA dietary intake or supplement use over
the course of the entire lifespan on behaviour should be addressed further.
ii
List of Contents
Abstract i
List of Tables and Figures vi
Acknowledgements viii
Author’s Declaration ix
CHAPTER 1. INTRODUCTION 1
1.1 Background 1
1.2 Essential fatty acid nomenclature, structure and metabolism 2
1.3 Dietary sources, consumption and cellular incorporation of n-3 PUFAs 3
1.4 The functions of n-3 PUFAs 4
1.4.1 Incorporation of DHA maintains neuronal cell membrane fluidity and function 5
1.4.2 DHA and EPA as precursors of secondary signalling molecules 6
1.4.3 N-3 PUFAs modulate gene expression 8
1.4.4 N-3 PUFAs modulate neurotransmission 8
1.4.5 N-3 PUFAs are neuroprotective 9
1.4.6 The cardiovascular effects of n-3 PUFAs 10
1.4.7 Summary of the functions of n-3 PUFAs 11
1.5 The behavioural effects of n-3 PUFAs 12
1.5.1 Animal evidence 12
1.5.2 Human evidence 14
1.5.2.1 The role of n-3 PUFAs in neuropsychiatric conditions 15
1.5.2.2 The role of n-3 PUFAs in neurodevelopmental disorders 25
1.5.2.3 N-3 PUFA supplementation and behaviour in healthy individuals 27
1.5.3 Summary of the behavioural effects of n-3 PUFAs 32
1.6 Rationale 33
CHAPTER 2. COGNITIVE AND MOOD EFFECTS OF 8 WEEKS’
SUPPLEMENTATION WITH 400 MG OR 1000 MG DHA IN HEALTHY CHILDREN
AGED 10-12 YEARS
35
2.1 Introduction 35
2.2 Materials and Methods 38
2.2.1 Design 38
2.2.2 Participants 38
2.2.3 Treatments 39
2.2.4 Cognitive and Mood Measures 40
2.2.4.1 Cognitive Drug Research (CDR) Battery 40
2.2.4.2 Internet Battery 42
2.2.4 Procedure 45
2.2.4.1 Primary assessment 45
2.2.4.2 Secondary assessment 46
2.2.4.3 Statistical methods 46
2.3 Results 48
iii
2.3.1 CDR battery 48
2.3.2 Internet Battery 48
2.4 Discussion 53
CHAPTER 3. THE RELATIONSHIP BETWEEN SERUM PUFAs AND COGNITIVE
FUNCTION AND MOOD IN HEALTHY ADULTS (18-35 YEARS)
57
3.1 Introduction 57
3.2 Materials and Methods 60
3.2.1 Design 60
3.2.2 Participants 60
3.2.3 Assessment of cognitive performance 61
3.2.3.1 COMPASS 61
3.2.3.2 Cognitive Demand Battery (CDB) 64
3.2.4 Assessment of mood 65
3.2.5 Procedure 65
3.2.5.1 Blood samples 66
3.2.5.1 Statistical methods 67
3.3 Results 69
3.3.1 Participant characteristics 69
3.3.2. Regression analyses 69
3.4 Discussion 73
CHAPTER 4. COGNITIVE AND MOOD EFFECTS OF DHA-RICH FISH OIL AND
EPA-RICH FISH OIL IN HEALTHY ADULTS (18-35 YEARS)
78
4.1 Introduction 78
4.2 Materials and Methods 82
4.2.1 Design 82
4.2.2 Participants 82
4.2.3 Treatments 83
4.2.4 Assessment of cognitive performance and mood 83
4.2.5 Procedure 84
4.2.5.1 Blood samples 85
4.2.5.2 Statistical methods 85
4.3 Results 88
4.3.1 Physiological data and compliance 88
4.3.2 Cognitive performance battery (COMPASS) 89
4.3.3 Cognitive Demand Battery (CDB) 93
4.3.4 Mood 93
4.4 Discussion 94
CHAPTER 5. CEREBRAL HEMODYNAMIC EFFECTS OF DHA-RICH FISH OIL
AND EPA-RICH FISH OIL IN HEALTHY YOUNG ADULTS
100
5.1 Introduction 100
5.2 Materials and Methods 104
5.2.1 Design 104
5.2.2 Participants 104
5.2.3 Treatments 104
iv
5.2.4 Physiological Measures 105
5.2.5 Cognitive Tasks 107
5.2.6 Procedure 108
5.2.6.1 Statistical methods 109
5.3 Results 110
5.3.1 NIRS 110
5.3.1.1 Oxyhaemoglobin (O2Hb) 110
5.3.1.2 Deoxyhaemoglobin (HHb) 110
5.3.1.3 Total haemoglobin (THb) 110
5.3.1.2 Cognitive Performance 111
5.4 Discussion 112
CHAPTER 6. THE COGNITIVE AND CEREBRAL HEMODYNAMIC EFFECTS OF
DHA-RICH FISH OIL: A DOSE-RANGING STUDY
114
6.1 Introduction 114
6.2 Materials and Methods 117
6.2.1 Design 117
6.2.2 Participants 117
6.2.3 Treatments 118
6.2.4 Near Infrared Spectroscopy 118
6.2.5 Cognitive Assessment 118
6.2.6 Procedure 121
6.2.6.1 Statistical methods 122
6.3 Results 123
6.3.1 Compliance 123
6.3.2 NIRS 123
6.3.2.1 Oxyhaemoglobin (O2Hb) 123
6.3.2.2 Deoxyhaemoglobin (HHb) 123
6.3.2.3 Total haemoglobin (THb) 124
6.3.3 Cognitive Performance 124
6.4 Discussion 128
CHAPTER 7. DISCUSSION 134
7.1 Summary of the objectives of the thesis 134
7.2 The relationship between dietary n-3 PUFAs and cognitive function and mood 135
7.2.1 Children 135
7.2.2 Adults (18-35 years) 137
7.2.2.1 Cognitive function 137
7.2.2.2 Mood 141
7.3 Cerebral hemodynamics 144
7.4 Dietary advice on n-3 PUFA intake 147
7.5 Limitations 149
7.6 Future research 152
7.7 General conclusions 154
vAPPENDICES 157
APPENDIX I:Depression, Anxiety and Stress Scales 157
APPENDIX II: Health and diet questionnaire utilised in Chapter 3 159
APPENDIX III: All analysed associations between serum n-3 PUFAs and behavioural
outcomes
161
APPENDIX IV: Health and diet questionnaire utilised in Chapter 4 166
APPENDIX V: Family background questionnaire 168
APPENDIX VI: Average scores by group on the cognitive tasks employed in Chapter 5 170
APPENDIX VII: Resting baseline NIRS data collected in Chapter 6 171
APPENDIX VIII: List of journal publications resulting from research conducted as part
of this thesis
172
REFERENCES 173
vi
List of Tables and Figures
CHAPTER 1
Figure 1.1 Metabolic pathways of n-3 and n-6 PUFAs. 3
CHAPTER 2
Table 2.1 Participant demographic details. 38
Figure 2.1 Study day running order of assessments. 46
Table 2.2 Mean data from CDR battery performance outcomes. 49
Table 2.3 Mean data from Internet Battery performance outcomes. 51
Table 2.4 Mean data from Internet Battery mood questionnaire items. 52
CHAPTER 3
Figure 3.1 Assessment schedule of all tasks and measures. 66
Table 3.1 Participant demographic information and serum fatty acid
concentrations.
69
Table 3.2 Mean data from cognitive performance and mood outcomes and
significant associations between serum concentrations of PUFAs and
outcomes.
71
CHAPTER 4
Table 4.1 Participant demographic information and baseline characteristics. 83
Figure 4.1 Baseline and Week 12 assessment schedule. 85
Table 4.2 Mean data from physiological measures at Baseline and Week 12. 88
Table 4.3 Mean data from COMPASS task performance and mood outcomes
at Baseline and Week 12.
91
Table 4.4 Mean data from the Cognitive Demand Battery outcome measures at
Baseline and Week 12.
93
CHAPTER 5
Figure 5.1 Photon path between NIRS emitter and detector pair. 106
Figure 5.2 Optode placement of the 2-channel NIRS headband (a) and NIRS
device (b).
106
Figure 5.3 Mean concentration changes of oxygenated and total haemoglobin
by treatment group during the cognitive tasks.
111
Table 5.2 Mean concentration changes of oxyhaemoglobin, deoxyhaemoglobin
and total haemoglobin.
111
CHAPTER 6
Table 6.1 Participant demographic details. 118
Table 6.2 Mean concentration changes of oxyhaemoglobin, deoxyhaemoglobin
and total haemoglobin.
126
Figure 6.1 Mean concentration changes of oxygenated and total haemoglobin. 127
Table 6.3 Mean data from cognitive task performance by treatment group. 128
vii
APPENDICES
Table III.1 Associations between serum DHA and COMPASS, mood and CDB
outcome measures.
163
Table III.2. Associations between serum EPA and COMPASS, mood and CDB
outcome measures.
164
Table III.3. Associations between serum Total n-3 PUFAs (ALA+DHA+EPA) and
COMPASS, mood and CDB outcome measures.
165
Table III.4. Associations between serum AA and COMPASS, mood and CDB
outcome measures.
166
Table III.5. Associations between serum AA:EPA and COMPASS, mood and
CDB outcome measures.
167
viii
Acknowledgements
It is a great pleasure to thank those who contributed to the writing of this thesis.
First and foremost, I would like to offer my sincerest gratitude go to my supervisors
Professor David Kennedy, Dr Jonathon Reay and Professor Andrew Scholey. Your
guidance and support have been unparalleled and it has been both a privilege and a
pleasure working with you. Thank you for imparting your knowledge and for inspiring
my research career.
I am indebted to Ginsana SA. Without their sponsorship and provision of the fish oil
capsules used in Chapters 4, 5, and 6 this thesis would not have been possible. I
am also grateful of the funding and capsules supplied by Martek Biosciences for the
study described in Chapter 2.
A special thank you to Michael Deary for all your hard work conducting the fatty acid
analyses. Thank you also to Anthea Wilde, Ruth Steinberg, Jade Elliott and Joanne
Forster for their technical assistance in collecting the blood samples for Chapters 3
and 4.
Thank you also to Jade, Bernadette Robertson, and Crystal Haskell who helped in
the data collection for Chapter 2. Additionally I would like to thank Brian Tiplady and
Tom Buchanan for their assistance creating the Internet Battery and CDR for
providing their battery for use in this study.
I have been blessed with exceptionally supportive colleagues; thank you to
everyone in the BPRNC for your friendship, practical help and good times. A big
thank you to Crystal and Jade especially for all your advice over the years and
above all for being true friends.
I thank my family for instilling in me the value of good education and supporting all
my studies thus far.
My heartfelt thanks go to Andi for your patience, understanding and encouragement
that have kept me focused and motivated to the end.
ix
Author’s Declaration
I declare that:
This work has not been submitted for any other award.
The author and the supervisors worked together on the designing the methodology
for each experimental chapter. For these chapters, the data collection, analysis and
interpretation was the sole work of the author, except where acknowledged.
The writing of this thesis is the sole work of the author.
Name: Philippa Alice Jackson
Signature:
Date:
1CHAPTER 1. INTRODUCTION
1.1 Background
A dietary supplement is a preparation of concentrated nutrients or metabolites such
as vitamins, minerals and amino acids that is intended to supplement the diet, often
when the nutrient is missing in the diet or is not consumed at sufficient levels.
Health benefits such as boosting the immune system or athletic performance and
reducing the risk of developing chronic age-related disease are also often listed as
motivations for dietary supplementation (Webb, 2006). Further to this, there is
increasing interest in optimising brain function with dietary supplements in light of
emerging evidence that suggests particular nutrients can influence brain
architecture, chemistry and function (Fernstrom, 2000). It is not surprising then that
the worldwide market for dietary supplements is forecast to reach $187 billion in
2010 and in the UK the industry was valued at approximately $827 million in 2006,
with projected growth at a further 1% each year until 2011 (Themedica, 2009).
Amongst the dietary supplements that have received increasing interest in recent
years are the omega-3 polyunsaturated fatty acids (n-3 PUFAs). These fatty acids
are naturally enriched in fatty fish such as salmon, mackerel and sardines; the sale
of supplements containing n-3 PUFAs represents 20% of the nutritional
supplements market share in the UK, second only to multivitamins (Themedica,
2009). A variety of products containing n-3 PUFAs are available, with labels
purporting to maintain healthy joints and muscles, cardiovascular health or brain
development and function. The marketing of these products is unambiguous,
particularly those aimed at supporting brain function (e.g. Eye q mind, Healthspan
Brain Boosters, Boots Smart Omega-3 Fish Oil, Vitabiotics Neurozan); however
there is very little in the way of human research to indicate what the effects of n-3
PUFA supplements on brain function and behaviour in the general healthy
population actually are.
This introduction outlines the many functions of n-3 PUFAs in the body and the
impact they may have on brain function and behaviour. The second part of this
chapter evaluates the effects of n-3 PUFAs on behaviour by examining the extant
2literature in animals and humans. These sections follow a brief overview of the basic
structure and metabolism of fatty acids.
1.2 Essential fatty acid nomenclature, structure and metabolism
Humans typically consume about 20 different types of fatty acids in the diet. These
can be metabolised for energy, stored in fat deposits or incorporated into cell
membrane phospholipids (Surette, 2008). Fatty acids are hydrocarbon chains
containing an even number of carbon atoms anywhere in the range of 2-30. The
hydrocarbon chain is flanked by a methyl group (CH3) at one end (the omega end)
and a carboxyl group (COOH) at the other. Fatty acids can be grouped into either
saturated or unsaturated fatty acids. Saturated fatty acids have single bonds
between the carbon atoms and are rigid in nature. Unsaturated fatty acids may have
one (monounsaturated) or more (polyunsaturated) double bonds and the position of
the first double bond in relation to the omega end determines whether a
polyunsaturated fatty acid is termed an omega-3 (n-3) or an omega-6 (n-6) fatty
acid. Mammals are capable of manufacturing every fatty acid required for biological
processes except for two; namely linoleic acid (LA, n-6) and α-linolenic acid (ALA, n-
3). These are termed the ‘essential’ fatty acids and must be acquired via the diet
(Simopoulos, 2000).
LA and ALA are sometimes referred to as ‘parent’ fatty acids as it is from these that
their respective long-chain biologically active metabolites are derived. Arachidonic
acid (AA, n-6) is the major metabolite of LA whereas eicosapentaenoic acid (EPA,
n-3) and docosahexaenoic acid (DHA, n-3) are the more biologically active
metabolites of ALA (Figure 1.1). AA, EPA and DHA are synthesised from their
respective precursor parent fatty acids by a series of elongations and desaturations
that, despite the fact that the conversion pathways for n-6 and n-3 fatty acids are
entirely independent, require the same enzymes at each step. There is also some
evidence to suggest that DHA can be ‘retro-converted’ into EPA, though rates of
only 20% have been observed (Gronn et al., 1991). The metabolism of LA and ALA
is predominantly carried out in the endoplasmic reticulum of the liver, in certain
structures in the central nervous system such as glial cells (Moore, 2001) and the
choroid plexus vasculature (Bourre et al., 1997), and has also been observed at low
rates in the placenta (Haggarty, 2004).
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4The consumption of n-3 PUFAs has been falling gradually over the past 100-150
years; the typical ‘Western’ diet of today is characterised by a marked decrease in
overall fish consumption and increased intake of n-6 PUFAs that are abundant in
cooking oils and processed foods (Simopoulos, 2008). There is evidence to suggest
that humans evolved on a diet where n-6 and n-3 PUFAs were consumed in
approximately equal amounts (1 to 4:1) (Simopoulos, 1991), whereas the
consumption ratio of n-6 and n-3 PUFAs in the current Western diet is estimated
anywhere between 10: to as much as 25:1 (Simopoulos, 2000). There is also
mounting evidence to suggest that decreased dietary intake of n-3 PUFAs, DHA
and EPA in particular, is a risk factor for a plethora of different diseases including
cardiovascular disease (Mori and Woodman, 2006), inflammatory disease (De
Caterina and Basta, 2001) and many neurodevelopmental and psychiatric
conditions such as attention deficit hyperactivity disorder (ADHD), dyslexia,
depression, schizophrenia and dementia (Bourre, 2005). It follows that for these two
n-3 PUFAs to be implicated in such a range of seemingly unrelated conditions, they
are likely to influence fundamental processes common to most cells.
Indeed, once consumed (or metabolised) DHA and EPA are incorporated at the sn-
2 position of cellular membrane phospholipids in every type of tissue, where they
compete for incorporation at the same position with AA (Calder, 2006a). Under
certain conditions, DHA and EPA (and AA) are released from the cell membrane by
the action of several phospholipases (Farooqui et al., 1997), where they are
metabolised further to form potent secondary signalling molecules classed as either
eicosanoids or docosanoids (Figure 1.1) (Tassoni et al., 2008). The dietary intake of
n-3 PUFAs is therefore reflected in the composition of all cell membranes which can
impact a number of cellular processes, described below.
1.4 The functions of n-3 PUFAs
N-3 PUFAs are incorporated into the membranes of every single cell in the body.
Since they cannot be manufactured de novo and the body relies on an external
supply provided by dietary sources, it follows that the quantity and type of fatty acids
consumed will impact the composition of cellular membranes and in turn influence
membrane function (Yehuda et al., 1999). It is this concept that is at the very heart
of understanding the different mechanisms by which n-3 PUFAs are believed to
5impact brain function and hence behaviour. Although the exact biochemistry of
these processes is still under investigation, key functions include maintaining
membrane fluidity and the regulation of eicosanoid production, gene expression and
neurotransmission. N-3 PUFAs have also been shown to modulate cardiovascular
function. Given that the brain relies on a constant supply of blood borne metabolic
substrates, modulation of cardiovascular parameters by n-3 PUFAs may potentially
have secondary effects on brain function and are therefore also briefly described.
1.4.1 Incorporation of DHA maintains neuronal cell membrane fluidity and
function
Communication between neurons relies on the exchange of ions across the cellular
membrane, with maximum efficiency occurring at an ‘optimal’ value where the
physical state of the membrane is neither too rigid or too fluid (Yehuda et al., 1999).
The structure of the cell membrane varies greatly depending on the fatty acids that
make up the hydrophobic ‘tail’ of the phospholipids. For example, rigid saturated
fatty acids allow phospholipids to pack tightly together whereas the insertion of
double bonds along the hydrocarbon chain alters the properties of the fatty acid.
Therefore, as the degree of unsaturation increases the chain becomes more flexible
and starts to ‘kink’. DHA, which has six double bonds and is preferentially
incorporated at the sn-2 position of the phospholipids phosphatidylethanolamine
and phosphatidylserine in particular, can adopt countless looped and helical
conformations and thus tight packing of these DHA-rich phospholipids is prevented
and consequently increases the fluidity of the membrane (Feller et al., 2002). EPA,
possessing five double bonds can also adopt multiple conformations, but the extra
double bond present in DHA renders this fatty acid unique and highly specialised,
as evidenced by its high density in selected tissues (Stillwell and Wassall, 2003).
More specifically, DHA is heavily concentrated in the cerebral frontal cortex of
mammals and comprises anywhere between 10-20% of total fatty acids of the brain
(McNamara and Carlson, 2006) and represents around 30-40% of the PUFAs found
in the retinal rod outer segment (Makrides et al., 1994). Modulation of membrane
fluidity in these tissues occurs with dietary manipulation of n-3 PUFAs (Anderson et
al., 2005, Connor et al., 1990), and has been shown to affect the activities of
membrane bound enzymes and ion channels.
6Although the area of cellular enzyme activity is very broad and is still under intense
research, two key enzymes associated with brain function that are modulated by n-3
PUFAs are protein kinase C (PKC) and Na+,K+-ATPase. PKC describes a family of
enzymes that regulate a number of key processes such as transcription, immune
responses, cell proliferation and others (Mellor and Parker, 1998), and has also
been implicated in learning and memory (Sun and Alkon, 2006). Slater and
colleagues (1995) discovered that PKC activity was inversely related to the degree
of unsaturation of phosphatidylcholine and phosphatidylserine present in the
membrane lipid bilayer, potentially demonstrating how dietary manipulations can
have an effect on signal transduction pathways. A positive relationship has also
been found to exist between the activation of the enzyme Na+,K+-ATPase and the
presence of DHA in the surrounding membrane (Turner et al., 2003). Considering
around 60% of the brain’s energy consumption can be attributed to the action of
Na+,K+-ATPase, this discovery highlights an important link between DHA and
membrane function.
As regards modulation of ion channel function, both DHA and EPA have been
shown to inhibit voltage-activated sodium (Kang and Leaf, 1996) and calcium (Xiao
et al., 1997) currents by binding directly to the channel proteins that control the
passage of these ions. Similarly, these two n-3 PUFAs have been shown to inhibit
voltage-activated potassium currents (Seebungkert and Lynch, 2002). Ion channels
have an integral role in the successful transmission of neuronal information along
the axon as this process is reliant on the passage of electrically charged atoms in
and out of the cell via these channels located within the cell membrane (Yehuda et
al., 1999).
Taken altogether, it is evident that the structure of cellular membranes, which is
modifiable by dietary intake of DHA and EPA, impacts upon cellular processes. In
the case of neuronal cell membranes these changes in cellular function may impact
upon brain function and hence behaviour.
1.4.2 DHA and EPA as precursors of secondary signalling molecules
In contrast to DHA, there is comparatively little EPA in the brain and it is found to
comprise less than 1% of total brain fatty acid composition (de la Presa Owens and
Innis, 1999), although it is incorporated into the membranes o
7EPA is released from membrane phospholipids under a variety of different stimuli
and subsequently undergoes enzymatic degradation to become one of several
possible lipid-derived messaging molecules (Figure 1.1) (McNamara and Carlson,
2006). These so-called eicosanoids (further categorised as leukotrienes,
thromboxanes or prostaglandins) are a class of powerful biological compounds
responsible for mediating many aspects of the inflammatory response (Calder,
2006a). Eicosanoids can also be derived from AA upon its release from the cell
membrane (see Figure 1.1), but are far more potent than those originating from EPA
and tend to be pro-inflammatory (Schmitz and Ecker, 2008). However, increased
intake of dietary EPA leads to increased incorporation of these molecules into the
membrane phospholipids in a dose response manner and at the expense of
membrane incorporation of AA (Calder, 2007). Consequently, there is a shift away
from production of pro-inflammatory, vaso-constricting, and platelet aggregating AA-
derived eicosanoids, and an increase in production of anti-inflammatory EPA-
derived ones (Gibney and Hunter, 1993).
Like eicosanoids, docosanoids are chemical signalling molecules, produced via
controlled oxidative degeneration of DHA within or adjacent to the cell membrane
(Kidd, 2007). Three classes of docosanoids have been identified—docosatrienes,
resolvins and protectins—and have been shown to have neuroprotective qualities.
The novel neuroprotectin D1 (NPD1) has been shown to attenuate apoptosis in the
presence of oxidative stress and provides protection to neuronal cells in animal
models of brain ischemia and neurodegeneration (reviewed in Bazan, 2006). More
specifically, in Alzheimer’s disease rat models NPD1 repressed the expression of
pro-inflammatory β-amyloid activated genes. Moreover, the recently discovered E-
series and D-series resolvins, derived from EPA and DHA respectively, have also
been identified as having anti-inflammatory properties that are not related to altering
lipid mediator profiles (i.e. inhibited production of AA-derived eicosanoids), but by
inhibiting the expression of pro-inflammatory cytokine genes such as nuclear factor
κ B and/or peroxisome proliferator activated receptor (Calder, 2006b). Taken
together, these are the many mechanisms by which DHA and EPA could potentially
prevent the occurrence or ameliorate the symptoms of inflammatory diseases linked
to n-3 PUFA intake including depression (Das, 2007), ADHD (Richardson, 2006),
schizophrenia (Yao and van Kammen, 2004), Alzheimer’s disease (Pratico and
Trojanowski, 2000), atherosclerosis (von Schacky, 2000) rheumatoid arthritis
8(Kremer 2000), inflammatory bowl disease (De Caterina et al., 2000), and possibly
some bronchial diseases such as asthma (Belluzzi et al., 2000).
1.4.3 N-3 PUFAs modulate gene expression
The switching on or off of genes, or control of gene expression, allows the cell to
control the production of proteins (e.g. enzymes, receptors or structural proteins) as
they are required by the cell or throughout the organism (Hawkins, 1991). Diet-
induced changes in gene expression have been demonstrated in animals following
n-3 PUFA supplementation. DNA microarrays in rats fed either a perilla-enriched
(high in ALA) or fish oil-enriched (high in DHA and EPA) chow found that expression
levels of a number of genes involved in synaptic plasticity, signal transduction, ion
channel formation, energy metabolism and regulatory proteins were modulated
compared to controls (Kitajka et al., 2002). In a follow-up experiment it was
demonstrated that the ratio of LA to ALA in the experimental diets can further
influence the expression of certain genes (Barcelo-Coblijn et al., 2003), highlighting
that the ratio of intake of n-6 and n-3 PUFAs can impact cellular function at a very
fundamental level. Based on their findings, these authors suggest that the n-3 fatty
acid induced alterations in expression of neural genes may be the link between
dietary intake and improvements in mental function, though this theory has yet to be
supported. Likewise, it is possible that a breakdown in these processes plays a role
in the aetiology of some neuropsychiatric or developmental conditions.
1.4.4 N-3 PUFAs modulate neurotransmission
Many neurotransmitters, such as serotonin and dopamine, are derived from
precursors that are found in the diet. Although there are no neurotransmitters
directly derived from n-3 PUFAs, variation of dietary intake of these has been shown
to influence production of certain neurotransmitters in the brain. Levels of dopamine
(Zimmer et al., 2000a), serotonin (de la Presa Owens and Innis, 1999) and
acetylcholine (Aid et al., 2003) have been observed to either increase or decrease
following either an n-3 enriched or deficient diet, thus potentially having an effect on
overall brain function. Indeed, altered levels of neurotransmitters have been
implicated in numerous conditions including depression (serotonin - Graeff et al.,
91996), schizophrenia (dopamine - Ohara, 2007), Alzheimer’s disease (acetylcholine
- Bartus, 2000) and ADHD (dopamine - Nieoullon, 2002), to name a few. Not only is
intake of n-3 PUFAs associated with neurotransmitter production, in the frontal
cortex dietary supplementation elevated the binding of dopamine at D2 receptors
(Chalon et al., 2001), and n-3 PUFA deficiency has been shown to alter dopamine
neurotransmission in the nucleus accumbens (Zimmer et al., 2000a). These
alterations of the dopaminergic system have been implicated in the reduced
learning ability of rats. In addition, abnormalities in animal behaviour following an n-
3 deficient diet have also been related to changes in hippocampal acetylcholine (Aid
et al., 2003). Further, as previously mentioned, DHA has been shown to modulate
ion channel function resulting in a shift in the inactivation curve to a more
hyperpolarised potential in the sodium and calcium currents, which could also
impact upon neurotransmission (Vreugdenhil et al., 1996). Taken together, these
studies suggest that a number of different neurotransmission pathways are
susceptible to modification via dietary intake of n-3 PUFAs, which in turn may
impact upon behavioural outcomes.
1.4.5 N-3 PUFAs are neuroprotective
In addition to the neuroprotective properties ascribed to DHA as regards its
docosanoid derivatives, DHA has also been shown to prevent apoptosis and reduce
oxidative stress. Apoptosis, or programmed cell death, is a part of normal, healthy
functioning of all multi-cellular organisms, helping to maintain homeostasis.
Evidence suggests that specific incorporation of DHA in the phospholipid species
phosphatidylserine (PS) in neuronal cell membranes prevents apoptosis.
Application of unesterified DHA promotes PS biosynthesis (Hamilton et al., 2000),
high levels of which in turn stimulate an increase in activity of a number of enzymes
involved in the prevention of this process (Akbar et al., 2005). DHA enrichment of
PS only prevents apoptosis in the presence of adverse conditions in vitro when
cultured cells have been pre-treated with DHA, suggesting that the benefit is only
incurred once DHA is metabolised into PS (Kim et al., 2000). Interestingly, DHA
appears to encourage apoptosis in non-neuronal cells by down-regulating the
expression of antiapoptotic genes and up-regulating several proapapototic ones,
implicating DHA in the slowing of proliferation of cancer cells (Narayanan et al.,
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2001). Overall it is appears that the antiapoptotic effects of DHA-rich PS in neurons
is specific and may be critical for their long-term survival.
Oxidative free radicals are generated under normal physiological conditions but
when these molecules are generated in excess, negative consequences may occur.
Oxidative cell damage has been linked to a number of conditions including
Alzheimer’s disease (Markesbery, 1997), ADHD (Selek et al., 2008), depression
(Das, 2008) and schizophrenia (Ranjekar et al., 2003). Dietary n-3 PUFAs may play
a vital role in oxidative pathology by replacing the lost PUFAs following attack by
oxyradicals. Evidence in support of this possibility comes from studies in humans
that have shown that oxidant stress was decreased following dietary
supplementation with either EPA and DHA or a daily fish meal (Mori et al., 2000).
An increase in the activity of two enzymes responsible for removing oxyradicals—
xanthine oxidase and superoxide dismutase—has also been demonstrated following
an n-3 supplemented diet, providing an alternative explanation (Songur et al., 2004).
Oxidative damage following a traumatic brain injury was also reduced in rats fed n-3
PUFAs prior to the injury and also attenuated reduced learning on the Morris Water
Maze task compared to controls, providing further evidence of the role of n-3 PUFAs
in reducing oxidative stress. One last point to note is that high doses of n-3 PUFAs
might actually be a source of oxidative stress; 5.3 g/d DHA+EPA increased lipid
peroxidation in healthy adult men, even in the presence of vitamin E (Allard et al.,
1997).
1.4.6 The cardiovascular effects of n-3 PUFAs
Over 30 years ago Bang and colleagues (1976) published a seminal paper
attributing the low rate of mortality from ischemic heart disease of the Greenland
Inuit to a diet rich in n-3 PUFAs as a result of their high consumption of fish, seal
and whale, despite the high total fat content of this diet. Since this publication,
further epidemiological studies have found an inverse relationship between fish
consumption and cardiovascular disease (e.g Kromhout et al., 1995, Gillum et al.,
2000, Rissanen et al., 2000), though one systematic review in the area failed to find
any conclusive evidence to suggest reduced risk of cardiovascular events or
mortality following treatment with n-3 PUFAs (Hooper et al., 2006). On the other
hand, a more recent review concluded that fish oil supplementation was associated
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with reduced risk of death from cardiac events but no effect on prevention of
arrhythmias or all cause mortality (Leon et al., 2008). Regardless of the
inconsistencies in the literature regarding the effects of n-3 PUFAs in preventing
cardiovascular disease, there are a number of known beneficial effects of n-3
PUFAs in the cardiovascular system that may contribute to overall cardiovascular
health, and their increased intake is currently recommended by the UK government
(SACN/COT, 2004), the American Heart Association (Lichtenstein et al., 2006) and
international scientific organisations (e.g. ISSFAL, 2004). A number of different
cardiovascular parameters have been shown to be modified by dietary n-3 PUFAs
including increased arrhythmic threshold via modulation of sodium and calcium ion
channels (Kang and Leaf, 1996), decreased platelet aggregation (Mori et al., 1997),
lowered triglycerides (Nestel, 2000), lowered blood pressure (Morris et al., 1993,
Geleijnse et al., 2002) and improved arterial and endothelial function via increased
nitric oxide synthesis (Harris et al., 1997, Armah et al., 2008). Given that
cerebrovascular events are a risk factor for neurodegeneration along with the fact
that the cardiovascular system is responsible for the delivery of nutrients to the
brain, it follows that any compound that modulates cardiovascular parameters could
exert a secondary effect on brain function and behaviour.
1.4.7 Summary of the functions of n-3 PUFAs
DHA and EPA are involved in a number of fundamental functions at the cellular
level. In the brain, DHA is heavily enriched in the cerebral cortex where its
incorporation into the phospholipid bilayer of neural cell membranes confers optimal
membrane fluidity resulting in improved membrane function as regards signal
transduction and neurotransmission. Further, there is evidence to suggest that the
expression of a number of genes and the production of various neurotransmitters is
sensitive to dietary intake of n-3 PUFAs, suggesting a role for n-3 PUFAs in these
processes. In addition, the DHA and EPA incorporated into cell membranes
throughout the body can be subsequently released and metabolised further to
produce potent secondary signalling molecules that are essential in the resolution of
the immune response and may also be neuroprotective. Finally, dietary n-3 PUFAs
modulate a number of cardiovascular parameters, which may contribute to reduced
risk of cardiovascular events. Given the fundamental nature of n-3 PUFAs and DHA
and EPA in particular, it is plausible that alterations in dietary intake could potentially
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impact upon brain function and behaviour. The following section reviews the current
literature on the behavioural effects of n-3 PUFAs in animals and humans.
1.5 The behavioural effects of n-3 PUFAs
1.5.1 Animal evidence
Our knowledge of the impact dietary n-3 PUFAs have upon cognitive function has
been greatly extended by the investigation of their effects in animals, the majority of
which have been conducted using rodents. In these animals, the role of n-3 PUFAs
is studied using two methods. The first involves the complete removal of n-3 from
the maternal diet (animals are fed chow containing LA but no ALA) throughout
gestation and lactation resulting in a 50-80% reduction of DHA in the nervous
system of the offspring (Fedorova and Salem, 2006). The second method involves
dietary supplementation with n-3 PUFAs either to the mother during gestation or
directly to the offspring after birth or weaning. In order to assess the effects of these
dietary interventions, a variety of tasks have been used, some of which are
described below.
A large number of studies have investigated the relationship between brain DHA
concentrations and performance on the Morris Water Maze (MWM) task, a task
developed to evaluate spatial learning and memory (Morris, 1984). Reduced latency
to find the hidden platform in a pool of water upon which the animal can escape is
indicative of better learning on this spatial task, performance on which was
positively associated with brain DHA status (Fedorova and Salem, 2006). Moriguchi
and Salem (2000) demonstrated that second and third generation n-3 deficient rats
had longer escape latencies and delayed acquisition of the task compared to
controls. In addition, third generation rats (87% reduction in brain DHA) were found
to perform worse than second generation rats (83% reduction in brain DHA).
Interestingly, in both sets of animals performance was inversely related to levels of
docosapentaenoic acid (DPA, n-6; though another form of DPA is also metabolised
from ALA in the n-3 metabolic pathway) in the frontal cortex, suggesting that the
reciprocal replacement of DHA with DPA has significant consequences. A 60%
reduction in brain DHA is sufficient to reduce performance on this task which cannot
be attributed to an overall reduction in 22 carbon fatty acids (both DHA and DPA
contain 22 carbon atoms), as animals reared on DPA perform the same as those
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solely fed LA (Lim et al., 2005), leading to the conclusion that optimal brain function
requires incredible structural specificity of neural phospholipids. Indeed, decrements
in spatial task performance can be reversed upon administration of a repletion diet
containing both ALA and DHA in third generation n-3 deficient rats which is
comparable to the performance of rats fed an n-3 adequate diet, demonstrating
further the necessity of n-3 PUFAs on certain behavioural outcomes (Moriguchi and
Salem, 2003). In terms of the brain regions that are affected by diets lacking n-3
PUFAs, one group discovered that deficient rats suffered reductions in brain DHA in
the range of 39-63% in all seven brain regions that were analysed including the
cerebellum, medulla, hypothalamus and midbrain with the greatest reductions
observed in the striatum, hippocampus and cortex (Xiao et al., 2006).
Olfactory discrimination tasks have also been used by researchers to investigate the
role of n-3 PUFAs in cognitive function in rodents. The advantage of this approach
is that it rules out the possibility of performance being adversely affected by
impairments to the structural visual system brought about by n-3 PUFA deficiency, a
phenomenon that as has previously been demonstrated (Neuringer and Connor,
1986). Two studies established that n-3 deficient animals are capable of learning a
strategy to solve two-odour discrimination tasks, but that they repeatedly make
more false alarms than their n-3 adequate counterparts (Greiner et al., 1999,
Greiner et al., 2001). The authors are quick to highlight however that although these
results could indicate poorer learning and memory in the deficient animals, these
results could also indicate that the deficient animals have lower attention to the
stimulus (due to imbalances in the dopaminergic system) and that further studies
are needed to tease out these subtleties.
Other paradigms used to evaluate the behavioural effects of n-3 PUFAs include the
radial arm maze (requiring reference memory and working memory) and avoidance
(learning) tasks. However, the results from these studies are mixed, with some
studies suggesting a benefit of n-3 supplemented diets over n-3 deficient diets while
others do not, although methodological oversights may offer one explanation as to
why these disparities have been found (reviewed in Fedorova and Salem, 2006).
Overall the evidence from these studies indicates that carefully controlled n-3
deficient diets lead to a decrease in levels of brain DHA which is associated with
poorer performance on a selection of learning and memory tasks, possibly due to
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disruptions in dopaminergic neurotransmission (Delion et al., 1994, Zimmer et al.,
2002).
In older rats, impairments in tasks that involve complex motor skills and spatial
memory decline throughout the lifespan (Shukitt-Hale et al., 1998), which may be
attributable to the observed reductions in brain lipids have been consistently
observed in aged animals (e.g. Ulmann et al., 2001). Long-term potentiation (LTP),
commonly thought to be the biological process underlying learning and memory, is
reduced in aged rats (Landfield et al., 1978). In addition, both AA and DHA are
significantly decreased in these animals (McGahon et al., 1999). Interestingly, the
ability of rat hippocampal dentate gyrus cells to sustain LTP is negatively correlated
with the concentration of both AA and DHA in these cells, suggesting a link between
the prevalence of long-chain PUFAs and learning and memory (McGahon et al.,
1999). Eight weeks of n-3 PUFA supplementation (10 mg/d DHA) is sufficient to
restore membrane DHA, which is accompanied by a reversal of the deficits in the
ability to sustain LTP (McGahon et al., 1999). Other studies have shown that DHA
supplementation can restore radial arm maze task performance in both n-3
deficient (Gamoh et al., 2001) and n-3 adequate (Carrie et al., 2000) aged rats.
Together these investigations in aged animals suggest a theoretical basis for and
observable benefit of n-3 PUFA supplementation in reducing or reversing age-
related impairments.
1.5.2 Human evidence
In humans, n-3 PUFA deficiency to the extent that is observed in animals is
extremely rare and only a handful of cases have ever been reported, most
commonly as the result of administration of total parenteral nutrition (feeding
exclusively via intravenous drip) containing very little or no ALA. Rough, dry skin
and hair, excessive thirst and abnormal vision are common features of this type of
deficiency; symptoms which can be reversed once ALA is re-introduced to the diet
(Holman et al., 1982). N-3 PUFA status can be determined in humans by measuring
the concentrations of ALA, DHA and EPA in peripheral tissues such as
serum/plasma or erythrocytes. By comparing the n-3 status of healthy normal
volunteers to those of various patient groups, it has been revealed that individuals
diagnosed with several neurodevelopmental disorders such as ADHD and autism
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(Bell et al., 2000, Burgess et al., 2000, Schuchardt et al., 2009), along with a
number of psychiatric conditions including depression (Edwards et al., 1998),
schizophrenia (Assies et al., 2001) and Alzheimer’s disease and dementia (Conquer
et al., 2000), have significantly lower levels of n-3 PUFAs. Collectively these
findings again suggest that adequate intake and incorporation of n-3 PUFAs is a
requirement for normal functioning. The results from studies that have used n-3
supplementation as treatment for symptoms of these conditions have been mixed,
however, and further investigation is required. In the next section the role of n-3
PUFAs in a number of neuropsychiatric and developmental conditions is outlined,
along with an evaluation of the current evidence of their use in the treatment of
these conditions. The section will end with a review of the current knowledge of the
effects of n-3 PUFA supplementation on behavioural outcomes in healthy
individuals.
1.5.2.1 The role of n-3 PUFAs in neuropsychiatric conditions
1.5.2.1.1 Depression
The WHO estimates that 121 million people suffer from depression worldwide; in the
UK it is estimated that at least two thirds of adults will experience depressed mood
of sufficient severity to influence their daily activities, with women twice as likely as
men to experience a depressive episode (Anderson et al., 2000). There is growing
evidence to support a link between depressed mood and dietary n-3 PUFAs.
Firstly, fish consumption is inversely related to prevalence of major depression
across different countries worldwide (Hibbeln, 1998). For example, in countries such
as Japan, Norway and Iceland where intake of fish and dietary n-3 PUFA are high
[0.24-0.44% energy, as opposed to 0.10% (UK, USA), 0.08% (Germany)] major,
bipolar and postpartum depression are less prevalent than in countries such as the
USA and UK where depression is one of the leading causes of disability (Hibbeln et
al., 2006). This inverse relationship between fish consumption and depressive
symptoms has also been supported by two other population-based cross-sectional
studies in Finland (Tanskanen et al., 2001) and New Zealand (Silvers and Scott,
2002) along with two epidemiological studies of older adults aged > 65 years
(Bountziouka et al., 2009, Mamalakis et al., 2006a).
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In addition to the data using subjective food diaries to assess n-3 PUFA intake,
there are other studies that have established a link between depression and n-3
PUFAs using physiological measures. Lower levels of adipose DHA have been
reported in mildly depressed healthy adults compared to controls (Tanskanen et al.,
2001). Adipose n-3 PUFAs are also negatively related to depression in elderly
individuals (Mamalakis et al., 2002) and in adolescents (Mamalakis et al., 2004b).
The same is true of erythrocyte membrane levels, where total n-3 PUFAs and DHA
are depleted in depressed patients taking medication compared to controls
(Edwards et al., 1998, Peet et al., 1998a). Further, the DHA content of the
orbitofrontal cortex in patients with major depressive disorder was found to be
significantly lower (by 22%) than matched controls (McNamara et al., 2007).
In the face of the mounting epidemiological and peripheral tissue evidence
implicating n-3 PUFAs in the pathophysiology of depression (e.g. Edwards et al.,
1998, Mamalakis et al., 2006a, Mamalakis et al., 2004a, Peet et al., 1998a,
Tanskanen et al., 2001), intervention trials using n-3 PUFAs as a monotherapy or
adjunctive treatment in depressive disorders have produced mixed results, though
the populations studied, length of treatment regimen (4-12 weeks) and dose (1 - 9.6
g/d DHA + EPA) and formulation (ratio of DHA:EPA) of treatment have varied widely
between studies. Similarly, two meta-analyses of the extant literature published
around the same time are not in agreement about the efficacy of n-3 PUFAs in the
treatment of depressive disorders. The first of these conducted both best and worst-
case scenario analyses in a random-effects model for intervention trials carried out
in the treatment of major depression and bipolar disorder, including only those
studies that used 1g/d doses in the best-case analysis and all doses in all trials for
the worst-case analysis. N-3 PUFA supplementation produced a statistical
improvement for both analyses, but the authors note high heterogeneity of the
results due to the substantially disparate methodologies between studies and
recommend caution interpreting these findings (Freeman et al., 2006b). The second
paper included studies that have used n-3 PUFAs as an intervention for depression
associated with chronic fatigue, post-partum depression, and personality disorder
and used fixed-effects analysis. These authors also note large heterogeneity
between studies however their results showed little evidence of efficacy of n-3
PUFAs in the treatment of depressed mood, contradicting the findings of the first
meta-analysis (Appleton et al., 2006). Among the possible reasons for this
discrepancy are the choice of analysis and the inclusion of large (non-significant)
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studies that are diverse in both the type of treatment used and population studied
(Richardson, 2008). The largest intervention trial to date, however, examined the
effects of 12 weeks dietary supplementation with 1.5 g/d DHA+EPA in 190 mild to
moderately depressed volunteers, but found no evidence to support the use of n-3
PUFAs in the treatment of depressive symptoms in this population (Rogers et al.,
2008), raising the possibility that the benefit of taking n-3 PUFAs for is negligible.
Only further large randomised controlled trials (RCTs) will be able to resolve this
issue.
1.5.2.1.2 Postpartum depression
Ten-20% of postpartum women are diagnosed with postpartum depression (PPD).
This condition is defined in the DSM-IV as a major depressive episode with the
onset within 4 weeks of delivery which can potentially have a negative impact upon
the child’s development (see Ness et al., 2003 for a review). As maternal stores of
fatty acids are depleted during pregnancy to ensure an adequate supply for central
nervous system development of the growing neonate, some researchers have
explored the hypothesis that without sufficient dietary intake of fatty acids, mothers
may increase their risk of suffering from PPD (Holman et al., 1991). In rats, it has
been observed that an inadequate supply of dietary DHA is enough to result in a
21% decrease in brain DHA in just one reproductive cycle (Levant et al., 2006), but
the extent and possible consequences of depletion in humans has yet to be
established. In a cross-national study, Hibbeln (2002) discovered that seafood
intake and levels of DHA in breast milk were inversely associated with depressive
symptoms as measured by the Edinburgh Postnatal Depression Scale (EPDS) in 22
countries worldwide, but another study of 80 new mothers found no relationship
between postnatal n-3 fatty acid status and postnatal depression (Browne et al.,
2006). In addition, the results from the few intervention trials that have been
conducted in this population generally do not support n-3 PUFAs as a treatment of
PPD, though large RCTs are still required. In a small open-label trial,
supplementation of 2.96 g/d DHA and EPA starting at between 34 and 36 weeks
gestation did not prevent PPD in four out of seven participants (Marangell et al.,
2004). Freeman and colleagues have conducted two intervention trials in woman
who have been diagnosed with depression following birth. The first of these studies
was an open-label pilot trial where participants (N = 15) received approx 1.9 g/d
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EPA+DHA for 8 weeks (Freeman et al., 2006a). Authors reported a 40.9% decrease
in depressive symptoms on the EPDS but in a second randomised dose-ranging
study where treatments ranged from 0.5g to 2.8 g/d as adjunctive treatment to
supportive psychotherapy, the authors found no difference between groups, with all
groups reporting reduced scores on the EPDS and Hamilton Depression Rating
Scale (Freeman et al., 2008). Taken together these studies are not conclusive but
do warrant further research. First and foremost, future projects would need to
adhere to randomised, double-blind and placebo-controlled procedures.
1.5.2.1.3 Bipolar Disorder
Patients with bipolar disorder (BD) fall into one of two categories: BD I is
characterised by the occurrence of one or manic episodes interspersed with
episodes of depression and BD II is defined by recurrent moderate to severe major
depressive episodes as well as lower intensity manic episodes (American
Psychiatric Association 2000). Unfortunately, response to treatment in patients with
BD is often poor and there is a need for safer and more effective interventions. To
this end, the similarities between the effects of mood stabilizers such as lithium and
valporate—commonly used in the treatment of BD—and DHA and EPA, on the
enzyme protein kinase C (PKC) have lead researchers to consider n-3 PUFAs as an
alternative to standard pharmacological treatment for BD. Further, epidemiological
studies have revealed a inverse relationship between seafood consumption and
lifetime prevalence rates of BDI, BDII and bipolar spectrum disorder (Noaghiul and
Hibbeln, 2003). However, evidence from intervention trials is inconclusive, with
some published trials reporting a benefit of n-3 PUFAs (Stoll et al., 1999, Frangou et
al., 2006, Sagduyu et al., 2005, Osher et al., 2005) whilst others do not (Keck et al.,
2006, Marangell et al., 2003). A systematic review of the extant literature in this area
concluded that although n-3 PUFAs are well-tolerated by patients with BD and the
evidence seems to show an association between n-3 use and symptom reduction,
further studies are required in order to confirm their efficacy in the treatment of BD
(Turnbull et al., 2008).
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1.5.2.1.4 Schizophrenia
Schizophrenia is a mental illness that affects around 0.4-0.6% of the population and
is characterised by impairments in the perception of reality, often resulting in social
dysfunction (Bhugra, 2005). The popular ‘dopamine hypothesis’ of schizophrenia
proposes that negative symptoms (flat affect) result from reduced activity of the
dopamine systems in the prefrontal area, and positive symptoms (delusions and
thought disorder) from increased activity of the dopamine systems in the limbic
system (Davis et al., 1991). This theory can explain the relationship between
dopamine kinetics and the psychiatric symptoms of schizophrenia, but fails to
address the cause of the abnormal activities of dopaminergic neurons (Ohara,
2007). Zimmer and colleagues discovered that rats who had been fed an n-3
deficient diet suffered a reduction in the number of presynaptic dopamine vesicles
and also that basal dopamine metabolism is increased (Zimmer et al., 2000b,
Zimmer et al., 2000a). Dietary n-3 deficiency has also been shown to reduce the
number of D2-receptors in the frontal lobe in both rats (Delion et al., 1994) and in
piglets (de la Presa Owens and Innis, 1999). It has also be observed that compared
to controls, schizophrenia patients have lower levels of plasma n-3 PUFAs (Assies
et al., 2001). Therefore, in an attempt to integrate all of the evidence, Ohara (2007)
proposed that the n-3 PUFA abnormalities found in schizophrenia stem from the
dysfunction of the enzyme phospholipase A2 (PLA2). The action of PLA2 releases
membrane fatty acids at the sn-2 position of membrane phospholipids (AA, EPA
and DHA), resulting in the generation of free fatty acids which are subsequently
metabolised to produce eicosanoids in the case of AA and EPA (Farooqui et al.,
1997) or docosanoids in the case of DHA (Tassoni et al., 2008). It follows that
increased activation of PLA2 observed in patients suffering from schizophrenia may
cause the excessive depletion of PUFA from the sn-2 position of cell membrane
phospholipids in the body and brain. Dopamine concentration, the number of
dopamine vesicles and the number of D2 receptors are decreased in the prefrontal
presynaptic terminals (resulting in the negative symptoms) and these decreases
having a knock-on effect for the limbic dopamine system (resulting in the positive
symptoms) (Ohara, 2007).
Despite the apparent plausibility of this integrated theory, a Cochrane review of
PUFA supplementation in schizophrenia concluded that data from the six trials that
met the inclusion criteria was inconclusive, and the value of treating schizophrenia
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with PUFA remains unfounded (Joy et al., 2006). This conclusion was formed
largely on the basis that, of the six trials, only one enrolled more than one hundred
participants (Peet and Horrobin, 2002a) and in only one study did the intervention
period exceed three months (Fenton et al., 2001). Neither of these studies produced
compelling evidence to support the use of n-3 in the treatment of schizophrenia. In
the first study (Peet et al., 2001), participants were randomly assigned to one of four
possible treatment groups; placebo or 1, 2 or 4 g/day ethyl-EPA. The authors also
categorised participants into three further groups according to their concurrent
medication (typical, new atypical and clozapine). Although improvements were
reported on all rating scales by participants in all treatment groups, for those
participants whose concurrent medications fell into the typical or new atypical drug
category, improvements were also see in the placebo group, rendering differences
between groups non-significant. In those participants who were taking clozapine
however, there was very little placebo effect and the responses made by
participants in the 2 g/day treatment were significantly better following treatment
compared to placebo. In a second trial of seventy-five schizophrenic patients
conducted by the same group of authors, participants were randomised to either
placebo or 3 g/day ethyl-EPA for 16 weeks; all were receiving concurrent
medication (Fenton et al., 2001). No differences were found between the active
treatment and placebo groups on any of the outcome measures, though the authors
are quick to highlight that unique to this study was the fact that participants in
previous studies (e.g. Peet et al., 1995, Peet and Mellor, 1998) were younger and
had a shorter duration of illness. Only large, longitudinal RCTs will be able to
provide sufficient evidence as to whether n-3 PUFAs have a significant positive
impact in the treatment of this illness.
1.5.2.1.5 Age-related cognitive decline and dementia
In the UK the population is ageing and living longer than ever before (ONS, 2009).
Cognitive function naturally declines with age and has been attributed to a number
of factors including reduced synaptic plasticity, decreased membrane fluidity and
increased oxidative damage (Willis et al., 2008). In functional terms ageing is
associated with decrements in working memory and top-down control in selective
attention (de Fockert, 2005). There is growing evidence, however, that various
lifestyle factors can either promote or attenuate cognitive ageing. These include
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smoking (Swan and Lessov-Schlaggar, 2007), alcohol consumption (Peters et al.,
2008), exercise (Colcombe et al., 2003) and diet (Barberger-Gateau et al., 2007,
Del Parigi et al., 2006). In particular, one of the dietary factors that has been
explored in detail is intake of fatty acids. For example, the Dutch prospective
population-based Zutphen Elderly Study identified that LA was positively associated
with cognitive decline over a 3 year period (defined as a >2 point drop in Mini
Mental State Examination) in 476 men aged 69-89 years (Kalmijn et al., 1997b). A
recent re-analysis of the same data was able to identify that in this sample of elderly
men, those who did not eat fish observed a 1.2 point decline in MMSE score at the
5-year follow up, as opposed to only a 0.3 point decline in men who reported eating
fish (van Gelder et al., 2007). Additionally, a cross-sectional study by the same
group identified that oily fish consumption (measured using a FFQ) was significantly
associated with a reduced risk of global cognitive function impairment and
psychomotor speed in participants of 45-70 years, independent of other
confounding factors (e.g. age, sex, education, smoking, alcohol consumption,
energy intake) (Kalmijn et al., 2004a). Findings from the Chicago Health and Aging
Project (CHAP), conducted in 2560 participants aged 65 years and older over a
period of 6 years also discovered that fish intake was associated with a slower rate
of cognitive decline at the 6-year follow up. More specifically, among those who
consumed one fish meal per week, decline was 10% slower than those who
consumed fish less than weekly and 13% slower for those who consumed two or
more fish meals per week, adjusted for age, sex, race, education, cognitive activity,
physical activity, alcohol consumption, and total energy intake. What the authors
could not conclude is whether it was n-3 PUFAs that were the relevant dietary
constituent in fish accountable for this finding (Morris et al., 2005). The prospective
population-based Etude du Vieillissement Ateriel (EVA) study evaluated fatty acids
in erythrocyte membranes and performance on the MMSE in a sample of 246 63-74
year olds (Heude et al., 2003). These authors found that higher proportions of
stearic acid (a saturated fatty acid) and total n-6 PUFAs (LA, AA, γ-linolenic acid
(GLA), DPAn-6) were associated with greater risk of cognitive decline and that a
higher proportion of total n-3 PUFAs (ALA, DHA, EPA, DPAn-3) was associated
with a lower risk of cognitive decline over a 4-year period. Similarly, intake of EPA
and DHA (estimated via a food frequency questionnaire) was inversely associated
with cognitive impairment (MMSE). Finally, higher plasma n-3 PUFA proportions in
a sample of 807 healthy participants aged 50-70 years predicted less decline in
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sensorimotor speed and complex speed over a 3 year period, though there were no
associations between n-3 PUFA proportions and memory, information processing
speed or word fluency, although no significant associations were detected at
baseline between n-3 status and performance in any of the 5 assessed cognitive
domains (Dullemeijer et al., 2007).
It is only now that large-scale prospective randomised intervention trials are
currently being conducted to evaluate the effects of fish oil intervention on cognitive
function in older adults. The OPAL (Older People And n-3 Long-chain
polyunsaturated fatty acids) study is a 24-month placebo-controlled trial which
aimed to assess the effects of a daily fish oil supplement containing 0.5 g DHA and
0.2g EPA on cognitive performance on the California Verbal Learning test and other
measures of memory and attention in 867 men and women aged 70-79 years (at
baseline) (Dangour et al., 2006). Preliminary results from the baseline data suggest
that associations between fish consumption and performance are not significant
after adjusting for a range of socioeconomic and heath factors, but only the final
analysis will be able to reveal the efficacy of the actual treatment (Dangour et al.,
2009). In addition, two further intervention trials from which data have yet to be
published, the MIDAS (Memory Improvement with Docosahexaenoic Acid Study -
Martek, 2006) and the MAPT (Multidomain Alzheimer Preventative Trial - Gillette,
2009) studies will be able to further elucidate the relationship between n-3 PUFA
and cognitive function in older adults.
The progression of age-related cognitive decline to cognitive impairment is rising
dramatically the world over and currently around 24 million people are affected by
dementia, with Alzheimer’s disease accounting for around 60% of cases. With the
yearly burden of dementia in the UK alone estimated at £17 billion, defining
strategies to prevent or delay cognitive impairment in the elderly should be a priority
for healthcare (Knapp and Prince, 2007). A person is diagnosed with dementia
when: cognitive impairment is greater than that found in normal ageing, affects two
or more cognitive domains and also the person’s ability to function (American
Psychiatric Association 2000). Alzheimer’s disease (AD) is the most common form
of dementia affecting around 60% of people, the early stages of which is
characterised by apathy, anxiety and depression. As the neurodegeneration
increases, symptoms progress to delusions and hallucinations, at which point full-
time care or institutionalisation are required (McKeith and Cummings, 2005).
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Vascular dementia is the second most common form of dementia, with several
different subtypes, and is accompanied by a range of different cognitive
impairments of the frontal lobe including verbal fluency, set-shifting and abstract
thought (Mariani et al., 2007).
A number of observational studies in humans have examined the relationship
between intakes of n-3 PUFAs, as measured by various food frequency
questionnaires (FFQ), and diagnosis of dementia or AD, but overall the results are
conflicting. Barberger-Gateau et al. (2002) found in their analysis of the PAQUID
epidemiological study (N = 1674 aged 68 years or more) that those participants who
consumed fish or seafood at least once a week were at a lower risk of developing
dementia, including AD at the 7 year follow-up. However, after adjusting for
education level, which was positively correlated with fish intake, the strength of the
association diminished somewhat. A publication from the CHAP cohort
demonstrated that after a mean follow up of 3.9 years that a higher intake of DHA
and weekly fish consumption reduced the risk of AD, though EPA was not
associated with a reduced risk (Morris et al., 2003). Conversely, results from the
prospective population-based Rotterdam study (N = 5395) found no association
between n-3 intake and risk for any type of dementia (Engelhart et al., 2002).
Similarly, results from the Canadian Study of Health and Aging also do not suggest
that an association between total n-3 PUFAs, DHA or EPA and incidence of
dementia or AD (Kroger et al., 2009). In addition, the results from two other large-
scale studies that initially indicated an inverse association between n-3 PUFAs and
incidence of AD and dementia were attenuated once sex, age and education were
adjusted for (Huang et al., 2005, Schaefer et al., 2006).
Despite these mixed reports, the biological basis for pursuing research in this area
is compelling; n-3 PUFAs possess three properties by which they may protect
against the development of dementia which include increasing cerebral blood flow,
attenuating inflammation and reducing amyloid production (reviewed in Fotuhi et al.,
2009). Results from animal studies are indeed encouraging; in their review of the
protective effects of n-3 PUFAs in Alzheimer’s disease, Boudrault et al. (2009)
conclude that treatment with DHA in rodent models of AD consistently protects
against AD, with a number of observable effects in the brains of animals fed DHA
compared to controls including decreased pro-apoptotic proteins and secretion of
amyloid beta (Aβ) and increased activity in the PI-3 kinase cascade, a
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neuroprotective pathway shown to be reduced in AD. Coupled with these
physiological changes are studies showing improvements in cognitive function. One
group from Japan have focused particularly on this issue, and have consistently
shown protective effects of n-3 PUFA administration on spatial learning ability in Aβ
infused rats (Hashimoto et al., 2005a, Hashimoto et al., 2002, Hashimoto et al.,
2008, Hashimoto et al., 2005b). However, it is worth nothing that the quantity of n-3
PUFAs given to these animals is 2-4 times greater than the current intake in
humans (Boudrault et al., 2009). Interestingly, in humans, levels of DHA in the
brains of Alzheimer’s disease patients does not significantly differ from normals,
though levels of stearic acid (frontal and temporal cortex) and AA (temporal cortex)
are reduced, and oleic acid is increased (frontal and temporal cortex), indicating
some differences in brain fatty acid composition (Fraser et al., 2009). Compared to
animal studies, intervention trials in humans however have not been met with the
same success. A dose-ranging intervention in 302 participants aged 65 years or
older with a MMSE score of >21 found no effect of either dose of fish oil containing
either 400 mg or 1800 mg DHA+EPA on cognitive function (memory, sensorimotor
speed, attention, executive function) compared with placebo following 26 weeks of
dietary supplementation (van de Rest et al., 2008). Similarly, the OmegaAD clinical
trial examined the effects of n-3 PUFA supplementation in 174 patients with mild to
moderate AD. In this one-way cross-over trial, the active treatment consisted of
daily dietary supplementation with 1.6 g of DHA and 0.6 g EPA. At six months there
was no difference between groups on either the MMSE or the Alzheimer’s disease
Assessment Scale. However, in a subgroup of participants with very mild cognitive
dysfunction there was a significant reduction in MMSE decline rate, and this was
replicated in the crossover group at 12 months (Freund-Levi et al., 2006). These
authors also suggest that in terms of the neuropsychiatric symptoms of AD, carriers
of the APOε4 gene might be more susceptible to the effects of treatment with n-3
PUFAs, though this is an avenue of investigation that needs to be pursued further
(Freund-Levi et al., 2007). Lim et al. (2006) conclude in their Cochrane review that
there is a growing body of evidence from biological, observational and
epidemiological studies suggesting a protective effect of n-3 PUFAs against
dementia. The level of this effect remains unclear, however, and to date dietary
recommendations in relation to fish and n-3 PUFA consumption and risk of
dementia cannot be made. It is hoped that the results of the DHA in Slowing the
Progression of AD study, a prospective 18 month intervention trial in 400
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participants aged 50 or older with mild to moderate cognitive impairment, could be
used to inform the efficacy of n-3 PUFA in the prevention of dementia (Quinn,
2007).
1.5.2.2 The role of n-3 PUFAs in neurodevelopmental disorders
Richardson and Ross (2000) were among the first researchers to link
neurodevelopmental disorders such as ADHD, dyslexia, developmental coordination
disorder (DCD) and autism with n-3 PUFA deficiency. These authors noted clinical
commonalities between these conditions such as the preponderance of males that
were affected, apparent links between allergies and other immune system disorders
such as proneness to infections and atopic conditions, abnormalities of mood,
arousal and sleep, as well as cognitive impairments in attention and working
memory, which suggest disruptions of visual or auditory processing (Richardson,
2006). It had also been observed some twenty-five years previously that individuals
with these conditions also shared physical characteristics seen in animals
specifically bred on n-3 deficient diets such as excessive thirst, frequent urination,
rough, dry hair and skin and follicular keratosis (Colquhoun and Bunday, 1981).
Indeed, several studies in children with ADHD have demonstrated that these
children have lower blood concentrations of PUFAs, namely AA, DHA and overall
concentrations of n-3 PUFAs (Burgess et al., 2000, Stevens et al., 2003, Stevens et
al., 1996, Bekaroglu et al., 1996). Given that there is no evidence to suggest that n-
3 PUFA intakes are lower in children with ADHD than in healthy children (Ng et al.,
2009), the low levels of n-3 PUFAs found in the blood of children with ADHD have
been attributed to either inefficient conversion of ALA to EPA and DHA or enhanced
metabolism of these fatty acids (Stevens et al., 1995, Burgess et al., 2000). There
have been five widely-cited intervention trials investigating the effectiveness of n-3
PUFA treatment on symptoms in children with ADHD and related developmental
disorders. These studies have varied in design but interestingly the three
experiments that report a positive effect of treatment all used a daily treatment
regimen lasting twelve weeks or longer and the treatments themselves originated
from fish oil, and therefore contained both DHA and EPA (Richardson and
Montgomery, 2005, Richardson and Puri, 2002, Stevens et al., 2003). The study by
Voigt et al. (2001) found no effect of 345 mg/d DHA for 16 weeks on a wide range of
behavioural and computerised measures of ADHD-related symptoms in 54 children
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diagnosed with ADHD and Hamazaki and Hirayama (2004) found no effect of
treatment on behavioural symptoms of ADHD with a daily fish oil supplement for 8
weeks, suggesting the possibility that both the composition of the n-3 PUFA
treatment and duration of regimen are key factors in ameliorating symptoms of
ADHD and related disorders.
Similarly, a relationship between n-3 fatty acid status and autism has also been
demonstrated, though intervention trials showing a pronounced benefit of treatment
with n-3 PUFAs are lacking. Vancassel et al. (2001) discovered that DHA was
decreased by 23% in the plasma phospholipids of autistic children and total fatty
acids by 20%. In contrast, a more recent study found that in 16 high-functioning
males with autism, DHA and the ratio between total n-3:n-6 PUFAs were increased
in plasma phospholipids compared to 22 matched controls, and consequently the
authors advised serious caution against treating this condition with n-3 PUFAs
(Sliwinski et al., 2006). Despite this, Amminger et al. (2007) published results from a
pilot trial wherein they administered seven 7 diagnosed with autistic disorder 7 g/d
fish oil for 6 weeks. When compared to matched controls who received a placebo
treatment for the same duration, the only significant difference found between
groups was on an irritability scale; no differences were found between groups on the
social withdrawal, stereotypy, hyperactivity or inappropriate speech measures. The
authors are quick to note the small sample size and the relatively short duration of
the trial. No adverse effects on behaviour were observed.
N-3 PUFAs have also been linked to dyslexia, and to this end Richardson et al.
(2000) examined the associations between the clinical signs of n-3 fatty acid
deficiency (excessive thirst, frequent urination, rough, dry hair and skin etc.) and
reading ability, spelling and auditory working memory in 97 dyslexic children. The
authors detected inverse associations between signs of n-3 deficiency and reading
and overall ability, and in boys alone poorer spelling and auditory working memory.
This finding was reflected in a study of dyslexic adults who filled out two self report
questionnaires; one on signs of fatty acid deficiency and another concerning signs
and severity of dyslexia. The authors reported that the signs of fatty acid deficiency
were significantly elevated in dyslexic participants and that this reached higher
significance in males (Taylor et al., 2000). Cyhlarova et al. (2007) also recently
examined the link between fatty acid status and literacy skills in thirty-two dyslexic
individuals and twenty matched controls. For both groups, better word reading was
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associated with higher total n-3 concentrations though it was only in dyslexic
participants that a negative correlation was found between reading performance and
the ratio of AA:EPA and with total n-6 concentrations, despite there being no
significant differences in membrane fatty acid levels between groups, suggesting
that, as in ADHD, the ratio of n-6:n-3 PUFAs or a intrinsic disruption in the
metabolism of these fatty acids may be a contributing factor in the aetiology of these
conditions. A collection of preliminary studies reported by Stordy (2000) seems to
indicate that impairments of the visual system can be improved with a high-DHA
supplement in dyslexic participants, although larger RCTs have yet to be carried out
investigating the full extent of the efficacy of n-3 PUFAs in the treatment of dyslexia.
1.5.2.3 N-3 PUFA supplementation and behaviour in healthy individuals
1.5.2.3.1 Infant development
The developing foetus requires a supply of both AA and DHA for structural and
metabolic functions (Haggarty, 2004). The brain and retina require a high
concentration of DHA to function optimally and as such, it is thought that the n-3
PUFA composition of the maternal diet can affect visual and intellectual
development (Innis, 1991). DHA is deposited in foetal fat stores in the last 10 weeks
of pregnancy in the quantity of around 10 g. If the diet is devoid of preformed DHA
in the first two months of life then this store is mobilised and would be largely used
up, supporting critical developmental processes (Farquharson et al., 1993). Whilst
the level of AA in breast milk has been found to remain constant at about 0.45% of
total fatty acids, the level of DHA, on the other hand, varies with the mother’s diet
from about 0.1-3.8% of total fatty acids. Unlike breast milk, until relatively recently
both term and pre-term infant formulas did not contain any n-6 or n-3 PUFAs and it
was observed that formula-fed infants have significantly lower levels of DHA in
plasma, erythrocytes and brain cortex compared to breast-fed infants, and lower
levels of AA in plasma and erythrocytes (Menon and Dhopeshwarkar, 1983). The
consequences of these differences in fatty acid status have been assessed using a
variety of methods, with sensory and global cognitive functions along with growth
and fatty acid status as outcomes. Overall the available evidence suggests that
DHA is essential for cognitive development, though there are discrepancies in the
literature.
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Studies that have investigated the advantage of breastfeeding over formula on
cognitive and developmental outcomes have indeed shown an advantage for
breastfeeding, even after controlling for various socio-economic factors. Benefits
include improved visual acuity (e.g. Birch et al., 1992, Birch et al., 1998),
psychomotor development at 4 months (Agostoni et al., 1995), intelligence (Lucas et
al., 1992, Kramer et al., 2008) and even later academic achievement (Horwood and
Fergusson, 1998). An obvious limitation of these studies is that human milk contains
any number of other components that could be responsible for the observed
differences between groups. Other studies have therefore looked at supplemented
versus unsupplemented formulas as a more reliable comparison. Supplemented
formulas have indeed been shown to be effective in successfully raising infant’s
levels of AA and DHA to that of infants who have been fed human milk, within about
10%. Carlson et al. (1996) were effective in mimicking the levels of AA and DHA in
American women’s milk, and when the formula contained 0.1% DHA and 0.43% AA,
there were no significant differences in plasma levels of AA and DHA between the
breast and formula fed groups of infants. Both AA and DHA have to be present in
the formula, however, as supplementation with DHA alone has been shown to result
in lower levels of AA between 15-40% (Auestad et al., 1997). By altering the levels
of the longer chain fatty acids in supplemented formulas and using unsupplemented
formulas (usually containing only LA and ALA) as a reference group, any
developmental effects of these manipulations can be investigated.
Carlson et al. (1996) found only a transient benefit of a supplemented formula (0.1%
DHA + 0.43% AA) over an unsupplemented formula (LA:ALA=22:2.2) on visual
acuity which was only present at 2 months but not at 4, 6, 9, and 12 months. In a
study using a very similar design and levels of DHA and AA, no advantage was
seen in the supplemented group at any testing point (1, 2, 4, 6, 9, and 12 months),
although the disparity in results could possibly be due to a different sources of fatty
acids i.e. egg phospholipids vs. fish oil, respectively (Auestad et al., 2001). Makrides
et al. (1995) on the other hand found that infants fed for 4 months on a
supplemented formula (0.36% DHA, 0.58% EPA, 1.52% ALA and 0.27% γ-linolenic
acid, n-6) had better transient visual evoked potentials (VEP) at 4 and 7.5 months
than the standard 1.6% ALA formula, and the same as the infants fed human milk.
Birch et al. (1998) also found that infants given higher levels of DHA in two separate
supplemented formulas (0.35% DHA and 0.36% DHA + 0.72% AA) had similar
steady-state VEP acuity at 6, 17 and 52 weeks to the infants in the human milk
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group, and significantly better than the VEP acuity of the standard formula group
(LA:ALA=15:1.5). These results suggest that in terms of visual development, the
level of DHA in the diet has to be higher than 0.1% to have a beneficial impact.
This theme is continued as regards the effects of supplemented formulas on
cognitive function. Only a handful of studies to date have found a positive impact of
added n-PUFAs, and these were with DHA at the levels of 0.35 or 0.36% of total
fatty acids (Birch et al., 2000, Drover et al., 2009, Birch et al., 2007). Other studies
that have used supplemented formulas where the level of DHA added to the formula
was around 0.1% DHA (e.g. Lucas et al., 1999, Auestad et al., 2001, Makrides et
al., 2000) have failed to show any differences in cognitive or motor development
between infants fed a supplemented formula over the standard one.
Altogether these studies indicate an important role for DHA in both visual and
cognitive development, and discrepancies between studies can be attributed to
methodological variation. Interestingly, as mentioned above, the level of DHA in
American mother’s milk is estimated at around 0.13% DHA, whereas only higher
levels of DHA in the formula have been shown to be effective at producing
improvements over placebo in these studies. It is a logical progression to then
investigate the developmental impact of supplementing the maternal diet with DHA
and other n-3 PUFAs (in the absence of a similar n-6 PUFA shortage in the
maternal diet). Several such studies have been conducted with some positive
results. Helland et al. (2003) recruited 341 women at 17-19 weeks of their
pregnancy and randomly allocated them to a daily regimen of 10 mL of either corn
or cod liver oil (1180 mg DHA + 803 mg EPA) until three months after delivery.
Plasma levels of DHA were significantly higher in both the infants and the mothers
of the cod liver arm compared to the placebo group, demonstrating that maternal
dietary supplementation with n-3 PUFAs is reflected in a simultaneous increase in
plasma lipid levels of the infant. Fish oil supplementation during pregnancy in this
way has been shown to have a positive impact on infant development. The same
authors assessed these children at 4 years using the Kaufman Assessment Battery
for Children (K-ABC) as an outcome for intelligence and achievement. All children
had been breastfed to at least 3 months of age. Those whose mothers were in the
cod liver oil treatment group scored higher on the Mental Processing Composite of
the K-ABC, and in a multiple regression model, maternal intake of DHA was the only
variable to significantly predict this difference in mental processing at age 4 (Helland
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et al., 2003). In another randomised double-blind trial study, children whose mothers
had been given a fish oil supplement (2.2 g DHA + 1.1 g EPA; N = 33) had better
hand-eye coordination at 2.5 years of age than those who mothers had been given
olive oil (N = 39) during pregnancy (Dunstan et al., 2008). There were, however, no
significant differences between groups on measures of receptive language or
behaviour. It is worth noting that maternal supplementation with 2.82 g/d ALA from
week 14 of pregnancy to 32 weeks following delivery had no impact on either the
infant’s DHA status as measured by plasma lipid levels or on their cognitive function
compared to the control group suggesting that the infant requires preformed DHA to
meet requirements (de Groot et al., 2004).
In a prospective epidemiological study, Hibbeln et al. (2007) investigated mother’s
seafood consumption during pregnancy. After adjustment for twenty-eight potential
confounding factors, these authors reported that consumption of less than 340 g of
seafood per week was associated with increased risk for suboptimal outcomes for
prosocial behaviour and fine motor, communication and social development scores
and increased risk for being the lowest quartile for verbal intelligence. This study is
the largest of its kind (N = 11,875) and provides strong evidence that maternal fish
and fish oil consumption can have an important positive impact on infant
development.
1.5.2.3.2 Normally developing children and healthy adults
As noted in the previous section, n-3 PUFAs appear to be important for certain
aspects of early development. A logical progression is to therefore examine the
behavioural effects of n-3 PUFAs in children and young adults. However, very few
intervention studies assessing behavioural parameters in healthy individuals have
been conducted. As regards cognitive outcomes, three studies in children (Dalton et
al., 2009, Osendarp et al., 2007, Ryan and Nelson, 2008) and four in adults (Fontani
et al., 2005, Rogers et al., 2008, Hamazaki et al., 1996, Antypa et al., 2009) have
included measures of cognitive function in n-3 PUFA intervention trials.
Dalton et al. (2009) found beneficial effects of a daily fish flour spread given to
healthy children aged 7-9 years (N = 183) for 6 months in a single-blind placebo-
controlled trial. Following the treatment, which contained 335 mg ALA, 82 mg EPA
and 192 mg DHA, participant’s plasma and erythrocyte concentrations of EPA and
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DHA significantly increased in the active treatment group and AA significantly
decreased. This was coupled with improvements on the Hopkins Verbal Learning
Recognition and Discrimination outcomes (Immediate and Delayed Word Recall,
Word Recognition), as well as on a spelling test. Marginally significant results were
also seen on a reading test, compared to placebo. Another study in a similar age
group did not report benefits of a fish oil intervention, though the quantities of n-3
PUFAs contained in the supplement were much lower (Osendarp et al., 2007). In
this study, as part of a large trial investigating micronutrient supplementation in
healthy Australian and Indonesian school children aged 6-10 years (N = 780), one
arm of the study consisted of an n-3 PUFA intervention, containing 88 mg DHA and
22 mg EPA. Despite the intervention successfully increasing plasma n-3 PUFA
concentrations, there was no effect of treatment on any of the cognitive outcome
measures, which included tasks to measure general intelligence, verbal learning
and visual attention. Similarly, another study in a slightly younger age group (4
years, N = 175) examined the effect of 400 mg/d algal DHA following 4 months of
supplementation and found no effect of treatment on any of the outcomes that
included measures of memory, attention, vocabulary acquisition, listening
comprehension and impulsivity, though the authors did find evidence of a positive
association between blood concentrations of DHA and performance on a measure
of vocabulary acquisition and listening comprehension (Ryan and Nelson, 2008).
The four studies conducted in healthy adults that have assessed cognitive
performance have also reported mixed results. Fontani et al. (2005) gave
participants 4 g fish oil containing 1.60 g EPA and 0.80 g DHA a day for 35 days (N
= 33, mean age 33 years). They were then tested on several tests of attention prior
to and following this regimen of supplementation. Results showed that participants’
reaction times were reduced on the Go/No-Go task and Sustained Attention task
following supplementation. It is noteworthy, however, that although this study had a
parallel group (n = 16) that were administered a placebo containing 4 g/d olive oil,
and the results for this group were null after the trial period, the results of the two
groups were not compared in the analysis and therefore the claims of efficacy of n-3
supplementation in this study should be regarded with caution. In comparison,
Antypa et al. (2009) followed a similar protocol to Fontani et al. (2005) where they
also looked at the effects of a comparable quantity of n-3 PUFAs (1.75 g EPA+ 0.25
g DHA) administered for 4 weeks on depression-relevant cognition and mood in
healthy adults. However, these authors did not detect any effects of treatment on
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any of the cognitive measures including attention, memory, response inhibition and
emotion recognition. A much larger double-blind placebo-controlled intervention
trial in 190 mild-to-moderately depressed but otherwise healthy adults only found a
trend for an effect of treatment on an impulsivity task, and no other significant
results from any other cognitive measures used to investigate the effects of a daily
fish oil supplement containing 630 mg EPA and 850 mg DHA for 12 weeks (Rogers
et al., 2008). Lastly, Hamazaki et al. (1996) reported an effect of 1.5-1.8 g/d DHA in
preventing an increase in extraggression (aggression towards others) during times
of mental stress (university exams) in healthy young adults, but no effect of
treatment on a Stroop task (a task of response inhibition) or dementia detecting
tests, in keeping with the mixed findings reported in this area.
1.5.3 Summary of the behavioural effects of n-3 PUFAs
Using models of n-3 PUFA deficiency and subsequent repletion, research that has
investigated the effects of n-3 PUFAs on behavioural outcomes in animals has
demonstrated that brain depletion of n-3 PUFAs occurs in the complete absence of
dietary n-3, and is associated with cognitive costs which can be ameliorated once n-
3 PUFAs are reintroduced into the diet. Human studies have been far less
conclusive. Low n-3 PUFA status is associated with poorer behavioural outcomes,
but the evidence provided by intervention studies in the treatment of conditions such
as depression, schizophrenia, ADHD and dementia has been mixed and
inconclusive as a whole, although results from a few positive studies have been
compelling enough to pursue further research in these areas. As regards the latter,
conclusive data regarding the efficacy of n-3 PUFAs in preventing cognitive decline
and dementia has yet to be published, and results from a number of large
prospective longitudinal intervention trials that are currently being conducted are
eagerly awaited. In terms of the relationship between dietary n-3 PUFAs and
behavioural outcomes in normal healthy individuals, to date bulk of the research has
focused on the effects of n-3 PUFAs on infant development, though a limited
number of trials have been conducted in older children and young adults. Overall
the benefit of providing n-3 PUFAs to infants on behavioural outcomes appears to
be transient, though the majority of studies have only evaluated the effects of
relatively low amounts of DHA, and those providing more than 0.3% DHA in the
formula have been more effective. Longitudinal research suggests that maternal
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supplementation with n-3 PUFAs during gestation through to breastfeeding could
confer long-term behavioural benefits. The issue of cognitive enhancement via n-3
PUFA supplementation in normal children and healthy young adults has yet to be
adequately addressed, but initial research indicates that supplementation may result
in improved behavioural outcomes, though the area is lacking in well designed and
executed studies.
1.6 Rationale
The breadth of the above evidence regarding the physiological and behavioural
effects of n-3 PUFAs is vast. The available evidence suggests that these fatty acids,
which are incorporated into every single cell in the body and can only be acquired
via dietary sources, have a significant impact on physiology and behaviour when
adequate intake is not met. A direct causal relationship has been most clearly
demonstrated in animals; although the available evidence suggests that reduced
intake and/or tissue incorporation is associated with poorer health outcomes in
humans, establishing a causal link between n-3 PUFAs and behaviour has been
largely inconclusive. Overall, mixed findings have been published from studies in
the same areas possibly in part due to the varied methodologies employed; sample
size, and type, dose and duration of the interventions have differed greatly, and as a
result firm conclusions about the effects of n-3 PUFAs on behavioural outcomes
have been difficult to draw.
One particular population that has been largely overlooked is healthy individuals;
very few data exist regarding the effects of dietary n-3 PUFAs on cognitive function
and mood in both healthy children and adults. In the UK, as in many other Western
countries, intake of n-3 PUFAs is low; the last National Diet and Nutrition Survey
revealed that 74% of the adult population aged 19-64 years does not consume any
oily fish, the predominant source of the more biologically active long-chain n-3
PUFAs, DHA and EPA (Henderson et al., 2002). Given the above evidence
regarding both the fundamental nature of n-3 PUFAs and the adverse correlates of
low n-3 PUFA intake, evaluating the effects of n-3 PUFA supplements in otherwise
healthy individuals seems both logical and valid. Should supplementation in healthy
children and adults confer a benefit on behavioural outcomes, then these results
would not only be able to increase our knowledge of the functions of n-3 PUFAs, but
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could also be used to inform dietary advice. To this end, Chapters 2, 3 and 4 will
investigate the relationship between dietary n-3 PUFAs and cognitive function and
mood in healthy children (Chapter 2) and adults (Chapters, 3 and 4), with a view to
evaluate their efficacy for cognitive enhancement.
It is also clear from the research presented above that the functions of n-3 PUFAs in
the brain have been studied in great detail at the cellular level, but their effects on
brain physiology have yet to be investigated in humans. The studies described in
Chapters 5 and 6 specifically evaluate the effects of n-3 PUFAs on cerebral
hemodynamics, and Chapter 6 examines the effects of n-3 PUFAs on cerebral
hemodynamics and cognitive function in parallel, with a view to further unravel the
relationship between dietary n-3 PUFAs and behaviour. This thesis will therefore
address three general research questions:
 What is the nature of the relationship between dietary n-3 PUFAs and
behaviour in healthy individuals?
 Are n-3 PUFA supplements effective as a cognitive enhancer?
 What are the cerebral hemodynamic effects of dietary n-3 PUFAs?
The studies that comprise this thesis include the first investigation of the effects of
DHA on specific cognitive functions and mood in school-aged children; further
reports of the effects of n-3 PUFAs on cognitive and function in mood in healthy
adults using a novel approach comparing the effects of DHA-rich and EPA-rich fish
oil, and the first investigation of the effects of n-3 PUFAs on cerebral hemodynamics
in humans.
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CHAPTER 2. COGNITIVE AND MOOD EFFECTS OF 8 WEEKS’
SUPPLEMENTATION WITH 400 MG OR 1000 MG DHA IN HEALTHY CHILDREN
AGED 10-12 YEARS
2.1 Introduction
The polyunsaturated fatty acid DHA cannot be synthesised by the body and must be
acquired via the diet. Although all cell membranes in the body contain this fatty acid,
DHA is heavily concentrated in the membranes of selected tissues, namely
synaptosomes, retinal rod outer segments and sperm, indicating a specialised role
for DHA in these cells. Incorporation of DHA into the phospholipids of the cell
membrane bilayer has been shown to result in changes to some of the basic
properties of the membrane including increased membrane fluidity, permeability,
fusion and protein activity (see Section 1.4.1). More specifically to neural cell
membranes, adequate incorporation of DHA in this tissue has been shown to
support a wide range of processes including enzyme activity and ion channel
function, neurotransmission and gene expression (see Sections 1.4.1, 1.4.3, 1.4.4).
The DHA found in neural cell membranes amounts to 10-20% of total fatty acid
composition of the brain (McNamara and Carlson, 2006), a large proportion of which
is rapidly accrued during the third trimester (Clandinin et al., 1980b), although levels
have been shown to continually increase up to the age of 18 years (Carver et al.,
2001). Given that DHA appears to function at a fundamental level, it follows that
inadequate incorporation of DHA during development would have a negative impact
upon neurological functioning. Indeed, there is evidence to suggest that deficiencies
in dietary DHA can result in a number of peripheral and central nervous system
impairments. These include impairments to visual acuity, cognitive development and
other neurological functions (McNamara and Carlson, 2006). There is also emerging
evidence that lower levels of n-3 PUFAs (as measured by plasma or erythrocyte
concentrations) are associated with psychiatric and neurological disorders in adults
(Edwards et al., 1998, Assies et al., 2001, Conquer et al., 2000) and a cluster of
common, related childhood disorders including attention-deficit/hyperactivity
disorder and autism (Bell et al., 2000, Burgess et al., 2000, Schuchardt et al., 2009).
However, a number of intervention studies that assessed the behavioural effects of
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dietary supplementation with either EPA and/or DHA in children suffering from the
neurodevelopmental disorders mentioned above have been met with mixed results,
with some studies reporting a beneficial effect of treatment upon symptoms
(Richardson and Montgomery, 2005, Richardson and Puri, 2002, Stevens et al.,
2003), while others found no effect (Hamazaki and Hirayama, 2004, Voigt et al.,
2001), though differences in sample size, treatment formulation, time-on-treatment
and behavioural measures varied greatly between studies (see Section 1.5.2.2).
To date, the effects of DHA supplementation on cognitive function in normal healthy
volunteers has predominantly focused on supplementing the diets of infants with a
DHA-enriched formula. However the results from these trials have been mixed, with
less than half of the randomised controlled trials reporting a beneficial effect of
supplemented formula on visual, mental and psychomotor functions in full-term
infants (Fleith and Clandinin, 2005). At the time of this study’s inception, only one
intervention trial had evaluated the effects of an n-3 PUFA supplement in healthy
children. This study examined the effects of 3.6 g DHA + 0.84 g EPA per week for 3
months on the Picture Frustration task (a measure of aggression), plus the Hostility-
Aggression Questionnaire for Children, in 9 to 12 year old children (Itomura et al.,
2005). The results from this study were mixed, with the authors loosely concluding
that fatty acid nutrition may effect physical aggression in school-aged girls. Despite
this lack of empirical evidence, a number of UK schools had begun to trial schemes
where free fish oil or omega-3 supplements were given to pupils and their academic
achievement was monitored (“Fish oil study’s GCSE successes” 2006; “Pupils test
fish brain food pills” 2006), motivated by the promising and the much publicised
results from the ‘Oxford-Durham Trial’. In this study, the behaviour and reading and
spelling ability of children diagnosed with Developmental Coordination Disorder
receiving n-3 PUFAs for 3-6 months dramatically improved (Richardson and
Montgomery, 2005). These subsequent ‘bandwagon’ trials were hailed as a
resounding success, so much so that the Department for Education and Skills
commissioned a report with the Food Standards Agency to investigate whether all
children should receive omega-3 at school to bolster performance (Oakeshott,
2006). Unfortunately, these studies were poorly conducted, and none adhered to
double-blind or placebo-controlled protocols. Consequently, the effect of n-3 PUFA
supplementation in an unselected population of cognitively intact children remains to
be adequately investigated. The evidence that the putative benefits of n-3 PUFAs
will include direct modulation of behavioural parameters is also far from conclusive.
37
In this double-blind, randomised, placebo-controlled, parallel-groups, dose-ranging
study the effects of 8 weeks dietary supplementation with two separate doses of the
n-3 PUFA DHA on the cognitive performance and mood of 90 normally-developing
healthy children aged between 10 and 12 years were therefore assessed. A
comprehensive assessment of cognitive performance and subjective mood was
undertaken in the laboratory pre-breakfast, and at 1 hour and 3 hours following a
standard breakfast on the day before commencement of treatment and the last day
of a treatment regime.
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2.2 Materials and Methods
2.2.1 Design
A placebo-controlled, double-blind design was employed with participants randomly
assigned to one of three treatment groups (placebo, 400 mg DHA, 1000 mg DHA;
see Section 2.2.3). For the primary outcome measures, assessment (pre-breakfast,
3h post-dose; see Section 2.2.4.1) comprised a second, within subjects factor. Prior
to the start of the study a restricted randomisation (30 X 3 treatments) list matching
treatments to participant code numbers was computer generated. Participants were
assigned to the next available participant code and therefore corresponding
treatment at the end of their introductory visit to the laboratory.
2.2.2 Participants
Ninety male and female children aged 10 to 12 years, who were rated by
themselves and parents as being healthy, took part in the study. Participants were
recruited using publicity sent to local newspapers and schools in the Newcastle-
upon-Tyne area. They were not admitted to the study if any of the following criteria
were present: food allergies or intolerance, use of any prescription, illicit, herbal or
recreational drugs including alcohol and tobacco, use of dietary supplements or fish
oil within the preceding 3 months, diagnosis with ADHD, any medical disorder that
might potentially interfere with the participation in the testing sessions, consumption
of significant levels of fish prior to ( > twice per week) and during the study period.
Of the total cohort of 90 participants enrolled into the study one participant withdrew
(for non study-related reasons). A further participant’s data was removed due to
failure to take the treatments according to protocol. Eighty-eight participants
therefore contributed datasets to the per-protocol analyses (see Table 2.1 for
demographics). Due to two data capture errors only 86 participants provided a full
set of data for inclusion in the analysis of the Internet Battery assessments (1 hour
post-breakfast on Day –1 and Day 56).
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Following a blind data review, a small number of individuals’ scores on single
measures were excluded from the analysis due to failure to perform the task
correctly according to pre-defined criteria (e.g. performance on a task that was at
chance or consistent with use of a single button). Where the analysis for a specific
task has been based on a reduced data-set the total number of participants
contributing is reflected in Tables 2.2 and 2.3. The study was approved by the
Northumbria University School of Psychology and Sport Science Ethics Committee
and was carried out in accordance with the Declaration of Helsinki (1964). All
participants and their guardians gave written informed consent prior to their
inclusion in the study.
2.2.3 Treatments
The parents of each participant were given 4 bottles of treatment containing soft-gel
capsules (100 capsules per bottle). Two bottles were labelled for consumption in the
morning and 2 bottles were labelled for consumption in the evening. To avoid any
potential negative gastrointestinal effects of the treatment, two capsules were
consumed in the morning and three capsules in the evening, all under parental
supervision, with the parent signing a diary card twice daily to confirm consumption.
Active treatment capsules contained 500 mg DHASCO-S (Martek Biosciences,
Maryland, USA) representing 200 mg DHA (+ approx 4 mg EPA) with the remainder
being a commercially available vegetable oil. The placebo capsules contained 500
mg vegetable oil. The combination of morning and evening capsules corresponded
to a daily dose of: 0 mg DHA (placebo), 400 mg DHA (active capsules taken in the
morning), or 1000 mg DHA (active capsules taken both morning and evening).
The organisation, coding and labelling of the bottles containing capsules was
undertaken by a disinterested third party who had no other involvement in the study.
With the exception of individual code-break envelopes, which were kept by the
Table 2.1. Participant demographic details recorded at Baseline by condition.
Means ± SEM given where appropriate.
Placebo 400 mg DHA 1000 mg DHA
N (M/F) 12/18 17/9 15/15
Age 10.87 0.18 11.11 0.15 10.70 0.15
BMI 18.64 0.50 18.16 0.59 18.02 0.57
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safety officer for the trial (all of which remained unopened), the information matching
participant to treatment was not available to the research team until after the blind-
data review.
Reference to the treatment diary cards, parental reports and returned capsules
suggested that the compliance of all of the participants included in the data-analysis
was ≥ 80%. There were no serious adverse events related to taking the active
treatments. No participant withdrew from the study due to intolerance of their
treatment, and in general the study treatments were well tolerated and that minor
adverse events during the 8-week treatment period were equally distributed across
the placebo and active treatment conditions.
2.2.4 Cognitive and Mood Measures
2.2.4.1 Cognitive Drug Research (CDR) Battery
A tailored version of the Cognitive Drug Research battery (CDR Ltd, Goring-on-
Thames, UK) was used. The CDR computerised assessment battery has been used
in hundreds of European and North American drug trials, and has been shown to be
sensitive to acute cognitive improvements as well as impairments with a wide
variety of nutritional substances (e.g. Kennedy et al., 2006, Scholey et al., 1999,
Scholey and Kennedy, 2004). In the current study a tailored version of the CDR
battery was used that has previously been shown to be sensitive to dietary
manipulations in children (Wesnes et al., 2003, Ingwersen et al., 2007).
The selection of computer controlled tasks from the system is administered with
parallel forms of the tests being presented at each testing session. Presentation is
via VGA colour monitors and, with the exception of written word recall tests, all
responses are recorded via two-button (YES/NO) response boxes. All reaction
times were recorded in milliseconds. The entire selection of tasks took
approximately 20 minutes to complete, administered in the following order:
2.2.4.1.1 Word Presentation
Fifteen words, matched for frequency and concreteness, were presented in
sequence on the monitor for the participant to remember. Stimulus duration was 1
second, as was the inter-stimulus interval.
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2.2.4.1.2 Immediate Word Recall (short-term secondary memory)
The participant was allowed 60 seconds to write down as many of the words as
possible. The task was scored for number correct, and errors.
2.2.4.1.3 Picture Presentation
Twenty photographic images were presented sequentially on the monitor at the rate
of 1 every 3 seconds, with a stimulus duration of 1 second, for the participant to
remember.
2.2.4.1.4 Simple Reaction Time (psychomotor function/attention)
The participant was instructed to press the ‘YES’ response button with their
preferred hand as quickly as possible every time the word ‘YES’ was presented on
the monitor. Thirty stimuli were presented with an inter-stimulus interval that varied
randomly between 1 and 3.5 seconds. Reaction time was recorded.
2.2.4.1.5 Digit Vigilance Task (vigilance/attention)
A target digit was randomly selected and constantly displayed to the right of the
monitor screen. A series of digits was presented in the centre of the screen at the
rate of 80 per minute and the participant was required to press the ‘YES’ button as
quickly as possible every time the digit in the series matches the target digit. The
task lasted three minutes and there were 45 stimulus-target matches. Task
measures were accuracy (% correct), reaction time and number of false alarms.
2.2.4.1.6 Choice Reaction Time (selective attention)
Either the word ‘NO’ or the word ‘YES’ was presented on the monitor and the
participant was required to press the corresponding button as quickly as possible.
There were 30 trials, of which the stimulus word was chosen randomly with equal
probability, with a randomly varying inter-stimulus interval of between 1 and 3.5
seconds. Reaction time and accuracy (% correct) were recorded.
2.2.4.1.7 Spatial Working Memory
A pictorial representation of a house was presented on the screen with four of its
nine windows ‘lit up’ in white while the other windows were black. The participant
was instructed to memorise the position of the illuminated windows. In 36
subsequent presentations of the house, one of the windows was illuminated and the
participant decided whether or not this matched one of the illuminated windows in
the original presentation. The participant made their response by pressing the ‘YES’
or ‘NO’ response button as quickly as possible. Mean reaction time was measured,
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and accuracy of responses to both original and novel (distractor) stimuli were
recorded as percentages.
2.2.4.1.8 Numeric Working Memory
Five digits were presented sequentially for the participant to hold in memory. This
was followed by a series of 30 probe digits for each of which the participant decided
whether or not it had been in the original series and pressed the ‘YES’ or ‘NO’
response button as appropriate as quickly as possible. Mean reaction time, and
accuracy of responses to both original and novel (distractor) stimuli were recorded
as percentages.
2.2.4.1.9 Delayed Word Recall (secondary memory)
The participant was again given 60 seconds to write down as many of the words
presented previously as possible. The task was scored as number correct, and
errors.
2.2.4.1.10 Delayed Word Recognition (secondary memory)
The original 15 words plus 15 novel (distractor) words were presented one at a time
in a randomised order. For each word the participant indicated whether or not it was
included in the original list of words by pressing the ‘YES’ or ‘NO’ button as
appropriate and as quickly as possible. Mean reaction time and accuracy of
responses to both original and novel (distractor) stimuli were recorded as
percentages.
2.2.4.1.11 Delayed Picture Recognition (secondary memory)
The original 20 pictures plus 20 novel (distractor) pictures were presented one at a
time in a randomised order. For each picture participants indicated whether or not it
was recognised as being from the original series by pressing the ‘YES’ or ‘NO’
button as appropriate and as quickly as possible. Mean reaction times were
measured in msec, and accuracy of responses to both original and novel (distractor)
stimuli were recorded as percentages.
2.2.4.2 Internet Battery
The Internet Battery comprised a selection of tasks programmed in JAVA language.
Timing of the test battery and reaction times were made independently of the
computer’s internal timing, guaranteeing consistent presentation of tasks and
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accurate timing of responses. The battery has previously been shown to be
sensitive to dietary supplementation in children (Haskell et al., 2008). The
presentation of parallel versions of stimuli for each individual task was
counterbalanced across the assessments. All reaction times were recorded in
milliseconds. The battery was completed in approximately 15 minutes.
The battery included the following cognitive performance elements (cognitive
domain in brackets where appropriate) and visual analogue mood items:
2.2.4.2.1 Word Presentation
Fifteen words appropriate for the age range of the participants drawn from the
Economic and Social Research Council’s ‘Children’s Printed Word Database’
(Masterson et al., 2003) and matched for familiarity, concreteness, and frequency
were presented at the commencement of the battery. Stimulus duration was one
second, as was the inter-stimulus duration.
2.2.4.2.2 Picture Presentation
Twelve age appropriate line drawings of items (from: Snograss and Vanderwart
1980) were presented at the commencement of the battery. Stimulus duration was
one second, with a two second inter-stimulus duration.
2.2.4.2.3 Arrow Reaction Time Test (psychomotor performance/attention)
An arrow appeared on the screen pointing to the left or right. Participants responded
with a left or right arrow key press corresponding to the direction of the stimulus
arrow. Each of the 80 stimuli remained on screen until the key press was registered.
There was a randomly varying inter-stimulus interval of between 1 and 3 seconds.
Outcomes were accuracy (% correct) and reaction time.
2.2.4.2.4 Arrow Flanker Test (focused/selective attention)
Five symbols appeared on screen, with the centre symbol always being an arrow
pointing to the left or right. The task was to press the right or left arrow key
corresponding to the direction of the central arrow. The flanking pairs of symbols
could be squares, crosses, congruent arrows (pointing in the same direction), or
incongruent arrows (pointing in the opposite direction). Each of the 80 stimuli
remained on screen until the key press was registered. There was a randomly
varying inter-stimulus interval of between 1 and 3 seconds. Outcomes were
accuracy (% correct) and reaction time.
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2.2.4.2.5 Paired Associate Learning (spatial working memory)
Two shape symbols (e.g. square, circle, triangle etc) were displayed on the screen
side by side for three seconds. Each of the two symbols was then repeatedly
presented alone in random order in the centre of the screen for a total of 10
repetitions. The participant had to indicate if the symbol was originally seen on the
left or right with a corresponding key press. A second pair of symbols was then
presented and the four symbols that were contained in the two pairs were
repeatedly presented (10 repetitions), with the participant once again indicating
whether each symbol was originally presented on the left or right. This was repeated
a further two times until responses were being made to one of eight symbols.
Outcomes include the number of errors, and reaction time.
2.2.4.2.6 Sentence Verification (semantic memory retrieval)
Fifty short sentences appeared on screen that were either true (e.g. ‘Bicycles have
wheels’) or false (e.g. ‘Tomatoes have wings’). Participants responded ‘true’ or
‘false’ via a key-press as quickly as possible. Outcomes included accuracy (%
correct) and reaction time.
2.2.4.2.7 Delayed Word Recognition (secondary memory)
Word recognition was tested by the presentation of the 15 words presented at the
commencement of the battery randomly mixed with 15 novel (distractor) words.
Participants responded either ‘yes’ or ‘no’ by key press to indicate whether the word
had previously been presented. Outcomes included accuracy (% correct), and
reaction time.
2.2.4.2.8 Delayed Picture Recognition (secondary memory)
Picture recognition was tested by the representation of the 12 drawings presented
at commencement of the battery plus 12 novel (distractor) drawings presented in
random order. Participants responded either ‘yes’ or ‘no’ by key press to indicate
whether the picture had previously been presented. Outcomes included accuracy
(% correct) and reaction time.
2.2.4.2.9 Mood and Fatigue Visual Analogue Scales (mood)
After completion of the cognitive tasks, participants were then asked to complete a
computer-adapted version of the self-report visual analogue scales (“relaxed”,
“alert”, “jittery”, “tired”, “tense”, “headache”, “overall mood” that have been used
extensively in previous research assessing dietary manipulations e.g. (Haskell et al.,
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2005, Rogers et al., 2003). The scale was completed by using the computer mouse
to place a cross on a line that represented a continuum between ‘not at all’ and
‘extremely’ for each of the seven mood items and a further three; “mental fatigue”
(‘not at all’ to ‘extremely’) and the bi-polar items ‘Do you normally feel’ “happy/sad”
and “stressed/calm”.
2.2.4 Procedure
2.2.4.1 Primary assessment
Participants attended the laboratory on three separate occasions (Training day, the
day before treatment commenced [Day -1] and the last day of treatment [Day 56]).
Each visit took place at the weekend and the first two visits (Training and Day -1)
were seven days apart. Testing took place in a dedicated testing facility in the
Cognition and Communication Research Centre at Northumbria University with
participants visually isolated from each other during testing.
The Training day visit comprised: obtaining informed consent; training on the CDR
battery, Internet Battery and questionnaire measures; health screening; collection of
demographic and breakfast consumption data; and random allocation to treatment
condition.
Following the Training day participants attended the laboratory at 8 am on the day
before commencement of treatment (Day -1) and the last (Day 56) day of the 8-
week treatment regimen. On Day -1, parents were given the bottles of study
treatment and the diary cards in which they were instructed to record the intake of
their child’s capsules along with any general health observations. On both testing
days, on arrival participants undertook an initial pre-breakfast assessment
comprising the CDR battery. They then consumed a standard breakfast on each
occasion, chosen to correspond most closely to their habitually consumed breakfast
from a selection provided in the laboratory. One hour after breakfast (9:45 am)
participants completed the Internet Battery and a further 2 hours later (11:45 am)
undertook a second parallel version CDR assessment (see Figure 2.1).
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breakfast) formed the within subjects factor. These analyses were conducted using
Minitab 15 Statistical Software (Minitab Inc., Pennsylvania, USA). The Internet
Battery data were analysed by one-way ANCOVA (treatment group) of the data
collected on Day 56, with the data collected on Day -1 as the covariate, and
analysed using SPSS statistical software for Windows version 15.0.1 (SPSS Inc.,
Chicago, IL).
A priori planned comparisons were made between placebo and both the active
treatments (400 mg DHA, 1000 mg DHA) utilising t tests with the mean squares
error from the ANCOVA as an error term and adjusted means (Keppel, 1991). To
ensure the overall protection level against Type I errors, comparisons were strictly
planned prior to the commencement of the study and only those comparisons
associated with a significant main effect or interaction on the omnibus ANCOVA
were calculated.
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2.3 Results
2.3.1 CDR battery
Analysis of covariance of data from the pre-breakfast and 3 hours post-breakfast
assessments on Day 56 did not reveal any significant effects of treatment or any
interactions between condition and assessment. The performance data on this
battery for both study days can be found in Table 2.2.
2.3.2 Internet Battery
Analysis of covariance of data on the Internet Battery outcomes on Day 56 (with
performance on Day -1 as the covariate) revealed a single main effect of treatment
on the visual analogue measure ‘alert’ [ F(2,82) = 3.88; p = 0.025 ]. Planned
comparisons revealed that ratings of alert were not significantly different from
placebo in either the 400 mg condition [ t(82) = 0.89; p = 0.375] or the 1000 mg
condition [ t(82) = 1.90; p = 0.061 ].
Mean performance outcomes from the cognitive measures can be found in Table
2.3 and mean scores on the mood questionnaire items can be found in Table 2.4.
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Table 2.2. CDR battery outcomes for placebo, 400 mg and 1000 mg DHA treatment groups on Day -1 and Day 56 of the study at
baseline and 3 hours post-breakfast. Means and SEM are presented with F and p values from the primary ANCOVA.
Day -1 Assessment Day 56 Assessment
Pre-breakfast 3 h post-breakfast Pre-dose 3 h post-dose
n Mean SEM Mean SEM n Mean SEM Mean SEM F p
Immediate
Word Recall
(no. correct)
Placebo 5.10 0.30 4.50 0.39 4.73 0.31 4.30 0.31
400 mg 85 4.73 0.27 4.12 0.32 85 4.77 0.34 3.85 0.35 0.16 0.853
1000 mg 4.69 0.37 4.52 0.30 4.76 0.37 4.34 0.34
Simple RT
Placebo 339.04 12.03 387.61 16.28 373.29 14.82 395.79 16.19
400 mg 87 352.47 11.33 392.93 17.32 87 389.37 16.64 413.41 19.72 0.54 0.583
1000 mg 345.82 8.97 410.93 20.32 371.68 10.34 409.59 17.62
Digit Vigilance
(% accuracy)
Placebo 80.79 3.19 75.40 3.45 80.08 2.39 79.05 2.59
400 mg 82 74.58 3.37 74.49 3.44 82 76.44 4.06 76.27 3.38 0.21 0.810
1000 mg 76.78 2.78 73.26 3.20 76.63 2.32 75.86 2.85
Digit Vigilance
(RT)
Placebo 502.40 11.63 534.60 11.68 510.58 9.84 523.30 11.01
400 mg 519.27 9.12 532.82 10.49 511.27 9.71 527.23 9.21 0.95 0.389
1000 mg 504.36 8.34 529.66 10.22 514.84 7.75 531.81 9.47
Digit Vigilance
(false alarms)
Placebo 4.25 0.50 5.39 0.86 3.68 0.47 7.57 2.01
400 mg 2.68 0.48 4.88 1.03 2.92 0.46 4.68 0.86 0.90 0.408
1000 mg 3.79 0.58 5.76 0.83 4.31 0.59 5.79 0.93
Choice RT
(% accuracy)
Placebo 91.11 1.22 89.11 1.39 90.78 1.37 88.67 1.36
400 mg 87 93.70 0.95 89.75 1.60 87 91.61 1.17 89.88 1.40 0.17 0.847
1000 mg 91.00 1.21 90.33 1.26 90.22 1.32 89.00 1.26
Choice RT
Placebo 552.49 20.04 561.37 19.72 536.78 14.63 595.28 28.21
400 mg 547.39 18.54 562.06 22.69 564.80 20.95 571.62 22.65 0.17 0.840
1000 mg 552.37 16.57 557.30 17.80 555.53 20.23 594.11 21.58
Spatial
Memory
(% accuracy)
Placebo 82.76 1.62 89.27 0.90 91.27 2.22 89.40 2.22
400 mg 86 85.45 2.04 86.47 1.48 86 89.80 1.79 91.45 1.27 0.01 0.986
1000 mg 87.50 1.89 88.79 0.79 91.92 1.90 89.72 1.71
Spatial
Memory
(RT)
Placebo 884.02 32.38 790.41 37.76 848.09 33.70 791.90 39.71
400 mg 948.92 48.91 798.27 48.62 917.23 36.39 775.41 31.46 0.90 0.409
1000 mg 847.64 33.99 757.22 35.30 862.03 33.26 824.05 43.06
Numeric
Working
Memory
(% accuracy)
Placebo 83.33 1.64 81.55 1.40 87.33 2.48 88.33 2.26
400 mg 88 80.95 1.75 73.81 2.55 88 86.55 2.32 89.29 2.05 0.12 0.890
1000 mg 84.67 1.41 70.22 2.03 87.33 2.64 88.22 1.60
Numeric
Working
Memory(RT)
Placebo 923.44 49.52 933.38 48.90 872.11 43.96 868.36 31.33
400 mg 977.83 52.36 900.57 67.37 889.16 46.93 875.15 49.08 0.35 0.703
1000 mg 894.45 34.39 581.67 28.48 868.07 35.78 884.98 41.51
Delayed Word
Recall
(no. correct)
Placebo 3.90 0.29 2.97 0.41 4.03 0.33 3.00 0.31
400 mg 86 3.52 0.38 2.15 0.30 86 3.26 0.27 2.19 0.26 2.65 0.074
1000 mg 3.48 0.34 2.03 0.27 3.83 0.36 2.86 0.41
Word
Recognition
(% accuracy)
Placebo 76.11 1.88 65.44 2.12 74.11 2.08 66.56 2.08
400 mg 88 74.29 2.66 68.57 2.14 88 74.76 2.01 68.57 2.60 0.65 0.521
1000 mg 72.67 2.18 64.67 2.24 74.67 1.92 68.11 2.44
Word
Recognition
(RT)
Placebo 941.92 32.02 843.45 26.31 893.21 32.11 853.77 36.55
400 mg 994.15 49.93 892.77 38.74 907.58 36.76 818.93 37.68 2.79 0.064
1000 mg 921.60 30.80 846.91 43.94 951.16 41.22 868.09 47.35
50
Day -1 Assessment Day 56 Assessment
Pre-breakfast 3 h post-breakfast Pre-dose 3 h post-dose
n Mean SEM Mean SEM n Mean SEM Mean SEM F p
Picture
Recognition
(% accuracy)
Placebo 85.93 1.60 82.50 2.04 83.58 1.85 78.75 2.02
400 mg 82.41 2.04 78.13 1.86 82.14 2.21 76.88 2.77 0.32 0.596
1000 mg 87.33 1.68 81.67 1.80 84.67 1.45 76.17 2.33
Picture
Recognition
(RT)
Placebo 1033.56 26.26 65.00 27.91 953.59 29.49 932.98 32.41
400 mg 1068.96 45.06 56.25 34.60 1032.06 46.36 932.28 43.27 2.04 0.133
1000 mg 1044.80 35.25 63.33 28.33 1030.60 31.35 967.66 38.86
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Table 2.3. Internet Battery performance outcomes for placebo, 400 mg and 1000 mg DHA on Day -1 and
Day 56, recorded at 1 hour post-breakfast (Day -1) or 1 hour post dose (Day 56). Means are presented
with F and p values from the primary ANCOVA.
Day -1 Day 56
n Mean SEM Mean SEM F p
Arrows
(RT)
Placebo 550.73 22.85 502.93 14.49
400 mg 86 539.37 17.32 535.00 18.47 2.52 0.086
1000 mg 527.38 22.27 508.93 10.30
Arrows
(% accuracy)
Placebo 92.97 0.93 94.49 0.81
400 mg 92.47 1.14 91.61 1.60 2.83 0.065
1000 mg 93.31 1.25 91.53 1.27
Arrow Flankers
(RT)
Placebo 662.72 25.63 632.24 19.84
400 mg 85 667.26 18.43 644.33 18.34 0.34 0.716
1000 mg 652.48 18.91 641.48 20.93
Arrow Flankers
(% accuracy)
Placebo 94.29 0.95 92.58 1.13
400 mg 95.21 1.13 95.21 1.00 1.66 0.197
1000 mg 93.25 1.45 93.92 0.91
Paired Associates
(RT)
Placebo 778.07 31.38 772.97 24.43
400 mg 85 831.19 36.30 786.81 26.84 1.32 0.274
1000 mg 760.90 27.46 799.83 45.64
Paired Associates
(% accuracy)
Placebo 3.40 0.48 3.67 0.56
400 mg 2.15 0.34 3.19 0.68 0.04 0.960
1000 mg 2.93 0.63 3.59 0.35
Sentence Verification
(RT)
Placebo 2400.10 171.39 2012.30 135.85
400 mg 85 2238.12 107.12 1846.12 95.14 0.35 0.707
1000 mg 2292.62 107.30 1878.31 87.01
Sentence Verification
(% accuracy)
Placebo 85.47 1.78 86.27 2.08
400 mg 88.08 1.74 87.54 2.11 0.23 0.794
1000 mg 89.17 1.59 88.55 1.84
Picture Recognition
(RT)
Placebo 844.10 22.99 766.27 21.09
400 mg 85 854.78 29.35 798.33 25.87 2.07 0.133
1000 mg 871.24 22.34 845.52 30.50
Picture Recognition
(% accuracy)
Placebo 86.59 1.52 84.92 1.81
400 mg 86.08 1.64 83.61 1.78 0.24 0.785
1000 mg 85.68 1.88 82.79 2.16
Word Recognition
(RT)
Placebo 845.00 26.36 780.63 38.42
400 mg 83 889.33 57.17 780.67 24.69 0.71 0.494
1000 mg 865.45 33.99 837.24 49.31
Word Recognition
(% accuracy)
Placebo 78.91 1.74 77.48 1.62
400 mg 79.06 1.47 80.60 1.84 1.18 0.312
1000 mg 77.39 1.43 76.92 1.58
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Table 2.4. Internet Battery mood questionnaire items for placebo, 400 mg and 1000 mg DHA on Day -
1 and Day 56, recorded at 1 hour post-breakfast (Day -1) or 1 hour post dose (Day 56). N = 86,
means and SEM are presented with the F and p values from the primary ANCOVA. All data are in
mm.
Day -1 Day 56
Mean SEM Mean SEM F p
Relaxed
Placebo 68.97 2.95 65.13 4.05
400 mg 54.74 4.65 68.59 3.90 2.67 0.075
1000 mg 63.07 4.40 72.72 3.72
Alert
Placebo 49.50 4.82 56.60 4.90
400 mg 57.81 4.14 66.78 3.36 3.88 0.025
1000 mg 51.52 4.47 47.10 5.83
Jittery
Placebo 27.87 4.41 20.63 4.94
400 mg 32.74 3.99 28.44 4.17 2.00 0.142
1000 mg 28.38 4.64 15.48 3.52
Tired
Placebo 55.57 5.00 42.30 5.25
400 mg 61.48 3.64 40.81 4.66 2.95 0.058
1000 mg 59.24 5.89 53.17 5.55
Tense
Placebo 22.03 4.01 18.03 4.00
400 mg 31.07 3.50 22.19 4.46 0.42 0.657
1000 mg 26.03 4.09 16.14 3.83
Headache
Placebo 13.27 4.74 5.67 2.31
400 mg 16.07 4.36 14.19 4.34 2.58 0.082
1000 mg 8.24 2.98 8.14 3.26
Overall Mood
Placebo 75.73 4.11 80.33 2.83
400 mg 72.15 4.17 77.22 3.05 0.57 0.567
1000 mg 74.52 3.47 82.34 3.46
Mentally Fatigued
Placebo 37.17 3.28 27.40 4.29
400 mg 36.44 4.28 32.56 5.25 1.14 0.326
1000 mg 37.72 4.87 23.45 4.96
Happy/Sad
Placebo 14.93 2.81 12.20 2.22
400 mg 20.26 2.88 17.67 2.96 0.37 0.690
1000 mg 17.97 3.08 14.55 3.03
Stressed/Calm
Placebo 71.53 3.31 78.30 3.77
400 mg 66.56 3.85 75.30 3.40 0.03 0.975
1000 mg 78.17 3.34 80.45 3.36
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2.4 Discussion
The results of the current study found that treatment with either 400 mg or 1000 mg
DHA per day for 8 weeks did not have any meaningful effect on the cognitive
performance or mood of healthy, 10 to 12 year old children. The entire analysis of
data recorded on Day 56 generated a single significant main effect of treatment on
participants’ self-reported rating of alertness. The planned comparisons, however,
failed to detect a difference between ratings from the placebo and either of the
active treatment conditions. In addition, the study included a second post-breakfast
assessment (3 h) using parallel versions of CDR battery in order to explore any
potential effect of the treatments during the natural declines in cognitive
performance that have been observed previously (Haskell et al., 2008, Wesnes et
al., 2003, Ingwersen et al., 2007), however no treatment x assessment interactions
were detected.
The above findings are consistent with other studies that have also not detected an
effect of n-3 PUFA supplements on cognitive performance outcomes in similar
samples. For example, the report from a large multi-centre randomised trial found
no effect of supplementation with 400 mg/d DHA for 4 months in 175 preschool
children aged 4 years, although levels of capillary DHA were found to be positively
associated with performance on the Peabody Picture Vocabulary Test, a test of
listening comprehension and vocabulary acquisition (Ryan and Nelson, 2008).
Similarly, another study did not report any benefits of a 12-month fish oil intervention
(88 mg DHA + 22 mg EPA) on measures of general intelligence, verbal learning and
visual attention in children aged 6-10 years, despite the fact that the intervention
successfully increased participants’ plasma n-3 PUFA concentrations, compared to
placebo (Osendarp et al., 2007). In fact, only one of the three published trials in this
population has actually reported a benefit of n-3 PUFAs on cognitive performance
outcomes. Dalton et al. (2009) revealed a beneficial effect of a daily fish flour spread
(providing 335 mg ALA + 82 mg EPA + 192 mg DHA) on episodic memory (Hopkins
Verbal Learning Recognition and Discrimination) and spelling tasks following a 6-
month intervention in children aged 7-9 years, compared to placebo. However,
given that this study followed a single-blind protocol, along with the null findings
reported by the present study and the other published trials described above, does
not provide adequate evidence to support n-3 PUFA supplementation for cognitive
enhancement in healthy, normally developing children.
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Turning back to the evidence provided by the present study, it would be premature
to conclude that there is no evidence of efficacy for n-3 PUFAs on cognitive function
and mood without first considering several methodological and cohort related
factors that might have influenced the pattern of results. The first concerns the
length of the treatment intervention. The previous behavioural studies in healthy
human participants have adopted treatment regimens of 35 days (Fontani et al.,
2005, Antypa et al., 2009) and three months or longer (e.g. Itomura et al., 2005,
Dalton et al., 2009, Osendarp et al., 2007). However, given that the results across
these studies are less than clear, they provide little guidance on this issue in
themselves. Reference to animal models suggests that 8 weeks supplementation
with DHA is sufficient to replete brain levels in n-3 PUFA deprived rats (e.g.
Moriguchi, Loewke et al. 2001) which has been shown to be accompanied by a
simultaneous recovery of behavioural performance (Moriguchi and Salem, 2003).
Similarly, cerebral DHA levels in deficient rhesus monkeys were attenuated rapidly,
with a doubling of levels within one week, and with total repletion being observed for
individuals within 6 to 12 week of commencing supplementation with fish oil (Connor
et al., 1990). The evidence provided by these studies suggests that whilst the 8-
week treatment regimen employed here would be sufficient for alterations in brain
composition to occur, the possibility still remains that this period underestimated the
time required for the effects of supplementation to be manifested in behavioural
modification.
The nature of the cohort of children is another consideration. The choice of a cross-
section of normal, healthy children aged between 10 and 12 years, with a single
dietary requirement of low consumption of fish, was made on the basis that this age
band is suitable for the type of sophisticated cognitive testing employed and also so
that the results could be generalised to other normally developing children, given
the lack of data available for this age group at the time of this study’s inception.
Firstly it should be noted that both the CDR battery (Wesnes et al., 2003, Ingwersen
et al., 2007) and the Internet Battery (Haskell et al., 2008) have previously been
shown to be sensitive to dietary manipulations in cohorts of a similar age to those
assessed here, so the null findings are probably not a result of the cognitive testing
employed. Therefore one possibility is that the beneficial effects of DHA on cognitive
function, should they exist, might only be seen if supplementation occurs at a
putatively more developmentally sensitive period in terms of brain maturation, for
instance the last pre-natal trimester or the early postnatal period (Clandinin et al.,
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1980b, Clandinin et al., 1980a, Dunstan et al., 2008, Helland et al., 2008, Hibbeln et
al., 2007). Considering that the other studies in this area (Dalton et al., 2009,
Osendarp et al., 2007, Ryan and Nelson, 2008) have also failed to provide
adequate evidence in support of n-3 PUFAs for cognitive enhancement in healthy
children, suggests instead that effects of n-3 PUFA supplementation are unlikely to
be seen in healthy children that do not exhibit any neurodevelopmental abnormality.
It is interesting, however, that the only study to report a benefit of n-3 PUFAs on
cognitive function in children also states (from anecdotal reports) that the study
population regularly consumed very little to no fish (Dalton et al., 2009), which also
raises the possibility that a benefit of n-3 PUFA supplementation may only be
observed in children with low n-3 status, a possibility that requires further
investigation.
A final consideration is the choice of a predominantly DHA (+ ~2% EPA)
supplement. Whilst the beneficial effects of DHA on cell membrane fluidity in the
brain may be important, it is also possible that the cellular effects also attributed to
EPA or its eicosanoid derivatives, including, for instance, the modulation of ion
channels (Jeng et al., 2009), phospholipases (Bell et al., 2004) and gene expression
(Salvati et al., 2008) may also be behaviourally relevant. This suggestion is
supported by evidence from Ryan and Nelson (2008) who also found no
behavioural effects of 400 mg DHA in healthy children, even though the treatment
period was longer than the present study, at 3 months. Interestingly, Voigt et al.
(2001) and Hamazaki and Hirayama (2004) did not find any effect of DHA
administered in isolation on symptoms in children with ADHD, compared with
studies that have reported a benefit of n-3 PUFAs who administered a mixture of
both DHA and EPA (Richardson and Montgomery, 2005, Richardson and Puri,
2002, Stevens et al., 2003). Even so, the current available data do not provide
sufficient evidence to support or refute the choice of either DHA or EPA or even the
relative and overall quantity of either n-3 PUFA in investigations of their effects on
behaviour. It is hoped that continued research in the area will elucidate this issue
further.
In conclusion therefore, the results presented here suggest that there is no evidence
of any behavioural benefit of DHA supplementation in a cohort of cognitively intact
schoolchildren. This challenges the popularly held, but unsubstantiated, notion that
n-3 PUFA supplements will improve brain function and thereby cognitive
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performance. The potential for enhancement following similar treatments requires
substantial further research.
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CHAPTER 3. THE RELATIONSHIP BETWEEN SERUM PUFAs AND COGNITIVE
FUNCTION AND MOOD IN HEALTHY ADULTS (18-35 YEARS)
3.1 Introduction
A number of studies have linked reduced dietary intake of n-3 PUFAs and/or low n-3
PUFA status (as indicated by low plasma or erythrocyte concentrations) to a wide
range of negative physical and metal health outcomes including but not limited to
cardiovascular disease (Mori and Woodman, 2006), immune disorders (Calder,
2007), ADHD and related neurodevelopmental disorders (Richardson, 2006),
depression (Freeman, 2006), Alzheimer’s disease (Morris et al., 2003) and
schizophrenia (Assies et al., 2001). It has been suggested that the rise in incidence
of these poor health outcomes is directly related to falling consumption of n-3 PUFA
rich oily fish, typical of a ‘Western’ diet (Hibbeln et al., 2006, Simopoulos, 2000).
Much less attention has been given, however, to the study of n-3 PUFAs and
specific cognitive functions, and only a handful of studies, all conducted in older
adults (60+ years), have examined this relationship. A large population-based study
revealed that higher concentrations of n-3 PUFAs in erythrocytes were associated
with overall reduced risk of cognitive decline (Heude et al., 2003), and in another
study higher baseline plasma n-3 concentrations predicted less decline over 3 years
on measures of sensorimotor and complex speed but not memory, information-
processing speed or word fluency, though a cross-sectional analysis did not reveal
any significant associations between n-3 PUFAs and performance on any of the
outcomes at baseline (Dullemeijer et al., 2007). Similarly, estimated intake of
DHA+EPA (from a food frequency questionnaire) was inversely associated with
information processing speed in participants aged 45-70 years, but no associations
were detected with memory, cognitive flexibility or overall cognitive function (Kalmijn
et al., 2004a). Another study reported an association between higher proportions of
plasma n-3 PUFAs and reduced decline in verbal fluency, but no associations were
detected for memory or psychomotor speed (Beydoun et al., 2007). Together these
studies suggest that n-3 PUFA status may be associated with reduced risk for
cognitive decline in the elderly and that this relationship may be specific to certain
tasks rather than global cognitive function, though there is a degree of variation in
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the reported findings. Whether cognitive decline can be attenuated via n-3 PUFA
supplementation is the aim of a number of currently on-going large-scale research
projects (Dangour et al., 2006, Gillette, 2009, Martek, 2006).
As regards evidence provided by supplementation studies, only a limited number of
studies in children have measured the relationship between fatty acid status and
cognitive function. Dalton et al. (2009) revealed that concentrations of DHA and total
n-3 PUFAs in erythrocyte phosphatidylethanolamine were positively associated with
performance on a verbal learning task, and the ratio of total n-6:n-3 PUFAs was
inversely associated with the same outcomes. No significant associations were
detected regarding reading or spelling. Similarly, Ryan and Nelson (2008) revealed
that capillary DHA was positively associated with scores on the Peabody Picture
Learning Task, though no associations were detected between levels of DHA and
performance on any other task (Day-Night Stroop task, Sustained Attention,
Continuous Performance Task), again suggesting that peripheral measures of n-3
PUFA status are only associated with certain tasks. To date, no study has examined
this relationship in healthy adults, though a limited number of trials have aimed to
investigate the effects of n-3 PUFA supplementation on cognitive function. The
evidence from intervention trials in healthy adults provides mixed results regarding
the efficacy of n-3 PUFAs, with a single study being interpreted as suggesting
benefits of supplementation (Fontani et al., 2005), and three others that do not
(Rogers et al., 2008, Hamazaki et al., 1996, Antypa et al., 2009), although all these
studies varied widely in terms of sample, treatment formulation and duration, and
outcome measures.
As regards mood and mood disorders, n-3 PUFAs have also been implicated in
their aetiology and/or treatment, with the bulk of research predominantly focusing on
depression. In the USA and other developed nations decreased n-3 PUFA intake
due to falling oily fish consumption has coincided with increased incidence of
depression over the last century (Hibbeln and Salem, 1995) and globally fish
consumption is inversely related to the reporting of major depression (Hibbeln,
1998). Similarly, studies that have analysed the fatty acid content of phospholipids
in serum/plasma, erythrocyte or adipose tissue have found correlations between
lower levels of omega-3 fatty acids and depression in patients (Edwards et al.,
1998) as well as community-dwelling elderly individuals (Tiemeier et al., 2003,
Mamalakis et al., 2006a) and adolescents (Mamalakis et al., 2006b). There is some
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indication that the ratio of AA:EPA may be an important factor with higher ratios
being associated with severity of depression (Adams et al., 1996) or the likelihood of
developing depression following myocardial infarction (Schins et al., 2007). Lowered
DHA and total n-3 PUFAs may also predict the occurrence of post-partum
depression (De Vriese et al., 2003) with just a 1% increase in plasma DHA being
associated with a 59% reduction in the reporting of depression in mothers (Makrides
et al., 2003). However, a significant relationship between n-3 PUFA status and
depressed affect has not been universally reported, with one study finding no
association between scores on the depression scale of the Depression, Anxiety and
Stress Scale (DASS) and plasma concentrations of EPA, DHA or both in
combination with the authors suggesting that there is no association between n-3
PUFA status and depressive symptoms in mild to moderately depressed and
otherwise healthy adults (Rogers et al., 2008).
Thus it remains unknown whether supplementation with n-3 PUFAs can improve
cognitive function and mood in cognitively intact populations, as to date this has
only been examined in a limited number of studies. Further to this, it still remains to
be established whether a relationship exists between peripheral fatty acid status—
known to be reflective of dietary n-3 PUFA intake—and cognitive function in healthy
adults. The current study therefore aimed to address this issue by exploring the
relationship between serum polyunsaturated fatty acids and specific cognitive
performance in an unselected population of healthy adults. To this end, participants
completed a range of cognitive tasks evaluating performance across the domains of
attention, memory and executive function. Self-report mood assessments were
included as secondary measures.
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3.2 Materials and Methods
3.2.1 Design
A cross-sectional design was employed. Serum concentrations (% total fatty acid
methyl esters, FAME) of DHA, EPA, total n-3 PUFAs (ALA+DHA+EPA; serum
concentration data for docosapentaenoic acid were not available) were the
independent variables used to assess the relationship between n-3 PUFAs and
cognitive function and mood. In addition, as previous research suggests that the
ratio of AA:EPA may be important when considering cognitive function (e.g. Fontani
et al., 2005, Heude et al., 2003), this relationship along with serum concentrations of
AA were also examined.
3.2.2 Participants
Two-hundred and thirty-nine males and females aged 18-35 years were recruited
via posters and emails sent to university staff and students. All volunteers were
either students attending Northumbria University or were university graduates living
in Newcastle-upon-Tyne and the surrounding area. Participants signed a declaration
stating that they were in good health and that they were a non-smoker, free from
prescription, herbal, illicit or recreational drugs (females taking the contraceptive pill
were included) and a native English speaker. Data from participants whose BMI was
recorded as 30 or more were excluded from the analysis (n = 20), as it was decided
that individuals classed as clinically obese could not be considered in good health.
One-hundred and nine participants were also enrolled in the study described in
Chapter 4.
The study was approved by the Northumbria University School of Psychology and
Sport Science Ethics Committee and was carried out in accordance with the
Declaration of Helsinki (1964). All participants gave written informed consent prior to
their inclusion in the study.
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3.2.3 Assessment of cognitive performance
3.2.3.1 COMPASS
Performance was assessed using the COMPASS (Computerised Mental
Performance Assessment) system, a piece of computer software that is used to
generate randomised parallel versions of cognitive task batteries. For the present
study, COMPASS presented a battery of standard cognitive tasks in the same order
as outlined below. All presentations were made via a laptop computer with the
exception of the Word Recall and Verbal Fluency tasks, where participants used
pen and paper to make their responses. All reaction times were measured in
milliseconds.
3.2.3.1.1 Word Presentation
A unique set of fifteen words is presented. Words were selected at random from a
large bank of words derived from the MRC Psycholinguistic Database and matched
for word length, frequency, familiarity and concreteness. Stimulus duration was one
second, as was the inter-stimulus duration.
3.2.3.1.2 Immediate Word Recall (episodic memory)
The participant was allowed 60 seconds to write down as many of the words as
possible. The task was scored for number correct, and errors.
3.2.3.1.3 Picture Presentation
Fifteen black-and-white photographic images of objects and outdoor and indoor
scenes were presented sequentially on screen for the participant to remember at
the rate of 1 every 3 seconds, with a stimulus duration of one second. The same set
of fifteen pictures was presented to each participant in a random order.
3.2.3.1.4 Face Presentation
A set of twelve passport-style photographic images of people were presented
sequentially in a random order to participants. A first and last name was assigned to
each photograph and presented on the screen underneath the person’s face.
Stimulus duration was one second, with a 3-second inter-stimulus duration.
3.2.3.1.5 Simple Reaction Time (psychomotor performance/attention)
The participant was instructed to press the ‘space bar’ on the laptop keyboard as
quickly as possible every time an upwards pointing arrow appeared on screen. Fifty
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stimuli were presented with an inter-stimulus duration that varied randomly between
1 and 3.5 seconds. Mean reaction time was recorded.
3.2.3.1.6 Choice Reaction Time (psychomotor performance/attention)
An arrow appeared on the screen pointing to the left or to the right. Participants
responded with a left or right key press corresponding to the direction of the arrow.
There was a randomly varying inter-stimulus interval of between 1 and 3 seconds
for a total of fifty stimuli. Accuracy (% correct) and mean reaction time were
recorded.
3.2.3.1.7 Four Choice Reaction Time (psychomotor performance/attention)
A visual representation of the four direction arrow keys of a standard keyboard was
presented on screen. The arrows ‘lit up’ at random on screen until the
corresponding key press was made. In all, each arrow was the target stimulus 12
times, forming a total of 48 stimuli for this task in all. Accuracy and mean reaction
time were recorded.
3.2.3.1.8 Stroop Task (attention/response inhibition)
A computerised version of the Stroop task (Stroop, 1992) was created. Words
describing colours (GREEN, BLUE, RED, YELLOW) were randomly presented in
incongruently coloured text (e.g. GREEN was presented in blue text etc.). For each
of the fifty stimulus presentations, participants were instructed to use the computer
mouse and cursor to click the colour box located on the right side of the screen that
matched the colour of the text the word was presented in. Accuracy and mean
reaction time were recorded.
3.2.3.1.9 Verbal Fluency(executive function/semantic memory)
Participants were presented with a letter on screen and were given 60 seconds to
write down as many words as they could beginning with that letter. There were 3
separate trials; the letters ‘F’, ‘A’ and ‘S’ were the targets. An overall ‘Verbal
Fluency’ score is achieved by summing the number of permitted words given in
each trial.
3.2.3.1.10 Numeric Working Memory
Five random digits from 1-9 were presented sequentially for the participant to hold in
memory. This was followed by a series of 30 probe digits (15 targets and 15
distractors) for each of which the participant indicated whether or not it had been in
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the original series by a simple key press. The task consisted of 3 separate trials.
Accuracy and mean reaction time were recorded.
3.2.3.1.11 Alphabetic Working Memory
This task was identical to Numeric Working Memory, the only difference being that
the stimuli were letters.
3.2.3.1.12 Corsi Blocks Task (spatial working memory)
In this task nine identical blue squares appeared on screen in non-overlapping
random positions. A set number of blocks changed colour from blue to red in a
randomly generated sequence. The cursor was locked in position until the entire
sequence had been presented, at which point the participants were instructed to
repeat the sequence by clicking on the blocks using the mouse and cursor. The task
was repeated five times at each level of difficulty. The sequence span increased
from 4 upwards, until the participant can no longer correctly recall the sequence,
resulting in a span measure of nonverbal working memory, calculated by averaging
the level of the last five correctly completed trials.
3.2.3.1.13 3-back Task (working memory)
A continuous string of letters (upper and lower case; inter-stimulus interval of 2.5
seconds) was presented; 45 letters in total with 15 target pairs. For each stimulus,
participants were instructed to indicate whether this was the same letter that
appeared three letters before. Accuracy and mean reaction time were recorded.
3.2.3.1.14 Telephone Number Working Memory Task
A nine digit ‘telephone number’ was presented on screen for 5 seconds which
participants were instructed to hold in their memory. After a delay of 10 seconds,
participants had to input the number using the numerical numbers at the top of the
computer keyboard. Participants scored correctly only if the entire 9 digit number
was entered exactly as the number that was presented. There were 8 trials in total.
Accuracy and mean total time taken to complete the trials were recorded.
3.2.3.1.15 Delayed Word Recall (episodic memory)
The participant was again given 60 seconds to write down as many of the words
presented previously as possible. Total number of correct responses was recorded.
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3.2.3.1.16 Delayed Word Recognition (episodic memory)
The original 15 words plus 15 distractor words were presented one at a time in a
random order. For each word the participant indicated whether or not it was
included in the original list of words by pressing appropriate ‘yes’ and ‘no’ keys as
quickly as possible. Stimuli remained on screen until an appropriate response had
been made. Accuracy and mean reaction time were recorded.
3.2.3.1.17 Delayed Picture Recognition (episodic memory)
The original 15 pictures plus 15 distractor pictures were presented one at a time in a
randomised order. For each picture participants indicated whether or not it was
recognised as being from the original series by pressing appropriate ‘yes’ and ‘no’
keys as quickly as possible. Stimuli remained on screen until an appropriate
response had been made. Accuracy and mean reaction time were recorded.
3.2.3.1.18 Names-to-Faces Recall (episodic memory)
The twelve original photographs presented at the outset were again presented on
the screen, one at a time. Underneath each picture there was a list of 4 different first
names and 4 different last names. For each photograph, participants were
instructed to choose the first and last name that was originally presented with the
photograph. The numbers of correct responses for first and last names were
recorded and collapsed to give an overall score for this task.
3.2.3.2 Cognitive Demand Battery (CDB)
Three repetitions of a 10-minute computerised ‘Cognitive Demand Battery’
comprised the second half of the testing session. The battery has four components:
Serial 3 subtractions (2 min), Serial 7 subtractions (2 min), Rapid Visual Information
Processing (RVIP—5 min) and a ‘mental fatigue’ visual analogue scale. For the
serial subtraction tasks, participants subtracted either 3 or 7 consecutively from an
original randomly generated number between 800 and 999 for the duration of the
task. The RVIP task required that participants respond with a key press every time
they detected three consecutive odd or even numbers in a sequence of rapidly
(100/min) presented single digits (1-9). Previously the battery has been effectively
used to investigate the effects of various nutritional interventions on cognitive and
mental fatigue during periods of sustained cognitive processing (see Reay et al.,
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2006 for a full description). For this study, data from the three repetitions of the
battery was averaged for each of the battery’s four component parts.
3.2.4 Assessment of mood
Two subjective ratings of mood were taken. A computerised version of the 16 Bond-
Lader visual analogue scales was delivered prior to the cognitive demand battery.
The results were combined to form 3 mood factors: ‘alert’, ‘calm’ and ‘content’ (Bond
and Lader, 1974). Participants also completed the Depression, Anxiety and Stress
Scales (DASS). This 42-item self-report questionnaire requires participants to rate
how much each statement of negative emotional state applied to them during the
past week. This measure is designed to assess both current state and change in
state over time (Appendix I, see Lovibond and Lovibond, 1995 for a full description).
3.2.5 Procedure
Participants attended the laboratory on one single occasion commencing at 8:00
am. On the day of testing, participants were in an overnight fasted state, having
consumed nothing but water for approximately 12 hours prior to and for the duration
of the session. Testing took place in a suite of laboratories with participants visually
isolated from each other. On arrival participants completed a short diet and health
questionnaire that included questions about estimated intake of oily fish in a month
and whether they currently were taking any form of n-3 dietary supplement
(Appendix II). In order to familiarise the participants with the directions and format of
each performance measure, a 20-minute practice session was completed with
shortened versions of each task. One repetition of the CDB was also completed at
this time. Data from the practice session were not analysed. After a 5 minute break
the formal testing was carried out and was completed within 75 minutes by all
participants. Completion of the DASS was followed by collection of demographic
data and a single 5mL blood sample. An outline of the assessment schedule can be
found in Figure 3.1.
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dryness under a nitrogen flow at 40C, and the residue re-suspended in 0.1ml n-
hexane.
Analysis was carried out using a Thermo Scientific Focus gas chromatograph fitted
with a 30m DB5 column (0.25mm internal diameter) and a DSQ mass spectral
detector operating in single ion monitoring (SIM) mode to maximise sensitivity (GC
conditions were: 140C initial, hold for 5 minutes, ramp to 280C at 4C per minute,
hold for two minutes). All components had eluted by 35 minutes. The split ratio was
7:1 and the injection port temperature 270C. Individual FAME concentrations were
calculated from the ratio of peak areas for the component and the internal standard,
corrected for the previously determined relative response factor of the component
and expressed as a weight percent (i.e. mg per 100mg) of the total FAME
concentration (excluding the internal standard).
3.2.5.1 Statistical methods
Associations between performance on the cognitive tasks and mood scales and
DHA, EPA, total n-3 PUFAs, AA and the ratio of AA:EPA were explored using
simple linear regression and performed with the SPSS statistical software for
Windows version 15.0.1 (SPSS Inc., Chicago, IL). All regression analyses were
carried out using the relevant fatty acid or ratio as the predictor variable.
Prior to receiving the fatty acid data, scores on individual tasks were excluded if it
was evident that the participant had not understood or engaged with the task
correctly (e.g. performance on a task that was at chance or consistent with use of a
single button, coupled with large variations in reaction times suggesting inattention
to the stimuli). This led to participants’ scores being excluded in the analysis of the
Stoop task (n = 5), Numeric Working Memory task (n = 1) and the RVIP task (n =
11). In addition, three participant’s data were missing from the analysis of the
Alphabetic Working Memory task and four participants’ data for all three repetitions
of the CDB due to data capture errors.
An outlier was detected for one participant on the AA:EPA variable, who had a ratio
of 115.54 AA:EPA. Cook’s distance was utilised to asses the influence of this case
on the model for each of the separate analyses. For the majority of regression
models Cook’s distance ≥ 1, and so the case was removed for these analyses.
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Given the large amount of data generated by these analyses, only significant
findings are reported in the tables and text in the current chapter; complete analyses
can be found in Appendix III.
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3.3 Results
3.3.1 Participant characteristics
The mean age of the sample was 22.60 years; 80% were aged between 18-25
years and more females (62%) than males (38%) volunteered to take part. A quarter
of participants reported eating oily fish four or more times a month but 26% said
they never ate any oily fish. Fourteen participants reported taking an omega-3
supplement, 7 participants took the supplement every day. Self-reported oily fish
intake correlated with serum concentrations of DHA [ r(215) = 0.16, p = 0.016 ] and
inversely with AA [ r(216) = -0.17, p = 0.010 ] but surprisingly not with EPA [ r(214) =
-0.05 NS ]. Participant PUFA profiles and demographics can be found in Table 3.1.
The levels of DHA in particular are below what has been previously reported in
normal healthy adults (e.g. Morse, 2009) though in the current study 63% of
participants reported eating 2 portions or less of oily fish a month, which may
account for the low observations.
Table 3.1. Participant demographics and serum fatty acid concentrations (% total FAME).
n Mean SEM
Age 219 22.60 0.27
BMI 219 22.84 0.17
Linoleic acid (n-6) 219 33.44 0.30
Arachidonic acid (n-6) 218 6.26 0.15
α-Linolenic acid (n-3) 179 0.24 0.02
Docosahexaenoic acid (n-3) 217 1.04 0.04
Eicosapentaenoic acid (n-3) 216 0.84 0.03
AA:EPA 215 9.49 0.60
3.3.2. Regression analyses
Significant associations between cognitive performance and serum fatty acids are
presented in Table 3.2. EPA was found to be positively associated with performance
(% accuracy/no. correct) on a cluster of four of the memory tasks; Alphabetic WM,
Immediate Word Recall, Picture Recognition, Names-to-Faces Recall. In contrast,
DHA was significantly associated with only two outcomes, and in both cases this
fatty acid was associated with poorer performance. A negative association was
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detected between DHA and accuracy on the Numeric WM task, and positively
associated with reaction time on the Telephone Number WM task.
Total n-3 PUFAs were associated with performance in keeping with the above
associations relevant to EPA and DHA; total n-3 PUFAs were positively associated
with reaction time on the Telephone number WM task, number of correctly recalled
items on the Immediate Word Recall task, accuracy on the Picture Recognition task
and number of correctly matched names and faces on the Names-to-Faces Recall
task.
AA was positively associated with accuracy and number of correct items on the
Picture Recognition and Names-to-Faces Recall tasks, respectively. In addition, AA
was also positively associated with average reaction time on the RVIP task
component of the CDB.
A higher ratio of AA:EPA was predominantly associated with poorer performance;
AA:EPA was negatively associated with accuracy on Alphabetic WM and Stroop
and number correct on Names-to-Faces Recall. However, AA:EPA was also
negatively associated with the Corsi Blocks Speed outcome, indicating faster
response time. A positive association was found linking a AA:EPA and mental
fatigue and the Anxiety scale of the DASS.
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Table 3.2. Means and SEM of performance measures are presented with significant associations between cognitive performance and serum fatty acid concentrations.
Domain Outcome Mean SEM n1 Associated Fatty Acid (β; p; 95% C.I.; r2; n)
Attention Simple RT 287.70 2.67
Choice RT 412.79 3.75
Choice RT (% accuracy) 95.75 0.21
4 Choice RT 499.52 5.84
4 Choice RT (% accuracy) 99.19 0.10
Working Memory (WM) Numeric WM (RT) 893.03 15.34
Numeric WM (% accuracy) 95.57 0.34 DHA(-0.18; 0.010; -2.42, 0.34; 0.03; 216)a
Alphabetic WM (RT) 547.76 43.09
Alphabetic WM (% accuracy) 94.50 0.30 EPA (0.16; 0.018; 0.25, 2.57; 0.03; 213)
AA:EPA (-0.15; 0.029; -0.33, -0.02; 0.02; 211)a
Telephone Number WM (RT) 7058.91 199.18 DHA (0.15; 0.030; 80.61, 1588.82; 0.02; 217 )
Total n-3 (0.14; 0.043; 14.82, 860.51; 0.02; 218 )
Telephone Number WM (% accuracy) 32.48 1.73
Corsi blocks Span 5.90 0.08
3-Back Task (RT) 1184.81 49.32
3-Back Task (% accuracy) 80.89 1.04
Episodic Memory Immediate Word Recall (no. correct) 6.21 0.16 EPA (0.23; 0.001; 0.049, 1.80; 0.05; 216 )
Total n-3 (0.17; 0.014; 0.09, 0.77; 0.03; 219 )
AA:EPA (-0.24; <0.001; -0.18, -0.05; 0.06; 214)a
Delayed Word Recall (no. correct) 4.73 0.16
Word Recognition (RT) 961.92 13.53
Word Recognition (% accuracy) 80.35 0.68
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Domain Outcome Mean SEM n1 Associated Fatty Acid (β; p; 95% C.I. .; r2; n)
Picture Recognition (RT) 1069.47 16.24
Picture Recognition (% accuracy) 87.21 0.77 EPA (0.15; 0.027; 0.41, 6.71; 0.02; 216)
Total n-3 (0.16; 0.020; 0.30, 3.58; 0.03; 218)
AA (0.19; 0.006; 0.29, 1.70; 0.03; 218)
Names-to-Faces Recall (no. correct) 10.93 0.40 EPA (0.20; 0.003; 0.83, 4.10; 0.04; 216)
Total n-3 (0.14; 0.035; 0.07, 1.77; 0.02; 218)
AA (0.17; 0.011; 0.11, 0.85; 0.03; 218)
AA:EPA (-0.18; 0.008; -0.38, 0.06; 0.03; 214) a
Executive Function Stroop (RT) 870.36 11.65 214
Stroop (% accuracy) 99.45 0.08 214 AA:EPA (-0.19; 0.007; -0.08, -0.01; 0.03; 209)a
Verbal Fluency (total, no. correct) 40.32 0.57
Cognitive Demand Serial 3 Subtractions 31.88 0.89 215
Serial 7 Subtractions 18.22 0.64
RVIP (RT) 477.18 6.39 204 AA (0.15; 0.032; 0.53, 12.01; 0.02; 203)
RVIP (% accuracy) 45.79 1.41 204
RVIP (false alarms) 9.87 0.66 204
Mental Fatigue 71.34 1.01 215 AA:EPA (0.51; 0.013; 0.11, 0.91; 0.03; 210)a
Mood Bond-Lader Alert 45.03 0.89
Bond-Lader Calm 55.17 0.87
Bond-Lader Content 56.75 0.91
DASS Stress 10.60 0.51
DASS Anxiety 5.10 0.33 AA:EPA (0.19; 0.005; 0.03, 0.18; 0.04; 215) a
DASS Depression 6.84 0.48
1 n = 219 unless stated otherwise, a Fatty acid/ratio is associated with poorer outcome
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3.4 Discussion
Overall, two overarching patterns of results emerged from the individual regression
analyses. The first of these was the pattern of positive associations detected
between total serum n-3 PUFAs (ALA+DHA+EPA) and performance (% accuracy or
no. correct) on a number of episodic memory tasks (Immediate Word Recall, Picture
Recognition, Names-to-Faces Recall). It is interesting that several studies in older
adults have not reported similar associations between physiological measures of n-
3 PUFAs and memory. For example, Dullemeijer et al. (2007), Beydoun et al. (2007)
and Kalmijn et al. (2004a) all employed a task that assessed episodic memory
(word learning or delayed word recall) in their respective investigations in older
adults. However, none of these studies detected an association between individual
n-3 PUFAs or total n-3 PUFAs and episodic memory in either cross-sectional or
longitudinal analyses. On the other hand, a recent study in children reported
associations between DHA, total n-3 PUFAs and the ratio of total n-6/n-3 PUFAs
and performance on a task requiring episodic memory following 6 months
supplementation with a fish flour spread (Dalton et al., 2009), which, to the author’s
knowledge, is the only other report of an association between n-3 PUFAs and
performance on a memory task. As regards the present study, what is also
interesting is that serum concentrations of EPA (and not DHA) were significantly
associated with these three same outcome measures, suggesting that it is EPA that
is the most relevant component of the total n-3 PUFAs variable. In addition, serum
EPA was also positively associated with accuracy on the Alphabetic WM task.
Given that there is very little EPA (< 1%) contained in the brain compared to DHA
(10-20% total fatty acids - McNamara and Carlson, 2006), these findings were
unexpected. However, the many actions of EPA or its eicosanoid derivatives
including modulation of ion channels (Jeng et al., 2009), phospholipases (Bell et al.,
2004) and gene expression (Salvati et al., 2008) elsewhere in the body may also be
behaviourally relevant as regards memory function. This novel finding requires
further investigation and an evaluation of the effects of supplementation with EPA in
healthy young adults seems justified.
The second pattern that came out the data concerns the ratio of AA:EPA, found to
be associated with poorer outcomes in terms of both task performance as well as
selected mood measures. Taking the cognitive task performance first, inverse
associations were detected between the ratio of AA:EPA and performance (%
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accuracy or no. correct) on number of tasks requiring working memory (Alphabetic
WM), episodic memory (Immediate Word Recall, Names-to-Faces Recall) and
attention/response inhibition (Stroop). An elevated ratio of AA:EPA has been
previously associated with a range of adverse health and behaviour outcomes
including depression (Adams et al., 1996), reading ability in dyslexics (Cyhlarova et
al., 2007) and inflammatory disease (reviewed in Calder, 2006a), but the results of
the current study comprise the first report of an inverse relationship between the
ratio of AA:EPA and specific cognitive functions. Fontani et al. (2005) reported a
significant within-group reduction in the AA:EPA blood fatty acid ratio of participants
receiving 4 g/d fish oil for 35 days along with significant within group reductions in
participants’ reaction time on sustained attention and response inhibition tasks, but
unfortunately the authors failed provide data regarding relationship between these
outcome measures. Given the above results, consideration of the ratio of AA:EPA in
future evaluations of the relationship between PUFAs and cognitive function may be
an interesting avenue to pursue.
The ratio of AA:EPA was also positively associated with the Anxiety scale of the
DASS as well as with subjective mental fatigue during 30 minutes of cognitively
demanding tasks. These findings are particularly interesting in light of the extant
literature linking both anxiety and fatigue to inflammatory processes.
Epidemiological data suggest a positive association between elevated pro-
inflammatory cytokine levels and tiredness (Whalley et al., 2007), and anxiety
disorders have also recently been linked to elevated levels of pro-inflammatory
cytokines (Hoge et al., 2009). Given that plasma n-3 PUFAs are associated with
lower levels of pro-inflammatory cytokines and higher levels of anti-inflammatory
ones (Ferrucci et al., 2006), a future extension of this study could investigate the
relationship between self-reported mental fatigue and anxiety and these biomarkers,
and the effect of increased intake of n-3 PUFAs on both immunological and
subjective mental fatigue and anxiety outcomes. It is possible that low-grade
inflammation and the ability of n-3 PUFAs to dampen the inflammatory response
may link these two findings, though this would need to be confirmed. Interestingly,
neither EPA nor AA alone was associated with either of these two mood outcomes,
possibly suggesting that the balance between the two PUFAs is more important
than individual fatty acid concentrations.
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There was no further evidence to suggest a link between mood and n-3 PUFAs in
this sample, despite low n-3 PUFA status being previously linked to increased
incidence of depression at the epidemiological level (Hibbeln, 1998, Tanskanen et
al., 2001, Silvers and Scott, 2002) as well as in clinical studies (Peet et al., 1998b,
Edwards et al., 1998, Adams et al., 1996). For this study there were very few
participants who scored at the higher end of the DASS (n = 15 scoring 21 or more)
so it may be that this sample was too homogenous to enable a detection of an
association. However, a large intervention trial found that the baseline scores on
these same scales were not related to plasma n-3 PUFA concentrations for either
high or low scorers (Rogers et al., 2008), in line with the data presented here. Other
research does suggest that major depression at least, is associated with a pro-
inflammatory phenotype and elevated ratio of n-6:n-3 PUFAs (Dinan et al., 2009),
so again, introducing cytokine or other related immunoassays to future intervention
study protocols in this area may promote understanding of the subtle relationship
between these variables.
Turning to the other individual fatty acids, there was little evidence to suggest that
peripheral DHA concentrations are associated with cognitive performance; in fact
the two significant associations that were detected revealed that serum DHA is
associated with worse performance. This is not consistent with studies in children
that have reported a positive association between plasma DHA and measures of
learning, reading and spelling (Dalton et al., 2009, Ryan and Nelson, 2008). It is
known that the brain relies on an adequate supply of dietary DHA in order to
maintain an optimal state of membrane functionality and that DHA also beneficially
contributes to a host of processes involved in cellular signalling and
neurotransmission (Yehuda et al., 1999, Youdim et al., 2000). However, in piglets at
least, concentrations of brain DHA are only related to erythrocyte concentrations of
DHA and not plasma concentrations (Blank et al., 2002), suggesting perhaps that
there is little justification in associating serum DHA concentrations with cognitive
performance. In a similar vein, the detected associations between serum AA and
cognitive performance outcomes were also mixed and largely uninterpretable with
AA associated with better performance on two of the outcome measures; Corsi
Blocks Speed and Names-to-Faces Recall, and with slower reaction time on the
RVIP task. AA is essential for optimal brain development and like DHA, is a major
structural component of the brain (Innis, 1993). It is not surprising then that
erythrocyte concentrations of both AA and DHA have been shown to be associated
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with developmental quotient at 24 months (Agostoni et al., 1997). However on the
other hand, total n-6 fatty acids have been shown to be associated with greater risk
for cognitive decline (Heude et al., 2003). In the case of healthy young adults, given
the very limited and mixed findings, the association between AA and cognitive
function requires further investigation, though as mentioned above, the balance of
AA and EPA may likely be more important than either AA or EPA concentrations
alone.
While these results present the possibility that concentrations of individual fatty
acids and hence dietary intake are associated with distinct cognitive task
performance (memory), overall caution should be exercised when interpreting these
associations. Firstly, a large number of regression models were analysed therefore
increasing the probability that the significant associations were detected by chance.
In light of this, although all the findings have been described, an emphasis has been
placed on patterns of results rather than individual associations. Another potential
limitation is the possible existence of a covariate(s) that could also account for these
findings. The sample was homogenous in terms of age group and education level
as all participants were healthy young adults that had attained or were enrolled in an
undergraduate level degree. Further, all participants asserted to be non-smokers
and medication-free. Other potentially confounding factors such as parental socio-
economic status were not controlled for, however, and could be included in future
investigations. The use of serum fatty acids as a biomarker of status in this study
may have also had an impact on the results. Although widely used as a valid
measure of fatty acid intake (e.g. Metherel et al., 2009, Welch et al., 2006), serum
fatty acids have a 4-6 times shorter half life (about 1-2 weeks) than those found in
erythrocytes (Katan et al., 1997), which are believed to be a more accurate measure
of long-term intake and incorporation (Harris and von Schacky, 2004), and therefore
potentially a more accurate correlate of cognitive function. In spite of these
limitations, what this investigation may have highlighted is that certain cognitive
domains are especially sensitive to fluctuations in PUFA status. Indeed, the issue of
whether dietary supplementation with n-3 PUFAs has an effect on cognitive
performance in cognitively intact adults has yet to be fully investigated.
In summary, it was observed that performance on a number of cognitive tasks is
associated with serum n-3 PUFA concentrations; the majority of significant
associations indicate a positive relationship between serum n-3 PUFAs and
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performance, although this was not universally observed. In addition, a higher ratio
of AA:EPA was generally associated with poorer performance as well as increased
mental fatigue and anxiety. A causal relationship between n-3 PUFAs and cognitive
performance in healthy young adults has yet to be established, however, but given
these results further investigation in this population seems justified.
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CHAPTER 4. COGNITIVE AND MOOD EFFECTS OF DHA-RICH FISH OIL AND
EPA-RICH FISH OIL IN HEALTHY ADULTS (18-35 YEARS)
4.1 Introduction
The connection between nutrition and cognitive function is widely accepted and a
large number of varied micro- and macronutrients have been identified as having
important actions in the brain that can influence brain function (Fernstrom, 2000).
On the one hand, the impact of nutrient deficiency upon behaviour is well
documented; deficiencies in Vitamin D (Holick, 2007), folic acid (Reynolds, 2002)
and iron (Pollitt, 1993) are all associated with poorer cognitive function and
conversely, increasing levels of nutrients via supplementation in otherwise healthy
individuals has been shown to have beneficial effects. For example, increased
intake of vitamins E and C is associated with reduced cognitive decline in the elderly
(Morris et al., 2002, Paleologos et al., 1998, respectively), and multivitamin/mineral
supplementation has been shown to have a beneficial effect upon mood and stress
in healthy adults (Carroll et al., 2000, Schlebusch et al., 2000, Kennedy et al., In
press-a), and measures of attention in children (Haskell et al., 2008). Further, the
role of amino acids such as tryptophan and tyrosine, as precursors of
neurotransmitters have been explored, with recent evidence suggesting that
tryptophan in particular may be able to beneficially modify mood in healthy adult
volunteers (Markus et al., 2008).
The behavioural impact of dietary intake of n-3 PUFAs docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA) has also been increasingly examined in recent
years. The effect of n-3 PUFA deficiency in animals has been well documented; an
inadequate supply of dietary n-3 PUFAs can result in a 50-80% decline in brain
DHA and is associated with impaired learning and memory (see Section 1.5.1).
Such data are not readily translated into humans, however, where equivalently low
levels of n-3 PUFAs are rare, although there is evidence to suggest that lower n-3
PUFA status (compared to controls and measured by plasma/serum or erythrocyte
concentrations) is associated with a number of adverse outcomes. These included
several neurodevelopmental disorders such as ADHD and autism (Bell et al., 2000,
Burgess et al., 2000, Schuchardt et al., 2009), along with a number of psychiatric
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conditions including depression (Edwards et al., 1998), schizophrenia (Assies et al.,
2001) and Alzheimer’s disease and dementia (Conquer et al., 2000). Further to this,
the results presented in Chapter 3 suggest that serum PUFA concentrations may be
associated with performance on a number of cognitive tasks as well as mood in
healthy young adults. Serum concentrations of total n-3 PUFAs (ALA+DHA+EPA)
and EPA alone were found to be positively associated with performance on a cluster
of episodic memory tasks, and the ratio of AA:EPA was associated with poorer
performance on a number of tasks spanning several different cognitive domains
(episodic memory, working memory, attention). In addition, AA:EPA was positively
associated with subjective anxiety and mental fatigue (see Table 3.2 for details).
Together the overall results from the study suggested that dietary supplementation
with n-3 PUFAs in this population may be an interesting avenue to pursue, although
to date only a handful of studies have addressed this issue. Hamazaki et al. (1996)
reported that 1.5-1.8 g/d DHA (from fish oil) for 3 months in healthy students
prevented increases in aggression towards others during times of mental stress
(university examinations), but did not perform differently than the control group on
the Stroop or dementia-detecting tests. Two other studies have examined the
effects of dietary supplementation with fish oil on performance and mood. In the first
of these Fontani et al. (2005) investigated the effects of 4 g/d fish oil (1.6 g DHA +
0.8 g EPA) for 35 days in healthy amateur athletes. Participants in the fish oil
treatment group achieved faster reaction times on a go/no-go task and a sustained
attention task, and also improved ratings of anger, anxiety, fatigue, depression,
confusion and vigour on the self-report Profile of Mood States (POMS)
questionnaire compared to their pre-treatment scores, but no comparison was made
between the treatment and placebo groups. Antypa et al. (2009) attempted to
directly expand on these findings using a similar sample (healthy adults, but not
athletes), intervention period (4 weeks), and comparable quantity of n-3 PUFAs,
although the ratio of DHA to EPA was much higher and in the opposite direction
(1.75 g EPA+ 0.25 g DHA). These authors specifically aimed to examine the effects
of the supplement on depression-relevant cognition and mood, but did not detect
any effects of treatment on any of the cognitive measures including attention,
memory, response inhibition and emotion recognition; the only reported effect on
mood was a small effect on self-rated mental fatigue (POMS). Participants in the n-3
PUFA group did however demonstrate increased risk-seeking behaviour on a
gambling decision-making task, which the authors attributed to increased mental
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effort and not increased impulsiveness. It must be noted that whilst the statistical
analysis of Antypa et al. (2009) was more appropriate than that of Fontani et al.
(2005), the authors note two limitations with their study; the effects of the
manipulation may have been masked due to the fact that the treatment group had a
higher average level of DHA in plasma at baseline and also that levels of DHA
inexplicably increased in the placebo group following treatment.
From these studies it is clear the effects of n-3 PUFA supplementation on
behavioural outcomes in healthy adults remains to be adequately addressed.
Animal studies suggest that the intervention period of both the latter studies would
not be sufficient for adequate incorporation of the fatty acids to occur in certain
tissues including the brain (Connor and Neuringer, 1988), therefore the reported
results may not reflect the effects that might occur following a longer intervention
period. Further, a recurrent theme in the n-3 PUFA supplementation literature, both
in healthy and patient populations is the use of a wide range of treatment
formulations and doses. Both dietary DHA and EPA are known to influence
mechanisms that support cognitive function, but given the evidence provided by the
studies listed above, it is not possible to say at this time which type of n-3 PUFA
supplement, one higher in DHA than EPA (‘DHA-rich’) or visa versa (‘EPA-rich’)
would have an effect on cognitive performance. In addition, while these
aforementioned studies that have specifically examined cognitive function in healthy
adults are useful for ‘proof of concept’, the doses involved would not be easily
achieved by dietary intake of oily fish alone, and therefore not readily translated into
meaningful advice for the general population. Lastly, the results provided by the
study described in Chapter 3 suggest that n-3 PUFA status is associated with a
number of cognitive functions in healthy adults including attention, episodic memory,
working memory and executive function, yet previous intervention studies have
either only utilised a small number of tasks (Hamazaki et al., 1996), focused on one
cognitive domain (Fontani et al., 2005), or using tasks specifically involving
emotional information processing (Antypa et al., 2009). In order to address these
issues, the present study assessed the effects of two different formulations of fish oil
in parallel, and at doses consistent with the current recommended daily intake of
oily fish, across a range of cognitive domains. The aim of the present investigation
was therefore to specifically evaluate the effects of 12 weeks supplementation of
DHA-rich fish oil and EPA-rich fish oil dietary supplements on cognitive function in
healthy young adults maintaining a regular diet containing oily fish not more than
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once a week. Self-report mood assessments formed the secondary part of this
investigation.
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4.2 Materials and Methods
4.2.1 Design
A placebo-controlled, double-blind independent measures design was employed
with participants randomly assigned to one of three treatment groups (placebo,
DHA-rich fish oil, EPA-rich fish oil; see Section 4.2.3). Prior to the start of the study
a restricted randomisation (55 X 3 treatments) list matching treatments to participant
code numbers was computer generated. Participants were assigned the next
available code upon completion of the Training day.
4.2.2 Participants
Volunteers were invited to participate if they declared that they were in good health
and that they were a non-smoker, free from prescription, herbal, illicit or recreational
drugs (females taking the contraceptive pill were included), omega-3 supplements,
that they were a native English speaker and eating no more than one portion of oily
fish a week on average (≤ 4 portions/month). All volunteers were either students
attending Northumbria University or were university graduates living in Newcastle-
upon-Tyne and the surrounding area.
Of the 159 that were enrolled in the study, nine participants did not attend the
Baseline session and eight participants were excluded on the basis that their
declared average oily fish intake exceeded four portions a month. Two participants
withdrew before the last day of the study (Week 12), though in both cases the
reasons were unrelated to the intervention (glandular fever, moving home). Two
participants had below 50% compliance as they had only taken 1 x 500 mg
capsule/d and were excluded from the analysis at the blind data review point. The
remaining per-protocol sample consisted of 140 males and females; their
demographic details are presented in Table 4.1.
The study was approved by the Northumbria University School of Psychology and
Sport Science Ethics Committee and was carried out in accordance with the
Declaration of Helsinki (1964). All participants gave written informed consent prior to
their inclusion in the study.
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4.2.3 Treatments
The 1 g daily dose was provided by 2 x 500 mg capsules. The active capsules
contained 497.5 mg of deodorised fish oil (FO) plus 2.5 mg mixed tocopherols. The
total daily dose of n-3 PUFAs for the DHA-rich FO was 450 mg DHA + 90 mg EPA
(5:1 DHA to EPA) and for the EPA-rich1 FO this amount was 300 mg EPA + 200 mg
DHA (3:2 EPA to DHA). The total daily dose for the placebo treatment was 1 g olive
oil. The ratios of DHA and EPA contained in the active treatments are reflective of
those that are found naturally; the DHA-rich FO resembles that of yellowfin tuna and
herring, and some species of salmon have a similar ratio to that present in the EPA-
rich FO. Treatment oils were purchased from EPAX AS (Aalesund, Norway) and
encapsulated by Cardinal Health UK. All capsules used a brown bovine gelatine
casing and all treatments were packaged, labelled and randomised on site by a
disinterested third party.
4.2.4 Assessment of cognitive performance and mood
Performance was assessed using the COMPASS (Computerised Mental
Performance Assessment) system, which presented a battery of standard cognitive
tasks identical to the battery presented to participants in the previous chapter (see
1 It is noted that the ratio of EPA:DHA in the EPA ‘rich’ FO is closer to 1 compared to the
DHA-rich FO, however in this case EPA-rich denotes containing more EPA than DHA.
Table 4.1. Participant demographic information and baseline characteristics. Means and SEM are
given where appropriate. P values are given for separate one-way ANOVAs that were conducted
on this baseline data.
Placebo DHA-rich FO EPA-rich FO p
N (M/F) 11/37 17/29 18/28 0.193
Age 21.94 3.66 21.96 4.14 22.74 3.47 0.506
BMI 24.83 3.45 24.11 4.12 23.89 5.59 0.572
Average oily fish consumed/month 1.35 1.37 1.85 1.34 1.20 1.41 0.062
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Section 3.2.2.1 for details). All presentations were made via a laptop computer with
the exception of the Word Recall and Verbal Fluency tasks, where participants used
pen and paper to make their responses. All reaction times were measured in
milliseconds. Participants also completed three repetitions of the Cognitive Demand
Battery (see Section 3.2.3.2) along with the Bond-Lader visual analogue scales and
the DASS (see Section 3.2.4).
4.2.5 Procedure
Participants attended the laboratory on three occasions (Training day, Baseline and
Week 12). Testing took place in a suite of testing facilities with participants visually
isolated from each other. The Training day followed the exact protocol described in
Section 3.2.5 comprising obtaining of informed consent, completing a diet and
health questionnaire (Appendix IV), training on the cognitive tasks and mood
questionnaires, collection of demographic data and collection of a blood sample. No
more than 8 days following the Training day, participants then attended the
laboratory at 8:30 a.m. in an overnight fasted state on the first day (Baseline) and at
the end of the 12-week treatment regimen (Week 12 – average time on treatment
86.71 days). On arrival to the Baseline session participants were randomised to
treatment group and completed the full battery of COMPASS tasks, Bond-Lader
visual analogue scales, three repetitions of the CDB and filled in the DASS.
Participants’ blood pressure and heart rate were subsequently recorded and at the
end of the session each participant received their allocated capsules and
instructions on how to take them, and asked to commence taking the treatment that
day. Participants from whom a blood sample could not be obtained on the Training
Day were invited to attempt to give another sample at the end of this session. The
session at Week 12 followed exactly the same protocol as at the Baseline session
with the exception that all unused capsules were collected prior to testing and at the
very end of the session participants filled out a questionnaire regarding their socio-
economic status and which treatment they thought they had been taking (Appendix
V). The assessment schedule can be found in Figure 4.1.
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squares error from the ANCOVA as an error term and adjusted means (Keppel,
1991). To ensure the overall protection level against Type I errors, comparisons
were strictly planned prior to the commencement of the study and only those
comparisons associated with a significant main effect on the omnibus ANCOVA
were calculated. All testing was two-tailed and all data were analysed using SPSS
16.0 (SPSS Inc., Chicago, IL, USA).
4.2.5.2.1 Baseline characteristics
Results from separate between groups (treatment condition) ANOVAs using data
collected on either the Training day or Baseline session revealed no differences
between participants in all three treatment groups on age, BMI, oily fish
consumption (see Table 4.1), and serum concentrations of DHA, EPA (see Table
4.2). Additionally, no between group differences were detected on breastfeeding,
white fish consumption, and any of the family background questionnaire items
excepting mother’s level of education (M-Ed). For this item the ANOVA revealed a
significant main effect of treatment [ F(2, 137) = 3.91, p = 0.022 ]. Consequently all
of the separate one-way ANCOVAs of the data collected at Week 12 were carried
out twice, once using the appropriate outcome from the Baseline session and M-Ed
as covariates, and once without. Given that M-Ed inconsistently predicted the
outcome variable and the results from both sets of analyses were identical as
regards main effects, M-Ed was not included as a covariate in the main analysis.
There was also a trend towards a difference between groups on average oily fish
consumed (p = 0.062), with participants in the DHA-rich FO treatment group
reporting higher average consumption.
4.2.5.2.2 Missing data
Data capture errors lead to a reduced number of datasets for the Corsi Blocks task
and two participants’ data were lost from the entire CDB due to a fire drill during
their Baseline testing session. During the data cleaning process (conducted prior to
treatment unblinding), it was evident that some participants had either not
understood or followed the directions properly (e.g. performance on a task that was
at chance or consistent with use of a single button, coupled with large variations in
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reaction times suggesting inattention to the stimuli). Therefore reduced datasets
were also used in the analysis of the Stroop, Serial 7 subtractions and RVIP tasks,
and are reflected in Tables 4.3 and 4.4. For the subsequent ANCOVAs that were
carried out on the outcomes from these tasks, missing data were omitted using
listwise deletion.
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4.3 Results
4.3.1 Physiological data and compliance
Results for compliance as measured by capsule count were similar in all 3 treatment
conditions (91% DHA-rich FO, 90% EPA-rich FO, and 92% Placebo). Reference to
the serum fatty acid data presented in Table 4.2 shows that serum concentrations of
DHA and EPA increased significantly in both treatment groups but not in the
placebo group. More specifically, fatty acid concentrations of DHA increased by
48% and EPA increased by 30% in the DHA-rich FO group and for those taking the
EPA-rich FO, concentrations of DHA and EPA increased by 33% and 53%,
respectively. Paired samples t-tests were conducted to analyse the change in serum
DHA and EPA in all three treatment groups, results of which are presented in Table
4.2.
Table 4.2. Physiological measures by treatment group at Baseline and Week 12. Means and
SEM are presented. For serum concentrations of DHA and EPA (%total FAME) and the ratio
between concentrations of AA and EPA significant difference between Baseline and Week 12
concentrations (paired samples t-test) is indicated in bold typeface (*, p < 0.05; **, p < 0.01; ***,
p < 0.005).
Baseline Week 12
n Mean SEM n Mean SEM
Placebo 37 1.05 0.07 32 0.95 0.08
DHA DHA-rich FO 37 1.26 0.09 34 1.87*** 0.11
EPA-rich FO 38 1.12 0.09 33 1.49* 0.11
Placebo 37 1.07 0.09 32 1.31 0.12
EPA DHA-rich FO 37 1.05 0.06 34 1.36** 0.12
EPA-rich FO 38 1.16 0.09 33 1.78** 0.12
Placebo 37 8.03 0.45 32 10.66*** 0.73
AA:EPA DHA-rich FO 37 7.74 0.39 34 4.46** 0.31
EPA-rich FO 38 6.96 0.42 33 7.74 0.43
Placebo 48 62.98 1.62 48 64.88 1.37
Systolic BP DHA-rich FO 46 63.28 1.84 46 62.37 1.57
EPA-rich FO 46 61.37 1.46 46 63.50 1.43
Placebo 48 113.00 1.61 48 114.71 1.86
Diastolic BP DHA-rich FO 46 119.28 1.87 46 120.72 1.89
EPA-rich FO 46 117.30 1.64 46 116.80 1.91
Placebo 48 77.08 2.28 48 75.04 1.14
Heart rate DHA-rich FO 46 79.15 1.64 46 76.74 1.45
EPA-rich FO 46 77.28 2.00 46 77.96 1.24
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In a separate set of analyses, data from the serum samples collected at Week 12
were analysed by one-way ANCOVA with relevant serum data collected at Baseline
as the covariate to investigate the presence of between group differences on serum
PUFAs following the intervention. A significant main effect of treatment group was
revealed for serum concentrations of both DHA and EPA [ F(2, 85) = 18.10, p <
0.001; F(2, 84) = 3.24, p = 0.044, respectively ]. Post hoc calculations (Bonferroni)
revealed that participants in the DHA-rich FO group had higher serum DHA than
placebo (p < 0.001) and those in the EPA-rich FO group (p = 0.022). Those in the
EPA-rich FO group also had higher serum DHA than placebo (p = 0.004).
Interestingly, as regards serum EPA concentrations, post hoc calculations did not
reveal any significant differences between the treatment groups and placebo,
though there was a trend for higher serum EPA in the EPA-rich FO group compared
to the DHA-rich FO group (p = 0.080) and placebo (p = 0.097).
The same analysis was applied to the AA:EPA ratio data and a significant main
effect of group was also detected [ F(2, 84) = 33.61, p < 0.001 ]. The ratio of
AA:EPA was higher in the placebo group than both the DHA-rich FO (p < 0.001)
and EPA-rich FO (p < 0.001) groups. The was no significant difference between the
active treatment groups on the ratio of AA:EPA.
At the end of the Week 12 session participants were asked to say if they thought
they had been taking fish oil or placebo capsules; participants were just as likely to
give the correct answer in the EPA-rich FO treatment group (49%) as those taking
placebo (66%) [ χ2 (1) = 0.08; p = 0.109 ] whereas those in the DHA-rich FO group
were less likely (37%) to give the correct answer [ χ2 (1) = 0.003; p = 0.006 ].
As regards the other physiological measures that were taken, there was no
evidence of an effect of treatment on either blood pressure or heart rate. These data
can also be found in Table 4.2.
4.3.2 Cognitive performance battery (COMPASS)
Performance data collected at Baseline and Week 12 data for every outcome can
be found in Table 4.3.
There was evidence of a significant main effect of treatment on two of the outcome
measures including reaction time on the Stroop task [ F(2, 133) = 3.27, p = 0.041 ]
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and number of correctly matched items on the Names-to-Faces task [ F(2, 136) =
3.73, p = 0.026 ]. Planned comparisons revealed that participants in the DHA-rich
FO group were faster on the Stroop task compared to placebo [ t(133) = 2.50, p =
0.014, r = 0.26 ] but participants in both the DHA-rich and EPA-rich FO groups
matched fewer items on the Names-to-Faces task [ t(136) = 2.00, p = 0.047, r =
0.21; t(136) = 2.52, p = 0.013, r = 0.26, respectively ].
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Table 4.3. Cognitive task performance and mood outcomes by treatment group at Baseline and Week 12.
Means and SEM are presented with F and p values from the primary ANCOVA. Significant results are
presented in bold typeface.
Baseline Week 12
n Mean SEM n Mean SEM F p
Immediate Word
Recall
(no. correct)
Placebo 48 6.99 0.36 48 7.79 0.36
DHA-rich FO 46 6.90 0.30 46 7.17 0.30 1.39 0.252
EPA-rich FO 46 7.33 0.33 46 7.59 0.31
Delayed Word
Recall
(no. correct)
Placebo 5.08 0.41 5.93 0.32
DHA-rich FO 4.71 0.37 5.61 0.35 0.05 0.949
EPA-rich FO 5.00 0.33 5.87 0.31
Simple RT
Placebo 281.16 3.76 285.07 3.71
DHA-rich FO 289.56 5.20 288.52 5.14 0.13 0.880
EPA-rich FO 282.37 4.35 283.44 4.16
Choice RT
Placebo 399.49 6.05 410.65 9.90
DHA-rich FO 403.15 8.51 399.59 8.21 1.02 0.365
EPA-rich FO 396.88 6.28 404.37 11.30
Choice RT (%
accuracy)
Placebo 94.88 0.53 95.71 0.47
DHA-rich FO 95.30 0.56 95.78 0.44 1.45 0.238
EPA-rich FO 94.65 0.65 94.70 0.55
4 Choice RT
Placebo 464.35 6.67 464.78 6.35
DHA-rich FO 482.41 10.66 470.22 9.72 1.20 0.310
EPA-rich FO 479.96 8.73 481.22 11.64
4 Choice RT (%
accuracy)
Placebo 99.05 0.21 99.18 0.18
DHA-rich FO 98.55 0.26 98.96 0.28 0.64 0.527
EPA-rich FO 98.69 0.34 98.69 0.32
Stroop
(RT)
Placebo 817.44 13.33 47 855.68 16.44
DHA-rich FO 45 858.44 20.43 44 845.02 17.23 3.27 0.041
EPA-rich FO 843.00 17.21 863.87 20.64
Stroop
(% accuracy)
Placebo 99.38 0.16 99.40 0.16
DHA-rich FO 99.33 0.17 99.14 0.26 0.43 0.655
EPA-rich FO 99.00 0.27 99.26 0.18
Verbal Fluency
Placebo 38.64 0.38 41.66 1.24
DHA-rich FO 39.70 0.44 41.21 1.46 1.46 0.236
EPA-rich FO 41.17 0.42 41.97 1.09
Numeric Working
Memory
(RT)
Placebo 809.48 22.20 844.76 24.11
DHA-rich FO 829.36 24.40 877.76 26.92 0.61 0.545
EPA-rich FO 797.41 22.44 828.38 20.38
Numeric Working
Memory (%
accuracy)
Placebo 96.09 0.64 96.85 0.42
DHA-rich FO 96.40 0.41 95.99 0.54 1.31 0.270
EPA-rich FO 95.53 0.61 95.36 0.87
Alphabetic
Working Memory
(RT)
Placebo 466.10 12.66 479.76 12.86
DHA-rich FO 39 512.37 16.22 511.30 14.84 0.02 0.978
EPA-rich FO 459.46 13.59 472.33 13.65
Alphabetic
Working Memory
(% accuracy)
Placebo 94.65 0.52 94.40 0.54
DHA-rich FO 94.28 0.56 94.52 0.69 0.05 0.949
EPA-rich FO 94.52 0.71 94.57 0.58
Corsi Blocks
Span
Placebo 6.01 0.16 5.99 0.17
DHA-rich FO 6.18 0.15 6.07 0.23 0.20 0.818
EPA-rich FO 5.64 0.21 5.81 0.25
3-back task
(RT)
Placebo 45 1053.69 71.79 1020.13 78.79
DHA-rich FO 1146.98 98.39 1224.29 110.00 2.65 0.075
EPA-rich FO 37 1037.16 99.48 1196.88 111.93
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Baseline Week 12
n Mean SEM n Mean SEM F p
3-back task (%
accuracy)
Placebo 84.68 1.95 80.60 2.76
DHA-rich FO 81.52 2.63 82.83 2.36 1.96 0.145
EPA-rich FO 45 80.21 2.52 81.43 2.44
Telephone
Number task
(RT)
Placebo 5997.14 237.84 5758.90 204.10
DHA-rich FO 6578.48 259.07 6739.05 276.45 2.39 0.095
EPA-rich FO 6624.08 280.40 6588.26 297.23
Telephone
Number task (%
accuracy)
Placebo 35.42 3.87 35.16 3.99
DHA-rich FO 38.86 3.83 36.14 3.50 0.09 0.915
EPA-rich FO 38.59 3.80 37.77 3.82
Word Recognition
(RT)
Placebo 924.44 28.81 872.85 24.37
DHA-rich FO 892.43 21.04 894.11 24.64 2.72 0.070
EPA-rich FO 897.83 31.26 916.02 25.51
Word Recognition
(% accuracy)
Placebo 77.36 1.67 81.81 1.42
DHA-rich FO 75.36 1.46 79.35 1.53 0.42 0.659
EPA-rich FO 78.77 1.44 81.96 1.30
Picture
Recognition
(RT)
Placebo 954.67 34.89 992.96 32.70
DHA-rich FO 972.35 57.54 1053.98 38.59 1.70 0.187
EPA-rich FO 933.63 29.59 1067.30 32.80
Picture
Recognition (%
accuracy)
Placebo 88.40 1.47 83.40 1.65
DHA-rich FO 89.42 1.29 86.16 1.58 0.64 0.529
EPA-rich FO 91.96 0.79 87.17 1.40
Names-to-Faces
Recall
(no. correct)
Placebo 11.21 0.69 13.90 0.73
DHA-rich FO 11.98 0.62 12.67 0.60 3.73 0.026
EPA-rich FO 12.07 0.55 12.26 0.68
Bond-Lader Alert
Placebo 49.78 2.05 53.62 2.15
DHA-rich FO 50.59 1.76 52.47 2.12 0.14 0.871
EPA-rich FO 48.28 1.82 52.46 2.21
Bond-Lader Calm
Placebo 59.68 1.62 62.58 1.82
DHA-rich FO 58.05 1.88 60.64 1.77 0.12 0.901
EPA-rich FO 57.02 1.76 60.23 2.09
Bond-Lader
Content
Placebo 59.40 1.68 61.07 1.74
DHA-rich FO 57.87 1.86 61.98 1.74 0.39 0.680
EPA-rich FO 58.73 1.58 60.65 1.97
DASS Stress
Placebo 9.27 0.98 7.92 0.96
DHA-rich FO 7.74 0.85 7.98 0.93 0.52 0.595
EPA-rich FO 8.07 1.01 7.24 0.93
DASS Anxiety
Placebo 3.42 0.62 3.38 0.64
DHA-rich FO 3.54 0.56 3.24 0.50 0.21 0.808
EPA-rich FO 2.65 0.56 3.09 0.60
DASS Depression
Placebo 4.63 0.76 3.27 0.82
DHA-rich FO 5.54 0.94 4.52 0.82 0.40 0.672
EPA-rich FO 4.41 0.79 3.67 0.65
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4.3.3 Cognitive Demand Battery (CDB)
Performance data collected at Baseline and Week 12 on the CDB can be found in
Table 4.4.
There was no evidence of a main effect of treatment on any of the cognitive
performance measures from the CBD for either ANCOVA model. However a main
effect of treatment was detected using both models for self-reported mental fatigue
during the CDB [ F (2, 133) = 3.27, p = 0.041 ]. Planned comparisons revealed that
mental fatigue scores for participants in the EPA-rich FO group were significantly
lower compared to placebo [ t(134) = -2.67, p = 0.009, r = 0.27 ].
Table 4.4. Outcome measures on the Cognitive Demand Battery by treatment group at
Baseline and Week 12. Means and SEM are presented with F and p values from the
primary ANCOVA. Significant results are presented in bold typeface.
Baseline Week 12
n Mean SEM n Mean SEM F p
Serial 3
Subtractions
(no. correct)
Placebo 47 38.05 2.09 47 37.55 2.01
DHA-rich FO 45 35.86 2.02 45 35.51 1.97 0.08 0.925
EPA-rich FO 46 36.12 1.90 46 35.53 1.76
Serial 7
Subtractions
(no. correct)
Placebo 48 21.49 1.51 46 21.40 1.48
DHA-rich FO 44 21.11 1.46 45 20.99 1.55 0.15 0.863
EPA-rich FO 46 20.61 1.39 46 20.99 1.31
RVIP
(RT)
Placebo 47 484.87 9.20 44 485.64 10.23
DHA-rich FO 44 492.03 8.51 41 481.37 8.99 0.12 0.897
EPA-rich FO 42 473.61 7.14 43 475.46 9.53
RVIP (%
accuracy)
Placebo 47 50.83 3.30 44 50.31 3.69
DHA-rich FO 44 49.50 3.45 41 51.68 3.34 1.48 0.232
EPA-rich FO 42 53.40 3.26 43 55.33 3.73
RVIP
(false
alarms)
Placebo 47 8.14 1.63 44 8.55 1.59
DHA-rich FO 44 6.58 1.04 41 6.76 1.04 0.35 0.705
EPA-rich FO 42 8.50 1.63 43 10.36 2.38
Mental
fatigue
(/100)
Placebo 48 66.75 2.32 47 68.78 2.02
DHA-rich FO 46 61.67 2.16 46 65.35 2.54 4.36 0.015
EPA-rich FO 46 63.93 2.29 45 59.36 2.67
4.3.4 Mood
There was no effect of treatment on either the Bond-Lader visual analogue scales or
on the DASS. The scores from both these measures can be found at the bottom of
Table 4.3.
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4.4 Discussion
Of the cognitive performance tasks, it was found that a faster reaction time was
achieved by participants in the DHA-rich FO group on the Stroop task. It was also
found that participants receiving both the active treatments matched fewer names to
faces in the Name-to-Faces Recognition task. In addition, there was no effect of
either treatment on any of the Bond-Lader or DASS mood measures, but
participants administered the EPA-rich FO reported reduced mental fatigue
compared to placebo during thirty minutes of cognitively demanding tasks. Given
the number of different tasks, along with the small number of significant outcomes
that were detected and the bi-directional nature of the results, overall these findings
do not provide solid evidence of cognitive or mood enhancement following
supplementation with either active treatment for 12 weeks.
The serum blood analysis revealed that both doses of DHA contained in the DHA-
rich FO (450 mg) and the EPA-rich FO (200 mg) was sufficient to raise serum DHA
above that of participants in the placebo group at Week 12. However neither dose of
EPA (300 mg - EPA-rich FO; 90 mg – DHA-rich FO) achieved this despite the active
treatments being successful in increasing within-group serum concentrations of EPA
at Week 12 compared to Baseline concentrations. As regards the other
physiological measures, there was no evidence of an effect of either of the active
treatments on heart rate or blood pressure. This is in agreement with a meta-
analysis reported by Morris et al. (1993) who found no effect of n-3 PUFA
supplements on blood pressure in healthy adults. More recently Shah et al. (2007)
reported that 1 g/d fish oil for 14 days reduced resting heart rate and improve
endothelial function in healthy men and women, though the sample was much
smaller (N = 26) with a higher mean age (31 years) than the current study, which
could potentially account for the differences.
Whilst the current results provide little evidence of cognitive enhancement following
n-3 PUFA supplementation, there are some interesting parallels with findings from
studies in similar samples. For example, the reduced reaction time on the Stroop
task observed in the DHA-rich FO group is consistent with Fontani et al. (2005) who
reported a beneficial within-treatment effect of fish oil on a go/no-go task and
Rogers et al. (2008) who reported a trend indicating improved performance on a
task of impulsivity following twelve weeks supplementation with a DHA-rich FO in
mild to moderately depressed adults. One hypothesis that could be drawn from the
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available evidence is that tasks requiring response inhibition may be sensitive to
increased intake of n-3 PUFAs. In addition, taking into account the results of the
present study it could be added that increased intake of DHA and not EPA may
responsible for the observed improvement on the Stroop task, considering the same
finding was not observed in the EPA-rich FO group, where the amount of DHA
contained in the supplement was less than half of that contained in the DHA-rich FO
(200 mg as opposed to 450 mg). Although mechanisms that might mediate
cognitive performance cannot be discerned from the present results, one potential
avenue to explore in future investigations is modulation of dopaminergic
neurotransmission by DHA-rich FO. Dopamine is known to modulate response
inhibition (Le Moal and Simon, 1991), and research in both animals and humans
has linked changes in n-3 PUFA intake to alterations in the dopaminergic system.
For example, n-3 PUFA deficiency in rats has previously been associated with
reduced levels of dopamine and dopamine D2 receptors in the frontal cortex (Delion
et al., 1996), to which behavioural changes including increased activity and reduced
motivation observed in n-3 deficient animals have been attributed (Zimmer et al.,
2002). Further, Chalon et al. (1998) revealed that n-3 PUFA supplementation
increased endogenous cortical dopamine levels in rats and Hershey et al. (2004)
demonstrated the involvement of dopaminergic neurotransmission in response
inhibition in healthy adults; administration of Levodopa—a dopamine agonist—
modulated activation of go/no-go task-specific areas of the brain. Altogether this
evidence may suggest a role for n-3 PUFAs, and DHA in particular, in tasks
requiring response inhibition, though this would need to be investigated further. One
last point to note is that in contrast to the finding reported here, Hamazaki et al.
(1996) did not report an effect of a high DHA oil supplement on a Stroop task. The
version of the task used in their study was modified, however, so that participants
were required to respond using a pen and paper. One possibility is that responses
were less accurately recorded compared to the computerised version utilised here.
Another parallel with previous research concerns the beneficial effect of the EPA-
rich FO on self-reported mental fatigue. This finding is consistent with previous
reports revealing reduced ratings of mental fatigue on the Profile of Mood States
following FO supplementation for 4 weeks in healthy adults (Antypa et al., 2009,
Fontani et al., 2005). What is interesting is that the average serum concentration of
EPA collected at Week 12 in the EPA-rich FO treatment group was not significantly
different from placebo. However, reference to the serum AA:EPA data shows that
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this ratio was significantly higher in the placebo group and had in fact increased in
Week 12 compared to Baseline. It is therefore possible to speculate that the
underlying mechanism responsible for the reduced mental fatigue reported by those
in the EPA-rich FO group might be modulation of the production of either AA or
EPA-derived eicosanoids, known to be regulators of many key immune, endocrine
and cardiovascular functions (Tassoni et al., 2007). This hypothesis is also
consistent with the results reported in Chapter 3, where the ratio of AA:EPA was
positively associated with mental fatigue on the same battery of cognitively
demanding tasks. Together these results suggest that mental fatigue could be
linked to an endogenous balance of AA and EPA, and that reducing this ratio or
preventing it from elevating via increased intake of n-3 PUFAs may have a
beneficial impact on subjective reporting of mental fatigue. An interesting point to
note is that despite reduced reporting of mental fatigue, there was no observable
benefit of either intervention on the performance outcome measures of CDB. This
could be an artefact of the task difficultly, with participants disengaging with the
tasks, or simply that neither treatment modulates performance on these tasks. A
further note is that the same effect of reduced mental fatigue was not observed in
the DHA-rich FO condition where the serum AA:EPA ratio of participants in this
group was also significantly lower than that of the placebo group. However, the daily
dose of EPA in the DHA-rich FO was less than a third of that present in the EPA-
rich FO (90 mg as opposed to 300 mg), so it is possible that this may be a
contributing factor, even though serum concentrations of EPA were not significantly
different from placebo at Week 12 in the EPA-rich FO group. On this point it must be
noted that the failure of the EPA-rich FO to raise participants’ serum concentrations
of EPA above that of the placebo group is a limitation of this study that would need
to be addressed in future studies. Given that serum concentrations of EPA were
found to be significantly positively associated with performance on a cluster of
episodic memory tasks in Chapter 3 suggests that the possibility of enhancement on
these tasks being observed following higher doses, although unlikely, cannot be
ruled out.
Returning briefly to the mental fatigue data, a related observation concerns the fact
that participants who were administered the active treatments were not able to
correctly identify if they had been taking fish oil or placebo capsules. Of those that
did guess correctly, none listed feeling less fatigued as a reason, regardless of
group, so the reduced mental fatigue experienced by participants taking the EPA-
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rich FO induced under laboratory conditions may have been too subtle to have an
impact on everyday functioning. One future extension could evaluate the efficacy of
EPA-rich FO to ameliorate symptoms of fatigue, both mental and physical, in
populations who subjectively report fatigue such as individuals in full-time work,
primary caretakers of children, and carers, for example.
Also in relation to the serum AA:EPA ratio data reported here, it is potentially
surprising that no effect of treatment was detected on any of the subscales of the
DASS, especially given the significant positive association between anxiety and
serum AA:EPA reported in Chapter 3. Previously, n-3 PUFA supplements have
been shown to be effective at reducing feelings of anxiety in substance abusers
(Buydens-Branchey and Branchey, 2006), and DHA-rich fish oil reduced levels of
noradrenalin—a hormone mediator of the stress response—in students under
continued exam stress (Hamazaki et al., 1999). Considering that psychological
stress and anxiety are also linked to elevated pro-inflammatory cytokine profiles
(Maes et al., 1998), which are in turn modulated by dietary intake of n-3 PUFAs
(Ferrucci et al., 2006), future research could incorporate paradigms that induce
psychological stress or anxiety akin to the laboratory-induced mental fatigue
achieved by the CDB, as a more appropriate evaluation of the efficacy and
underlying mechanisms of n-3 PUFAs on these outcomes. As it stands these data
presented here do not suggest that DHA-rich or EPA-rich FO modulates stress,
anxiety or depression as measured by the DASS in healthy young adults.
Fish oil supplementation was also associated with some cognitive costs. Both
treatment conditions were associated with poorer performance on the Names-to-
Faces Recall task. To the author’s knowledge this is the first reporting of a
detrimental effect of fish oil or n-3 PUFA supplementation on cognitive function and
there is no theoretical basis that would support these particular observations. In
addition, Chapter 3 reported a positive association between serum concentrations of
EPA and total n-3 PUFAs and number of correctly matched items on this task (see
Table 3.2), which is not consistent with this finding. As previously mentioned
however, a limitation of this study is the large number of tasks that were utilised,
which generated an even larger number of separate outcomes. It is possible
therefore that this negative finding is a result of Type I error. As such, this and all
the results reported in the current chapter should be interpreted with caution,
however the decision to use many different performance measures can be
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defended considering the findings of the study described in Chapter 3, where serum
fatty acid levels were associated with performance across a number of different
cognitive domains, rendering it difficult to specifically select tasks where an effect of
treatment could be predicted.
On a similar note it should be emphasised that significant benefits of
supplementation were only observed on a single outcome on the COMPASS
battery. Animal studies that have administered supplemental n-3 PUFAs to rats
raised on a balanced and n-3 adequate diet performed no better on behavioural
tests than the animals given no supplement (de Wilde et al., 2002), suggesting that
performance cannot be enhanced when n-3 PUFAs are supplemented to excess. In
the present study, a sample of healthy adults was recruited, selected only on the
basis of not consuming a high amount of oily fish (≤ one portion of oily fish a week
on average), with a view to providing information about the effects of
supplementation in an otherwise unselected population about which very few data
existed. As such, the results presented here suggest that performance benefits
incurred from dietary supplementation with fish oils in a healthy unselected
population at a dose that is roughly equivalent to the current UK recommendation
(SACN/COT, 2004), are minimal. One possible interpretation of the findings could
be that even though three quarters of the present sample reported consuming less
oily fish than the current recommendation, and despite the fact that serum
concentrations of DHA at least were generally lower than what has been observed
in normal healthy participants in previous studies (Morse, 2009), endogenous n-3
PUFA levels were not below a certain threshold where performance deficits are
observed and can be subsequently improved when n-3 PUFAs are administered.
One particular study in animals does support the suggestion of a threshold of n-3
PUFA intake (and subsequent cellular incorporation), below which performance is
adversely affected. Jensen et al. (1996) compared the effects of four different diets
on brain phospholipids and performance in rats on the Morris Water Maze (MWM)
task after four generations of dietary intervention. The diets were seal oil (rich in
DHA and EPA, but containing less EPA than fish oil), fish oil (rich in DHA and EPA),
flaxseed oil (containing the parent n-3 fatty acid α-linolenic acid; ALA) and normal
rat chow containing 2% fat with a mixture of ALA and linoleic acid (n-6). These
authors report that when brain levels of n-3 PUFAs (DHA + docosapentaenoic acid)
contained in phosphatidylethanolamine were between 24 and 27% as they were in
the rats fed vegetable and marine oils, there was no difference in performance on
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the MWM, however when these levels fell to 22%, as they were in the control rats
fed the normal chow, performance was worse, with significantly longer escape
latencies. As regards the current study, more significant and notable improvements
in performance may be seen, perhaps, if a sample were selected on the basis of
non-consumption of oily fish, and also at higher dosages, considering ineffectual
modulation of serum EPA levels by both treatments. It is also possible that benefits
of n-3 PUFA supplementation on cognitive function, if they indeed exist in healthy
populations, may be better observed at times when resources are in high demand,
considering the beneficial effect of the EPA-rich FO on mental fatigue reported here.
One potential future paradigm could possibly reverse the order of the test batteries,
so that mental fatigue was induced prior to further cognitive testing with the
COMPASS battery.
The current study describes the first investigation where the effects of DHA- and
EPA-rich fish oils on cognitive function and mood have been investigated in parallel
under the exact same conditions. The primary aim of this study was to assess the
effects of n-3 PUFA supplementation in a population where few data are available
regarding cognitive performance and mood. A 1 g dose of FO was chosen so that
the results could be readily translated into meaningful dietary advice. As such, the
data presented here do not favour the use of fish oil supplements for cognitive or
mood enhancement.
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CHAPTER 5. CEREBRAL HEMODYNAMIC EFFECTS OF DHA-RICH FISH OIL
AND EPA-RICH FISH OIL IN HEALTHY YOUNG ADULTS
5.1 Introduction
The n-3 PUFAs DHA and EPA, abundantly found in oily fish are essential and must
be supplied via dietary sources. In the brain, DHA is required to maintain the
structural integrity of neuronal cell membranes, and comprises approximately 10-
20% of fatty acids found in this organ (McNamara and Carlson, 2006). The
presence of DHA in cell membranes increases membrane fluidity and permeability,
which in turn can impact upon signal transduction pathways (see Section 1.4.1).
EPA, though not a major component of the brain, could potentially influence brain
physiological function and therefore behaviour via the action of its many eicosanoid
derivatives; regulators of key immune, endocrine and cardiovascular functions (see
Section 1.4.2). Animal studies have demonstrated that when n-3 PUFAs are absent
from the diet, cognitive deficits are observed, compared to n-3 adequate control
animals (see Section 1.5.1). In humans, low n-3 PUFA status is associated with a
number of adverse health and behavioural outcomes, however n-3 PUFA
intervention trials have provided mixed results with some studies showing a benefit
of n-3 PUFAs on symptom reduction or behavioural measures, while others do not
(see Sections 1.5.2.1 and 1.5.2.3). More recently, the issue of cognitive and mood
enhancement via n-3 PUFA supplementation has been explored in healthy
volunteers (e.g. Dalton et al., 2009, Fontani et al., 2005, Hamazaki et al., 1996,
Hamazaki et al., 1998, Itomura et al., 2005, Osendarp et al., 2007, Rogers et al.,
2008, Chapter 2, Chapter 4), but again these studies have not yielded conclusive
findings overall. Despite the relative lack of consistent data regarding the
behavioural effects of dietary n-3 PUFAs, it is possible that n-3 PUFAs are still
impacting upon various physiological functions of the brain. For example, the DHA
content of the brain is indeed influenced by dietary intake; in animals DHA
supplementation has been shown to increase levels of this fatty acid in the brain
(Moriguchi et al., 2001, Connor et al., 1990). In contrast, reduced dietary DHA in
rats is reflected in lower membrane phospholipid levels in the brain (fronto-parietal
cortex, hippocampus and suprachiasmatic nucleus), which appears to be related to
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reductions in regional metabolic rate (da Silva et al., 2002). Further, one study in
aged rhesus monkeys (mean age 18 years) discovered that DHA supplementation
for four weeks restored age-related cerebral blood flow response to tactile
stimulation (Tsukada et al., 2000a).
Similarly, in humans n-3 PUFA intake (from two 24-hr food recall interviews) has
been shown to be positively associated with grey matter volume in corticolimbic
areas (Conklin et al., 2007), however to the author’s knowledge only three studies
have directly examined the relationship between n-3 PUFAs and physiological brain
function. The first discovered that administration of n-3 PUFAs (either 8.4 g or 2 g
DHA+EPA) for 4 weeks in patients with bipolar disorder resulted in decreased
whole-brain T2 relaxation times (as measured by fMRI 2), compared to placebo,
which the authors interpreted as reflecting increased membrane fluidity due to
incorporation of n-3 PUFAs in neuronal cell membranes (Hirashima et al., 2004).
Another study reported that fish oil supplementation (1.60 g EPA + 0.80 g DHA)
resulted in increased amplitude of the negative peak preceding and the positive
peak following stimuli on a go/no-go task (EEG; CNV and P300, respectively),
though only within-group comparisons were made before and after treatment
(Fontani et al., 2005). More recent work has revealed that plasma levels of PUFAs
(DHA and AA) were correlated with metabolic activity in a number of brain regions in
depressed patients using PET (Sublette et al., 2009). More specifically, DHA and
AA were positively associated with glucose metabolism (rCMRglu) in the
temporoparietal region and DHA was negatively correlated with rCMRglu in the
frontal cortex and anterior cingulate cortex. Taken together, evidence from both
animal and human studies suggests that brain physiology and function are
associated with dietary n-3 PUFAs, although the nature of this relationship is only
beginning to be investigated.
One viable approach to evaluate the effect of dietary n-3 PUFAs on brain
physiological function is by measuring cerebral hemodynamics using functional
Near Infrared Spectroscopy (NIRS), a non-invasive optical imaging technique. The
guiding principle of NIRS is that the chromophores oxyhaemoglobin (O2Hb) and
deoxyhaemoglobin (HHb) absorb light at different wavelengths. Therefore, by
2 Increased T2 relaxation time is indicative of decreased activity in a brain region (Anderson
et al., 2002)
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measuring the amount of light absorbance at a specific wavelength, the
concentrations of O2Hb and HHb can be calculated (Fallgatter and Strik, 1997).
Total haemoglobin (THb) is the third outcome to be produced by NIRS
measurements and is simply the sum of O2Hb and HHb. In this way NIRS can been
used as a measure of activation of neural tissue or simply as a measure of cerebral
blood flow. THb is closely related to cerebral blood volume (CBV), from which
changes in regional CBF (rCBF) can be inferred (Steinbrink et al., 2005). THb also
correlates well with rCBF changes as measured using the labelled-water technique
(Villringer and Dirnagl, 1995), although studies using rat brain models suggest that
O2Hb is a better measure of rCBF than THb (Hoshi et al., 2001). Changes in
concentrations of either O2Hb and HHb are related to changes in cerebral metabolic
rates (Tamura et al., 1997), and the concentration of HHb and to a lesser extent
O2Hb, is strongly correlated with the fMRI BOLD signal (Huppert et al., 2006). NIRS
has been successfully used to image activation in the frontal cortex (e.g. Fallgatter
and Strik, 1997, Fallgatter and Strik, 1998) and other areas of the brain including the
temporal, visual and parietal cortices (e.g. Schecklmann et al., 2008, Jasdzewski et
al., 2003). The use of NIRS in pharmacological interventions is a novel application
of this technique, with only a small number of trials published to date (e.g.
Kanamaru et al., 2008, Bonoczk et al., 2002). Using NIRS in this way, the opposite
effects for a vasodilator (resveratrol - Kennedy et al., 2010) and a vasoconstrictor
(caffeine - Haskell and Kennedy, In preparation) have been demonstrated. In
comparison with fMRI, the current ‘gold standard’ for measuring brain activation,
NIRS has the advantage of being safe, non-invasive and inexpensive (Bunce et al.,
2006). It is also highly portable, and allows for neuroimaging in a more natural
setting (Hoshi, 2007). On the other hand, a disadvantage of the NIRS imaging
technique is that it has low spatial resolution in comparison to other methods,
however it does have the benefit of providing high temporal resolution (Obrig and
Villringer, 2003). Finally, because the apparatus is easily and quickly applied to the
head, this a valuable tool in studies that require a large number of participants or
testing sessions.
To date only a limited number of studies have assessed the relationship between n-
3 PUFAs and physiological brain function in humans. Given that dietary
supplementation with n-3 PUFAs has previously been shown to modulate fatty acid
concentrations in the frontal cortex (e.g. Connor et al., 1990), this area was selected
as the region of interest for the current study. In addition, al
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literature has primarily focused on the mechanisms of action of DHA in relation to
brain function given the high proportion of this fatty acid to be found there, it is also
possible that EPA could affect cerebrovascular parameters, given that this fatty acid
is also readily incorporated into endothelial cell membranes elsewhere in the
cardiovascular system, albeit to a lesser degree than DHA (Hashimoto et al., 1999).
Therefore, the objective of this pilot trial was to investigate any treatment related
effects upon task-related cerebral hemodynamic response, in the prefrontal cortex
following a DHA-rich and an EPA-rich fish oil supplement in healthy volunteers.
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5.2 Materials and Methods
5.2.1 Design
A placebo-controlled, double-blind independent measures design was employed
with participants randomly assigned to one of three treatment groups (placebo,
DHA-rich fish oil, EPA-rich fish oil; see Section 4.2.3).
5.2.2 Participants
Twenty-two healthy adults took part in the study; demographic details can be found
in Table 5.1. All participants declared they were in good health, a non-smoker, free
from prescription medication and social drugs, free from omega-3 supplements and
a native English speaker. Participants also declared they did not consume more
than 1 portion of oily fish per week. At the time of testing, participants were enrolled
in a larger intervention trial (see Chapter 4) and were invited to take part in an extra
testing session once they had completed their Week 12 cognitive assessment.
The study received approval from the Northumbria University School of Psychology
and Sport Sciences Ethics Committee and was conducted according to the
Declaration of Helsinki (1964). All participants gave their informed consent prior to
their inclusion in the study.
Table 5.1. Participant demographic data by treatment group. Means and SEM are
presented.
Placebo DHA-rich FO EPA-rich FO
N (Male/Female) 2/5 4/3 3/5
Age 22.43 1.54 20.71 0.78 22.75 1.83
BMI 23.29 1.12 22.94 0.86 22.88 1.89
5.2.3 Treatments
The three treatments (DHA-rich FO, EPA-rich FO, placebo) used in the current
study were identical to those described in Section 4.2.3. Participants were instructed
to consume 2 x 500 mg capsules per day for 12 weeks.
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5.2.4 Physiological Measures
5.2.4.1 Near Infrared Spectroscopy (NIRS)
Relative changes in the absorption of near infrared light were measured using a 2-
channel continuous wave Oxymon system (Artinis Medical Systems B.V.). This type
of system applies continuous light to tissue and allows the observation of changes
in regional cerebral blood flow by measuring changes in the concentration of
cerebral haemoglobin (Hoshi, 2007). The sources were laser diodes emitting light at
discrete wavelengths; 765 and 855 nm. So that the attenuation data could be
converted into relative concentration changes of oxygenated haemoglobin (O2Hb),
deoxygenated haemoglobin (HHb) and total haemoglobin (THb), a modified Beer-
Lambert law3 (Obrig and Villringer, 2003) was applied using the proprietal software,
with the differential pathlength factor (the gradient of the attenuation with respect to
the absorption coefficient of the tissue, used to determine the absolute pathlength of
the photons, Kohl et al., 1998), adjusted according to the age of the participant. The
resulting measurement is considered to express concentration changes in
micromoles per litre (Toichi et al., 2004). Measurements were recorded at a time
resolution of 10 Hz.
For this experiment, a 2-channel configuration was used (i.e. 2 emitter/optode pairs)
with an emitter/optode separation distance of 40 mm. The emitter/optode pairs were
positioned over the left and right frontal cortex using a standard optode holder
headband (see Figure 5.2a), corresponding to points Fp1 and Fp2 in the 10-20
system. At this distance, the NIR signal is sensitive to hemodynamic changes within
the top 2-3 mm of the cortex (Chance et al., 1988, see Figure 5.1). Since the same
headband was used throughout the experiment, the relative positions of the
emitter/optodes did not change from participant to participant. The emitter/optode
pairs were attached to the Oxymon machine via 3 m long fibre optic bundles; the
machine itself was connected via USB to a laptop for data acquisition (see Figure
5.2b). Recorded data were stored as a .TXT file and analysed using SPSS 16.0
(SPSS Inc., Chicago, IL, USA).
3 The Beer-Lambert law expresses a linear relationship between absorbance and
concentration. A modified Beer-Lambert law is used for a highly scattering medium e.g. brain
tissue.
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5.2.5 Cognitive Tasks
Four tasks were selected that have previously been shown to activate the prefrontal
cortex in brain imaging studies; Stroop Task (Vanderhasselt et al., 2009), Tower of
London (Fitzgerald et al., 2008), 3-back task (Fitzgerald et al., 2008) and Wisconsin
Card Sorting Task (Toone et al., 2000). Tasks were presented via a laptop
computer in the same order as listed below. Progress through the battery of tasks
was controlled by the participant, with brief instructions given on-screen prior to the
start of each task. A 60-second rest period between each task was incorporated into
the battery commencing as soon as the last response of the previous task had been
made and ended with the presentation of the on-screen instructions for the next
task. Data from these tasks were not analysed, but average scores can be found in
Appendix VI.
5.2.5.1 Stroop Task
A computerised version of the Stroop task (Stroop, 1992) was presented. Words of
colours (GREEN, BLUE, RED, YELLOW) were randomly presented in incongruently
coloured text (e.g. GREEN was presented in blue text etc.). For each stimulus
presentation, participants were instructed to press the coloured button on a
response box that matched the colour of the text the word was presented in. This
task was 5 minutes in duration. Overall accuracy (% correct) and reaction time were
recorded.
5.2.5.2 Tower of London (TOL)
In this computerised version of the executive function task participants were
presented with two configurations of three coloured balls (blue, green, red) on three
pegs that hold three, two and one ball respectively. The subjects have to rearrange
the balls from the starting configuration so that they match the position of the balls in
the goal configuration. Subjects are asked to work out the entire planning sequence
and indicate the minimum number of moves required prior to moving the balls using
the mouse/cursor. The rules concerning the moving of the balls correspond to those
of (Shallice, 1982): (1) only one ball could be moved, (2) a ball could only be moved
if there was no ball above it on the peg and (3) the length of the pegs should be kept
in mind. Subjects randomly complete 3 trials each which can be solved in 3, 4, and
5 moves respectively. Average planning time and time to complete the moves were
recorded.
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5.2.5.3 3-back Task
A continuous string of letters (upper and lower case; inter-stimulus interval of 2.5
seconds) was presented; 78 letters in total with 36 target pairs. For each stimulus,
participants were instructed to indicate using a yes/no key press whether this was
the same letter that appeared three letters previously. Average accuracy (% correct)
and reaction time were recorded.
5.2.5.4 Wisconsin Card Sort Task (WCST)
This is a standard clinical measure that is commonly used as a measure of
executive function and is thought to require cognitive flexibility, problem solving, and
the use of feedback to guide behaviour. In this computerised version of the test,
subjects are asked to match cards that vary by colour, shape, and number to four
“key cards.” Subjects are not told how to sort the cards, but must determine the
correct category from the feedback given to their responses, which changes
periodically throughout the test. In total the current version comprised the
presentation of 128 cards. Overall accuracy (% correct) and time to complete the
task were recorded.
5.2.6 Procedure
As part of a larger intervention trial investigating the effects of two types of fish oil on
cognitive function and mood, participants had been taking a daily 1 g supplement of
either EPA-rich FO, DHA-rich FO or olive oil placebo for 12 weeks. Towards the end
of the 12 week period, participants were invited via email to take part in an extra
cognitive testing session with concurrent NIRS data collection. In all cases this
session was either on the day of the final behavioural testing session or the
following day (average time on treatment 88.59 days). Testing took place in the
afternoon (the cognitive assessments described in Chapter 4 took place in the
morning), and participants were instructed to refrain from consuming food and drink
except water for a minimum of 2 hours prior to testing.
On arrival participants were seated in front of the laptop computer used for
presenting the cognitive tasks. They were fitted with the NIRS headband and were
instructed to sit quietly with their eyes closed until they were given further instruction
by the researcher to start the cognitive tasks. Recording of NIRS data was initiated
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following 30 seconds of eyes-closed relaxation and the participant was instructed to
begin the tasks after a further 2 minutes of eyes-closed relaxation. This 2 minute
period was utilised as the NIRS resting baseline measurement. Participants
completed each task as described above with NIRS data collected throughout.
5.2.6.1 Statistical methods
NIRS data were initially converted to 'change from baseline' (2 minute pre-testing
rest period), the resultant data therefore representing the change in concentration of
each of the chromophores with respect to the pre-testing measurements.
Prior to the primary analysis a within subjects Analysis of Variance (ANOVA) was
carried out with left/right optode included as a factor (hemisphere x treatment group)
for each task. As there were no treatment related interactions involving hemisphere
the data from the 2 channels were averaged across hemispheres for the analysis
and figures reported below.
The Stroop task was 5 minutes in length so NIRS data for this task was taken from
300 s of measurement. Due to the fact that the other three tasks were completed in
variable lengths of time, the minimum duration of each task was identified and data
for every participant were truncated accordingly. Therefore, data from TOL were
averaged from 160 s of NIRS recording, for the 3-back task data were averaged
over 250 s and for the WCST data were averaged over 180 s of NIRS recording. As
the duration of each task of averaged NIRS data entered into the analysis was
substantially longer than the potential physiological oscillations that can cause drift
in shorter periods of NIRS recording (e.g. heartbeat, respiration Hoshi, 2007), no
adjustment was required for this phenomenon (Kennedy et al., In press-b).
The primary analysis of the averaged NIRS data was conducted by one-way
ANOVA for each task with a priori planned comparisons of the data from each task
being made between placebo and each treatment group (DHA-rich FO, EPA-rich
FO) using t tests calculated with the mean squares error of the overall ANOVA
(Keppel, 1991). To protect against an increased Type I error rate, only those
planned comparisons associated with a significant main effect of treatment on the
ANOVA are reported.
110
5.3 Results
5.3.1 NIRS
5.3.1.1 Oxyhaemoglobin (O2Hb)
There was a significant main effect of treatment on O2Hb whilst participants
completed the Stroop task [ F(2, 19) = 3.72, p = 0.043 ]. Reference to the planned
comparisons showed a significant increase in the concentration of O2Hb following
the DHA-rich FO during this task compared with placebo [ t(19) = 2.73, p = 0.013, r
= 0.59 ]. Trends for an effect of treatment were observed for TOL and the 3-back
task [ F(2, 19) = 3.35, p = 0.057; F(2, 19) = 2.69, p = 0.093, respectively] (See
Figure 5.3).
5.3.1.2 Deoxyhaemoglobin (HHb)
The ANOVAs revealed no treatment-related effects on concentrations of HHb during
any of the cognitive tasks.
5.3.1.3 Total haemoglobin (THb)
The ANOVA showed that there was a significant effect of treatment on THb during
the Stoop task, TOL and 3-back task [ F(2, 19) = 4.93, p = 0.019; F(2, 19) = 4.21, p
= 0.031; F(2, 19) = 3.57, p = 0.048, respectively]. Reference to the planned
comparisons showed a significant increase in THb in the DHA-rich FO treatment
condition compared to placebo during all three of these tasks [ Stroop t(19) = 3.10,
p < 0.006, r = 0.64; TOL t(19) = 2.87, p < 0.009, r = 0.61 and 3-back task t(19) =
2.67, p < 0.016, r = 0.58 ] (See Figure 5.3).
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Figure 5.3. Concentration changes of oxygenated and total haemoglobin (Δ[O2Hb] and Δ[THb]) by 
treatment group (Placebo, DHA-rich FO, EPA-rich FO) during the cognitive tasks. Data are averaged
across both hemispheres (left/right). Significance is compared to placebo (planned comparisons). (*, p
< 0.05; **, p < 0.01).
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5.4 Discussion
The results of the current study revealed that participants administered 1 g/d DHA-
rich FO for 12 weeks had an increased CBF response to performing cognitive tasks
in the prefrontal cortex, in comparison with placebo, as indexed by changes in the
concentration of total haemoglobin (THb) and oxyhaemobglobin (O2Hb). A
significant difference between the placebo and DHA-rich FO treatment groups on
either of these chromophores was not universally observed, however. Reference to
the overall pattern of concentration changes during all the tasks for both these
chromophores suggests perhaps that the small sample size did not allow for
adequate detection of a difference in the concentration changes in the DHA-rich FO
treatment group compared to placebo during the other tasks. With regards to
concentration changes of deoxyhaemoglobin (HHb), no difference was observed
between either of the fish oil treatment groups and placebo during any of the tasks,
though change from baseline concentrations were similarly small in all three
conditions, a phenomenon that has been observed previously (Hoshi and Tamura,
1993). In addition, no significant effects of treatment were observed on any of the
cognitive performance measures.
The pattern of concentration changes in O2Hb and THb in the EPA-rich FO group
did not differ from placebo which suggests that the higher daily dose of DHA in the
DHA-rich FO (450 mg/d compared to 200 mg/d) contributed to the observed
concentration changes. More specifically, this finding suggests that rCBF response
to tasks is only modulated following supplementation with DHA at a dose that is
higher than 200 mg/d. Also, the pattern of increased O2Hb and THb in the DHA-rich
FO treatment group, compared to placebo, is comparable to data published from a
supplementation study in aged monkeys, in which DHA (150 mg/kg/d) was
administered to the animals for 4 weeks. The results of this study showed that
compared to placebo, the age-related impairment of the rCBF response to tactile
stimulation (as measured by PET) was restored (Tsukada et al., 2000b), again
providing evidence supporting a role for DHA in cerebrovascular function. On the
other hand, the data presented here suggest that despite the fact that EPA is known
to improve peripheral cardiovascular parameters, the addition of dietary EPA at a
dose of 300 mg/d for 12 weeks has no impact on cerebral hemodynamic response
to cognitive tasks.
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Overall the results of this pilot study therefore provide the first indication of possible
modulation of cerebral blood flow parameters following dietary supplementation with
DHA-rich FO, and at a dose (1 g/d) that would be achievable by dietary intake of oily
fish alone. Previously, studies that have aimed to evaluate the effect of n-3 PUFA
supplementation on behavioural outcomes in healthy individuals have provided
mixed results, but the data from the current study suggest that an n-3 PUFA dietary
supplement may indeed impact brain physiology as regards cerebral perfusion of
activated areas. Given these interesting and novel results, further studies using
NIRS to assess the causal relationship between n-3 PUFA intake and cerebral
blood flow parameters are warranted.
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CHAPTER 6. THE COGNITIVE AND CEREBRAL HEMODYNAMIC EFFECTS OF
DHA-RICH FISH OIL: A DOSE-RANGING STUDY
6.1 Introduction
The n-3 PUFAs DHA and EPA are vital for normal cell function; however the
distribution of these fatty acids is not uniform across bodily organs. For example,
10-20% of the total fatty acids in the brain are comprised of DHA, yet less than 1%
are comprised of EPA (McNamara and Carlson, 2006). The DHA composition of the
brain (and indeed the DHA and EPA content of other tissues) is incredibly labile,
owing to the fact that DHA, along with the other n-3 PUFAs, must be acquired via
dietary sources. Rats and non-human primates raised on diets deficient in n-3
PUFAs (DHA, EPA and their parent precursor fatty acid ALA) have reduced levels
of DHA in the brain, which is associated with modified cholinergic, serotonergic and
dopaminergic neurotransmission pathways (Delion et al., 1994, Aid et al., 2003). In
line with these physiological changes, reduced n-3 intake has also been shown to
be associated with behavioural changes. For example, rats showed reduced
learning on the Morris Water Maze task as evidenced by delayed acquisition and
longer escape latencies (Moriguchi et al., 2000, Jensen et al., 1996) and poorer
performance on olfactory discrimination tasks (Greiner et al., 2001). Similarly, rats
raised on n-3 deficient diets showed more working memory and reference memory
errors on the radial arm maze task, compared to those that were brought up on the
same n-3 deficient diet and then supplemented with dietary DHA (Gamoh et al.,
1999, see also Section 1.5.1).
A similar relationship between dietary n-3 PUFA intake, biological markers and
behaviour appears to exist in humans, though it is more difficult to separate the
impact of individual n-3 PUFAs. For example, the plasma n-3 PUFA profiles of
consumers of oily fish have higher concentrations of DHA, EPA and ALA than non-
consumers (Welch et al., 2006), and grey matter volume in healthy adults is
positively associated with total n-3 PUFA intake, estimated by 24-hour food recall
(Conklin et al., 2007). In terms of behaviour, low maternal intake of oily fish during
pregnancy is associated with increased risk for suboptimal cognitive, developmental
and behavioural outcomes in later childhood (Hibbeln et al., 2007). Further, in
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comparison with normal healthy individuals, those diagnosed with developmental
disorders such as autism and ADHD (Bell et al., 2000, Burgess et al., 2000,
Schuchardt et al., 2009) or certain neuropsychiatric illnesses including depression
(Edwards et al., 1998), schizophrenia (Assies et al., 2001) and Alzheimer’s disease
(Conquer et al., 2000) have lower tissue (plasma/serum, erythrocyte membrane,
adipose tissue) concentrations of n-3 PUFAs, however intervention trials to
investigate the potential for n-3 PUFAs in the treatment of these conditions have
yielded mixed results (see Section 1.5.2.1). N-3 PUFA supplementation for cognitive
and mood enhancement has also recently been explored in healthy volunteers, but
again these supplementation studies have not always shown benefits of the
intervention over placebo on behavioural outcomes (see Sections 1.5.2.3, 2.3, 4.3).
However, despite the lack of evidence to support the use of n-3 PUFAs for improved
behavioural outcomes, it is plausible to suggest that the addition of dietary n-3
PUFAs may still be having an impact on brain function. It is possible that the lack of
consistency in the behavioural data may be an artefact of methodological diversity
(e.g. sample, dose and treatment formulation, time on treatment, outcome
measures) between studies, or simply that the effects of n-3 PUFAs on
physiological function in the brain or elsewhere in the body are not large enough to
impact directly on behaviour.
In the pilot study described in Chapter 5, the effects of either a DHA-rich fish oil (FO;
450 mg DHA + 90 mg EPA) or EPA-rich FO (300 mg EPA + 200 mg DHA) on the
regional cerebral blood flow response to task performance was investigated using
Near Infrared Spectroscopy (NIRS) in healthy human adults. It was demonstrated
that, compared to placebo, participants administered the DHA-rich FO had
increased concentrations of total haemoglobin (THb) and oxyhaemoglobin (O2Hb)
in the prefrontal cortex when responding to a selection of cognitive tasks (see
Section 5.3 for details). Whilst this pilot study had low statistical power, the results
for the DHA-rich FO treatment were promising enough to take forward into a larger
trial which would have the added advantage of providing a more sufficient
assessment of treatment effects on task performance. The present study aimed to
address this issue, with a view to evaluating the effects of treatment on brain
function (cerebral hemodynamics) and behaviour (cognitive performance) in
parallel. Previous intervention studies in n-3 deficient rats have suggested that
supplementing the diet with n-3 PUFAs to excess does not result in any additional
positive effects on performance (Farkas et al., 2002), but the impact of n-3 PUFAs
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on cerebral blood flow at levels higher than that which would easily be achievable
by dietary means alone is not known. For this reason two doses of DHA-rich FO
were selected for evaluation in the present study; 1 g/d is roughly equivalent to
consuming one portion of oily fish per week (450 mg n-3 PUFAs), the minimum
intake recommended by the current advisory on fish consumption (SACN/COT,
2004), and 2 g/d, which would be equivalent to twice this amount and more difficult
to achieve through dietary sources alone. Further, non-consumers of oily fish were
invited to participate in the study in order to control for dietary intake of DHA during
the study period, given that oily fish is the most abundant dietary source of DHA.
Despite opting to select a sample according to this particular criterion, it could also
be argued that recruiting only non-consumers of oily fish is still representative of the
large proportion of the general population, given that in the last National Diet and
Nutrition Survey in 2002 it was revealed that 74% of adults aged 19-64 years do not
consume oily fish (Henderson et al., 2002). Therefore the current study aimed to
investigate the effects of two doses of DHA-rich FO on task-related cerebral
hemodynamic response and cognitive performance in healthy non-consumers of
oily fish.
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6.2 Materials and Methods
6.2.1 Design
A placebo-controlled, double-blind independent measures design was employed
with participants randomly assigned to one of three treatment groups (placebo, 1 g
DHA-rich fish oil, 2 g DHA-rich fish oil; see Section 6.2.3). Prior to the start of the
study a restricted randomisation (23 X 3 treatments) list matching treatments to
participant code numbers was computer generated. Participants were assigned the
next available code at the screening session. For the NIRS data analysis, task
comprised a second, within subjects factor.
6.2.2 Participants
Sixy-five healthy adults (mean age 20.58 years, range 18-29) were recruited via an
email advert sent to Northumbria University undergraduate students. All participants
declared they were in good health, a non-smoker, free from prescription medication
and social drugs, free from omega-3 supplements and a native English speaker.
They also declared that they were non consumers of oily fish. One participant
withdrew from the study due to illness; demographic details for the remaining 64
participants who completed the study can be found in Table 6.1.
The study received approval from the Northumbria University School of Psychology
and Sport Sciences Ethics Committee and was conducted according to the
Declaration of Helsinki (1964). All participants gave their informed consent prior to
their inclusion in the study.
Table 6.1. Demographic data by treatment group. Means are presented with SEM.
Placebo 1 g fish oil 2 g fish oil
Mean SEM Mean SEM Mean SEM
N (M/F) 6/14 7/15 3/19
Age 21.35 0.62 20.50 0.43 19.95 0.34
BMI 23.73 0.88 22.23 0.63 22.37 0.76
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6.2.3 Treatments
Participants received two containers of 196 capsules labelled Container 1 and
Container 2, along with instructions to take 2 x 500 mg capsules from each
container every day for the duration of the experiment (a daily total of 4 x 500 mg
capsules for 12 weeks). For the placebo group Container 1 and Container 2 both
held olive oil capsules, for the 1 g FO group Container 1 held active capsules and
Container 2 held olive oil capsules and for the 2 g FO group both containers held
active capsules. The DHA-rich FO and placebo capsules were identical to those
described in Section 4.2.3; each of the active capsules contained 497.5 mg of
deodorised FO plus 2.5 mg mixed tocopherols and each of the placebo capsules
contained 500 mg olive oil. The total daily dose of n-3 PUFAs for the 1 g FO group
was 450 mg DHA + 90 mg EPA and for the 2 g FO group these amounts were 900
mg DHA + 180 mg EPA.
Prior to the start of the study a restricted randomisation (30 X 3 treatments) list
matching treatments to participant code numbers was computer generated.
Participants were then assigned a participant code and the corresponding treatment
at the end of the screening visit. All treatments were packaged, labelled and
randomised on site by a disinterested third party who had no further involvement in
any aspect of the study.
6.2.4 Near Infrared Spectroscopy
The study utilsed a 2-channel continuous wave Oxymon system described
previously in Chapter 5.2.3.1. In this system the emitter/optode pairs were
positioned over the left and right frontal cortex using a standard optode holder
headband, corresponding to points Fp1 and Fp2 in the 10-20 system. NIRS data
were time stamped by the researcher at the start and end of each task so that only
NIRS data collected during the tasks were analysed.
6.2.5 Cognitive Assessment
Nine tasks were administered using the COMPASS (Computerised Mental
Performance Assessment) system, which presented a battery of standard cognitive
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tasks in the same order as outlined below (cognitive domain in brackets). For the
purposes of the behavioural analysis, the tasks were selected with the intention that
performance on a range of cognitive functions could be assessed including working
memory (WM), attention and executive function. Specifically, they were also
selected on the basis that execution of the same or a similar task had shown
activation in the frontal cortex in previous imaging studies (although it is assumed
that activation is not exclusively limited to this region), given that this was the region
of interest in the current study [ Corsi Blocks (Owen et al., 1996); NWM (Awh et al.,
1996); 3-back (Fitzgerald et al., 2008); SRT, 4CRT (Rosenthal et al., 2001); CRT
(Schluter et al., 2001); Stroop (Vanderhasselt et al., 2009); RVIP (Lawrence et al.,
2002); Serial 7s (Drummond et al., 1999)]. Progress through the battery of tasks
was controlled by the participant, with brief instructions given on-screen prior to the
start of each task.
6.2.5.1 Corsi Blocks Task (Spatial WM)
In this task nine identical blue squares appeared on screen in non-overlapping
random positions. A set number of blocks changed colour from blue to red in a
randomly generated sequence. The cursor was locked in position until the entire
sequence had been presented, at which point the participants were instructed to
repeat the sequence by clicking on the blocks using the mouse and cursor. The task
was repeated five times at each level of difficulty. The sequence span increased
from 4 upwards, until the participant can no longer correctly recall the sequence,
resulting in a span measure of nonverbal working memory, calculated by averaging
the level of the last five correctly completed trials.
6.2.5.2 Numeric Working Memory (NWM)
Five random digits from 1-9 were presented sequentially for the participant to hold in
memory. This was followed by a series of 30 probe digits (15 targets and 15
distractors) for each of which the participant indicated whether or not it had been in
the original series by a simple key press. The task consisted of 3 separate trials.
Accuracy and mean reaction time were recorded.
6.2.5.3 3-back Task (WM)
A continuous string of letters (upper and lower case; inter-stimulus interval of 2.5
seconds) was presented; 45 letters in total with 15 target pairs. For each stimulus,
participants were instructed to indicate whether this was the same letter that
appeared three letters before. Accuracy and mean reaction time were recorded.
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6.2.5.4 Simple Reaction Time (SRT – psychomotor speed/attention)
The participant was instructed to press the ‘space bar’ on the laptop keyboard as
quickly as possible every time an upwards pointing arrow appeared on screen.
Sixty-four stimuli were presented with an inter-stimulus duration that varied
randomly between 1 and 3.5 seconds. Mean reaction time was recorded.
6.2.5.5 Choice Reaction Time (CRT – attention/response inhibition)
An arrow appeared on the screen pointing to the left or to the right. Participants
responded with a left or right key press corresponding to the direction of the arrow.
Sixty stimuli were presented with a randomly varying inter-stimulus interval of
between 1 and 3 seconds. Accuracy (% correct) and mean reaction time were
recorded.
6.2.5.6 Four Choice Reaction Time (4CRT - attention)
A visual representation of the four direction arrow keys of a standard keyboard was
presented on screen. The arrows ‘lit up’ at random on screen until the
corresponding key press was made. In all, each arrow was the target stimulus 15
times, forming a total of 48 stimuli for this task in all. Accuracy and mean reaction
time were recorded.
6.2.5.7 Stroop Task (attention/response inhibition)
A computerised version of the Stroop task (Stroop, 1992) was used. Words
describing colours (GREEN, BLUE, RED, YELLOW) were randomly presented in
either congruently or incongruently coloured text (e.g. GREEN was presented in
blue text etc.). For each stimulus presentation during this 2 minute task, participants
were instructed to use the computer mouse and cursor to click the colour box
located on the right side of the screen that matched the colour of the text the word
was presented in. Accuracy and mean reaction time were recorded.
6.2.5.8 Serial 7 subtractions (Serial 7s – WM)
In this two-minute task, participants were instructed to count backwards in 7s as
quickly and as accurately as possible using the computer keyboard’s linear number
keys to enter each response. A random starting number between 800 and 999 was
presented on the computer screen, which was cleared by the entry of the first
response. Each subsequent 3-digit response was represented on screen by an
asterisk. Total number of subtractions and errors were calculated.
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6.2.5.9 Rapid Visual Information Processing task (RVIP – sustained attention)
During this 4 minute task the participants monitored a continuous series of single
digits (1-9) for targets of three consecutive odd or three consecutive even digits.
The digits were presented on the computer screen at the rate of 100 per minute in a
pseudo-random order, with the participant responding to the detection of a target
string with a space bar key press. Eight target strings are presented in each minute.
The task is scored for number of correctly identified target strings, average reaction
time for correct detections and number of false alarms.
6.2.6 Procedure
Each participant was required to attend the laboratory on three occasions. The first
of these was an initial screening visit, in which participants provided written informed
consent and were screened with regards to the study exclusion/inclusion criteria.
Demographic data were recorded, and particpants were randomly allocated to a
treatment group. They were given the two containers of capsules along with written
instructions for taking the study treatment and a diary card, which they were
instructed to complete every day that the capsules were taken. A training session
comprised the participant’s second visit to the laboratory, which took place in the
afternoon approximately 7 days before the final testing session. During this visit
participants completed the battery of cognitive tasks once, without concurrent NIRS
recording, in order to familiarise them with the demands of each task. Participants
were trained simultaneously in groups of no more than 6, but were visually isolated
from each other throughout the session.
The final testing session took place after participants had been taking the study
treatment for 12 weeks (average time on treatment 87.08 days). On this occasion,
participants were tested individually, with concurrent NIRS recording. They attended
the laboratory in the morning in an overnight fasted state, having consumed no food
or drink except water for 12 hours prior to testing. On arrival participants were fitted
with the NIRS headband; as soon as NIRS data capture was initiated participants
were instructed to close their eyes and relax for a duration of 5 minutes, with the last
minute of this period utilised as the NIRS resting baseline measurement. They were
then verbally instructed to start the battery of tasks as described above with NIRS
data collected throughout.
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6.2.6.1 Statistical methods
NIRS data were converted to ‘change from baseline’ (1 minute pre-testing rest
period) and averaged across each task during the cognitive task performance
period. The resultant data therefore represented the change in concentration of
each of the chromophores with respect to the pre-testing measurements.
Task length was fixed for the Stroop (120 s), RVIP (240 s) and Serial 7s (120 s)
tasks, but NIRS data from the remaining six tasks were truncated so that the same
amount of data was analysed from all participants during each task period. For the
Corsi blocks task only data from the first 210 s of testing was used, for NWM the
first 120 s of data were used, for the 3-back task the first 150 s were used and the
first 160 s were used for SRT, CRT and 4 CRT. As the duration of each task of
averaged NIRS data entered into the analysis was substantially longer than the
potential physiological oscillations that can cause drift in shorter periods of NIRS
recording (e.g. heartbeat, respiration - Hoshi, 2007), no adjustment was required for
this phenomenon.
Prior to the primary analysis a mixed Analysis of Variance was carried out with
right/left optode included as a factor [hemisphere x treatment group x task] to
examine any hemispheric differences in response. As there were no treatment
related interactions involving this factor the data from the two channels were
averaged across hemispheres for the analysis and figures reported below.
The primary analysis of the averaged NIRS data was conducted by mixed ANOVA
(treatment group x task) for each chromophore (O2Hb, HHb, THb) with a priori
planned comparisons of data from each task period being made between placebo
and each of the fish oil treatment groups (1 g, 2 g) using t tests calculated with the
mean squares error utilised from the omnibus ANOVA (Keppel, 1991). In order to
reduce the potential for Type I errors only those planned comparisons associated
with a significant main effect of treatment or interaction between treatment and task,
revealed in the ANOVA, are reported.
The performance data were analysed by between-subjects ANOVA for each
individual task outcome with planned comparisons for data as described above.
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6.3 Results
6.3.1 Compliance
Compliance was assessed using participants’ self-report diary cards to determine
on how many days the capsules had been taken along with the number of capsules
returned on the day of the final testing session; 1 participant failed to return their
unused capsules and diary card. For the remaining participants, compliance was
very good in all three treatment groups (96% placebo, 91% 1 g FO, 92% 2 g FO). At
the very end of the final testing session participants were also asked to guess which
treatment they had taken (FO or placebo). Participants who had received the DHA-
rich FO (either 1 g or 2 g) were equally as likely to guess correctly (52%) as those in
the placebo group (50%), at or about chance level [ χ2 (1) = 1.52, p = 0.22 ],
indicating a successful double-blind procedure.
6.3.2 NIRS
6.3.2.1 Oxyhaemoglobin (O2Hb)
The ANOVA showed that there was a significant main effect of treatment [ F(2, 472)
= 3.54, p = 0.035 ]. Planned comparisons of the overall treatment means revealed
significantly increased concentrations of O2Hb in both the 1 g and 2 g FO groups [
t(472) = 3.79, p = 0.0002, r = 0.52; t(472) = 4.71, p < 0.0001, r = 0.60 ]. In addition,
reference to the planned comparisons carried out on data from each task period
showed that both 1 g and 2 g FO were associated with a significantly (all p <
0.0001, see Figure 6.1) increased concentration of O2Hb during the performance of
each task.
6.3.2.2 Deoxyhaemoglobin (HHb)
The ANOVA did not reveal a significant effect of treatment on concentrations of
HHb.
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6.3.2.3 Total haemoglobin (THb)
The ANOVA showed that there was a significant effect of treatment [ F(2, 472) =
3.67, p = 0.032 ]. Planned comparisons of the overall treatment means revealed
significantly increased concentrations of O2Hb in both the 1 g and 2 g FO groups [
t(472) = 3.51, p = 0.0005, r = 0.49; t(472) = 4.64, p < 0.0001, r = 0.60 ]. The planned
comparisons carried out on data from each task period showed that 2 g FO was
associated with a significantly (all p < 0.001) increased concentration of THb during
the performance of each task. The 1 g FO treatment was also associated with
significantly increased concentration of THb during each task period, although these
associations were not as highly significant (all p < 0.05). These data are also
presented in Figure 6.1.
Figure 6.1. Concentration changes of oxygenated and total haemoglobin (Δ[O2Hb] and Δ[THb]) by treatment group 
(Placebo, 1 g fish oil, 2 g fish oil) during the cognitive tasks. Data are averaged across both hemispheres (left/right).
Significance is compared to placebo (planned comparisons). (*, p < 0.05; **, p < 0.01 ***, p < 0.001; , p < 0.0001).
6.3.3 Cognitive Performance
There was a significant main effect of treatment on reaction time for the CRT task [
F(2, 61) = 3.27, p = 0.045 ]. Planned comparisons revealed that reaction time on
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this task was faster in both treatment groups (1 g FO [ t(61) = 2.67, p = 0.027, r =
0.34 ], 2 g FO [ t(61) = 2.20, p = 0.032, r = 0.33 ] ). There was also a significant
main effect of treatment on the RVIP task [ F(2, 61) = 6.75, p = 0.002 ]. Reference
to the planned comparisons revealed that reaction time was significanly faster in the
2 g FO group, compared to placebo [ t(61) = 2.90, p = 0.005, r = 0.42 ].
Performance data for all tasks is displayed in Table 6.3.
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Table 6.2. Cognitive task performance by treatment group. Means and SEM are presented with
F and p values from the primary ANOVA. Significance is indicated in bold typeface.
Mean SEM F p
Corsi blocks
Span
Placebo 5.72 0.06
1 g fish oil 5.61 0.07 2.52 0.089
2 g fish oil 5.45 0.12
NWM
(% accuracy)
Placebo 96.28 0.83
1 g fish oil 96.52 0.89 0.44 0.646
2 g fish oil 95.51 0.68
NWM (RT)
Placebo 498.27 22.03
1 g fish oil 509.86 18.99 0.08 0.927
2 g fish oil 508.12 25.59
3-back
(% accuracy)
Placebo 90.00 2.09
1 g fish oil 91.62 1.29 0.60 0.551
2 g fish oil 89.09 1.62
3-back (RT)
Placebo 1207.44 104.80
1 g fish oil 1315.76 104.39 1.56 0.219
2 g fish oil 1060.13 103.79
SRT
Placebo 316.41 13.74
1 g fish oil 288.80 9.52 1.42 0.249
2 g fish oil 304.77 11.39
CRT
(% accuracy)
Placebo 97.72 0.70
1 g fish oil 95.74 0.80 1.99 0.146
2 g fish oil 96.53 0.57
CRT (RT)
Placebo 423.18 14.96
1 g fish oil 389.02 8.07 3.27 0.045
2 g fish oil 390.02 8.09
4 CRT
(% accuracy)
Placebo 98.74 0.42
1 g fish oil 98.54 0.32 0.11 0.901
2 g fish oil 98.43 0.62
4 CRT (RT)
Placebo 498.46 25.47
1 g fish oil 471.37 12.92 0.64 0.533
2 g fish oil 487.01 10.48
Stroop congruent
(% accuracy)
Placebo 98.34 0.60
1 g fish oil 97.90 0.68 0.17 0.841
2 g fish oil 97.82 0.66
Stroop congruent
(RT)
Placebo 651.10 23.72
1 g fish oil 626.91 22.78 0.56 0.573
2 g fish oil 619.00 19.47
Stroop incongruent
(% accuracy)
Placebo 97.30 0.79
1 g fish oil 96.96 0.65 0.75 0.476
2 g fish oil 98.02 0.44
Stroop incongruent
(RT)
Placebo 706.60 28.82
1 g fish oil 671.73 24.01 0.84 0.436
2 g fish oil 665.55 18.12
Table __. Cognitive task performance treatment group. Means and SEM are presented with
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Mean SEM F p
Stroop overall
(% accuracy)
Placebo 97.64 0.68
1 g fish oil 97.29 0.52 0.36 0.700
2 g fish oil 97.93 0.41
Stroop overall
(RT)
Placebo 687.20 26.11
1 g fish oil 655.73 23.11 0.81 0.450
2 g fish oil 649.14 17.30
RVIP
(% accuracy)
Placebo 59.22 5.03
1 g fish oil 58.38 4.55 1.30 0.281
2 g fish oil 67.14 3.19
RVIP (RT)
Placebo 479.27 19.34
1 g fish oil 487.05 8.20 6.75 0.002
2 g fish oil 422.78 12.23
RVIP
(false alarms)
Placebo 13.05 1.61
1 g fish oil 13.32 1.46 1.31 0.277
2 g fish oil 10.50 1.02
Serial 7s
(no. correct)
Placebo 20.20 2.26
1 g fish oil 24.68 3.22 0.64 0.531
2 g fish oil 23.45 2.89
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6.4 Discussion
The primary aim of the current study was to investigate the effects of 12 weeks
supplementation with 1 g/d or 2 g/d DHA-rich FO on task-related cerebral
hemodynamic response in non-consumers of oily fish. Supplementation with DHA-
rich FO was associated with a pattern of significantly increased regional cerebral
blood flow (rCBF) in the prefrontal cortex, in comparison with placebo, as indexed
by changes in the concentration of total haemoglobin (THb) and oxyhaemoglobin
(O2Hb) during the cognitive tasks. In contrast, there was no evidence of modulation
of deoxyhaemoglobin (HHb) by either dose of DHA-rich FO compared with placebo.
Overall these patterns of task-related hemodynamic response of both active
treatments and placebo are consistent with those observed in the pilot study
described in Chapter 5. In addition, two main effects of treatment were detected as
regards the cognitive tasks; participants in both treatment groups were faster than
placebo on the Choice Reaction Time (CRT) task, and those in the 2 g FO group
were quicker to respond on the RVIP task.
Given the lack of evidence of modulation of cerebral hemodynamics by the EPA-rich
FO treatment (300 mg EPA + 200 mg DHA) in the pilot trial described in Chapter 5,
it is reasonable to attribute the observed modulation of cerebral hemodynamics in
the current study to the DHA contained in the FO formulation and not the relatively
small quantity of EPA (90 mg/g DHA-rich FO). Indeed, the actions of DHA in the
(cerebro)vascular system are numerous and complex, and evidence from in vitro
investigations suggests that DHA could be acting on these parameters in a number
of different ways. DHA may facilitate the cerebrovascular coupling mechanism via
modulation of cholinergic neuronal transmission (Tsukada et al., 2000a, Tsukada et
al., 1997), possibly as a result of increased cerebral acetylcholine levels following
dietary intake of DHA (Minami et al., 1997). Even the incorporation of DHA into
endothelial cell membranes may beneficially impact cerebrovascular response by
promoting endothelial fluidity and improving membrane-bound protein function
(Hashimoto et al., 1999). In addition, DHA has been shown to modulate the
production of nitric oxide (Li et al., 2008), a potent second messenger that regulates
the cerebral blood flow response in the brain (Kitaura et al., 2007). In vivo studies
have also highlighted the effects of DHA on physiological functions in the brain. For
example, a recent study in rats discovered dietary supplementation with DHA-rich
FO (DHA 4:1 EPA) resulted in increased brain nitric oxide synthase activity
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(Engstrom et al., 2009). Interestingly, in the same experiment EPA-rich FO (EPA 3:2
DHA) did not have any effect, reflecting the results reported in Chapter 5 in which
cerebral hemodynamic response to tasks did not differ from placebo in the EPA-rich
FO (EPA 3:2 DHA) treatment group. In addition, the same pattern of observed
differences between placebo and DHA-rich FO treatment groups regarding cerebral
hemodynamics was consistently detected in both the pilot trial described in the
previous chapter (consumers; mean intake 2.05 portions/month) and the current
study (non-consumers); also lending support to the assertion that DHA does indeed
have an effect on cerebral hemodynamic response to tasks.
Turning to the cognitive performance measures that were employed, a significant
difference between treatment groups was revealed on two of the tasks; participants
in both treatment groups (1 g, 2 g) were faster than placebo on the Choice
Reaction Time (CRT) task and those in the 2 g treatment group were faster on the
RVIP task. Success on these two tasks requires response inhibition (CRT) and
sustained attention (RVIP). In light of the results presented in Chapter 4, in which it
was revealed that 12 weeks supplementation with 1 g/d DHA-rich FO (identical
formulation to the DHA-rich FO utilised in the current study) reduced reaction time
on the Stroop task compared with placebo, it is interesting that this effect was not
replicated here. One possibility could be that the difference in response modality—
the current study utilised a four-colour response box whereas the study described in
Chapter 4 utilised the mouse and cursor—could account for the difference in
findings between the two studies. The version chosen for the current study was
selected on the premise that responding to the stimuli requires less movement using
a button box than a mouse therefore reducing the possibility of motion artefacts. Of
course another possibility is that the current study simply lacked sufficient power to
detect an effect on this task; reference to the means presented in Table 6.3 do
reveal a pattern of reduced reaction time on this task in the active treatment groups,
compared to placebo.
In a similar vein, in light of the current study’s results the fact that no effects of DHA-
rich FO were observed on the CRT and RVIP tasks in the study described in
Chapter 4 could be attributed to a number of factors. Firstly, the presentation of the
tasks may be one factor, as this varied between studies. For example, the task
length for the CRT and RVIP tasks utilised in the current study were longer and
shorter respectively than in Chapter 4. The RVIP task in particular was employed in
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Chapter 4 as part of the Cognitive Demand Battery, and due to the taxing nature of
this battery there was evidence to suggest that participants were inclined to
disengage with the task; as evidenced by the reduced number of datasets that were
analysed for these outcomes (Table 4.4). It is also possible that performance on the
tasks described in the current study might have been affected by the concurrent
NIRS recording. Finally, the choice of a sample of non-consumers of oily fish is
another consideration. Healthy non-consumers were selected in an attempt to
control for past intake of DHA (and EPA) and also to control for intake during the
intervention period with the aim of recruiting of a largely homogenous sample, from
which stronger conclusions about the effects of the intervention on cerebral
hemodynamics could be made. One possibility is that consumers and non-
consumers of oily fish may perform differently on cognitive measures, although this
has yet to be directly investigated in humans. In addition, the tenacity with which the
brain retains DHA in particular—the half life of DHA in the brain is estimated at 2.5
years (Umhau et al., 2009)—could potentially explain why behavioural effects are
not consistently observed in healthy individuals who consume even just the
occasional portion of n-3 fatty acid-rich oily fish. Altogether these factors indicate
that direct comparison of participants’ performance on the tasks described in
Chapters 4 and 6 should not be made. However, it is interesting that in both studies
reaction time was reduced on attention tasks, perhaps representing an emerging
pattern of an effect of DHA-rich FO on attention task performance. However, the
results of the present chapter, taken as a study in and of itself, are in keeping with
previous behavioural studies that have failed to show consistent effects of n-3
PUFAs in healthy populations. Even in this sample of adults who do not eat any oily
fish (and presumably have low intake of dietary DHA and EPA), the results from the
cognitive performance outcomes described here provide little evidence of cognitive
enhancement following n-3 PUFA supplementation in healthy, cognitively intact
individuals.
Considering the behavioural data in conjunction with the NIRS data, the findings of
the current study reveal that DHA-rich FO is impacting brain physiological function—
as evidenced by the difference between hemodynamic response to tasks in the
active treatment groups and placebo—but that this is not consistently accompanied
by improved task performance. One possibility is that administration of DHA is
improving the overall function and health of the brain, but that this is not manifested
in observable behavioural measures in a healthy young population. However,
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increased cerebral blood flow might be a potential mechanism by which n-3 PUFAs
derived from fish oils exert a positive effect on cognitive function in later life, as
epidemiological studies have linked reduced cognitive decline and incidence of
Alzheimer’s disease in older adults with increased intake of fish and n-3 PUFAs
(Morris et al., 2003, Dullemeijer et al., 2007, Kalmijn et al., 1997a, Engelhart et al.,
2002). Indeed, reduced cerebral blood flow has been consistently observed in both
normally ageing and demented older adults (Farkas and Luiten, 2001), and in
animal studies reduced cerebral blood flow is associated with both
neurodegeneration in the hippocampus and cerebral cortex as well as spatial
memory deficits (Farkas et al., 2002). One hypothesis is that increased cerebral
blood flow to the brain throughout the entire lifespan may protect against neural
damage that occurs as part of the natural decline in cerebrovascular sufficiency
(Farkas and Luiten, 2001). Research in monkeys demonstrated that age-impaired
cerebral blood flow is indeed modulated by DHA; 4 weeks dietary supplementation
of this fatty acid (150 mg/kg/d) facilitated the cerebral blood flow response to tactile
stimulation (Tsukada et al., 2000a). Based on this group’s previous findings
(Tsukada et al., 1997), the authors suggest that the observed modulation of rCBF is
not due to changes in global CBF, but rather could be attributed to changes in the
coupling mechanism regulated by the cholinergic system. Given the above, an
interesting avenue to pursue would be to investigate the cerebral hemodynamic and
effects of DHA in elderly human participants.
As regards the methodology employed in the current study, a number of issues
should be addressed. The first of these is the absence of pre-treatment baseline
measures of cognitive performance and cerebral hemodynamics. As regards the
cognitive performance measures, although it is assumed that random allocation
would eliminate the possibility of systematic differences between treatment groups,
further reduced by the fact that the participants were drawn from the same
population (healthy university students), it is also widely accepted that adjusting for
pre-treatment performance increases the power of the post-treatment between
group analysis of variance (Van Breukelen, 2006), and would be a feature of future
studies. However, due to the fact that NIRS instruments can only provide data
regarding the relative concentration changes in cerebral hemodynamic parameters
in response to tasks (taken from an arbitrary measure i.e. the point at which the
machine was turned on), and does not provide any data regarding actual quantities
of the chromophores, an ANCOVA of the data collected on the last day of the
132
intervention, using baseline NIRS measures as a covariate would not be possible.
However, what a pre-treatment baseline measure of cerebral hemodynamics could
establish is the absence of between-group differences in hemodynamic response to
the tasks. This improvement to the paradigm could be used in future applications of
NIRS in pharmacological interventions of this kind. In relation to this, a second
improvement would be the addition of a measure of blood flow velocity to the brain.
As previously, mentioned, the data collected by NIRS only reflects relative task-
related concentration changes of the individual chromophores, and does not allow
for predictions to be made about the effects of treatment on overall cerebral blood
flow. Transcranial Doppler ultrasound follows the same principles and assumptions
of other applications of the Doppler effect to measure blood flow velocity in the main
intracranial vessels non-invasively, and with high accuracy. This measurement
reflects CBF in the brain regions supplied by the vessel under investigation (Deppe
et al., 2004, Panerai, 2009). Therefore, the addition of TCD in future investigations
would allow for quantifiable changes in general cerebral blood flow as well as during
the cognitive tasks following dietary intake of DHA to be calculated.
Also of note is the pattern of changes in concentrations of O2Hb and THb in the
placebo treatment group, which fell below the resting baseline measurement during
the tasks. This pattern of task-related concentration changes would not be expected
given previous NIRS investigations (e.g. Fallgatter and Strik, 1998, Richter et al.,
2009), but may simply reflect either the level of task difficulty, or a general pattern of
falling CBF as arousal levels of the participant fall following the start of the seated
experimental period (see Appendix VII for details). It is also possible that the use of
an eyes-closed resting baseline measure may be inappropriate as a resting
baseline measure, and which may have contributed to this observation in both this
study and the pilot trial described in Chapter 5. Changes in activation of several
brain areas including the visual cortex (Uludag et al., 2004) and ocular-motor
system (that includes prefrontal, parietal and occipital cortices - Marx et al., 2004)
varies between eyes-closed and eyes-open resting states. As regards the current
paradigm, this phenomenon requires further investigation. Even so, the data clearly
show that, compared to placebo, concentrations of THb and O2Hb were higher in
the DHA-rich FO treatment groups, suggesting modulation of task-related cerebral
hemodynamic response following DHA supplementation.
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In conclusion, supplementation with DHA-rich FO in non consumers of oily fish
appears to modulate task-related regional cerebral blood flow response, as
evidenced by the observed differences between cerebral hemodynamic parameters
in the active treatment groups compared to placebo. Moreover, the results suggest
that modulation may occur in a dose-response manner. To the author’s knowledge,
this is the first study to examine the parallel effects of fish oil supplementation on
cerebral hemodynamics and behavioural outcomes and as such has highlighted that
DHA may impact cerebral perfusion of activated areas in healthy young adults
without consistent effects on behaviour. Combining imaging techniques in the future
could further elucidate the relationship between brain physiological function and
behaviour and how dietary intake of n-3 PUFAs affects both of these outcomes, with
a view to inform prophylactic treatment of cognitive decline and dementia.
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CHAPTER 7. DISCUSSION
7.1 Summary of the objectives of the thesis
The aim of this thesis was to investigate the relationship between dietary n-3 PUFAs
and behaviour and brain function, and to evaluate their efficacy for cognitive
enhancement in healthy volunteers. Prior to this project’s inception, the majority of
research evaluating the relationship between n-3 PUFAs and behaviour had
focused on mood disorders (e.g. Peet and Horrobin, 2002b, Marangell et al., 2003,
Peet, 2003, Su et al., 2003, Fux et al., 2004, Silvers et al., 2005) and on childhood
developmental disorders (e.g. Richardson and Montgomery, 2005, Richardson and
Puri, 2002, Stevens et al., 2003, Hirayama et al., 2004, Voigt et al., 2001). However,
also at the time a number of widely reported ‘successes’ of fish oil supplements on
healthy schoolchildren’s performance were gaining a great deal of media attention
and the UK government was exploring the possibility of providing n-3 PUFA
supplements to all children (Oakeshott, 2006), though no study that the author is
aware of had empirically addressed the issue of n-3 PUFAs for cognitive
enhancement in normal healthy children. Chapter 2 of this thesis therefore
investigated the effects of two doses of DHA on a range of cognitive tasks and
mood in healthy schoolchildren.
In addition to this, very limited data also existed concerning the relationship between
dietary n-3 PUFAs and cognitive function and mood in healthy adults. Only one
study had investigated the effects of fish oil and behavioural outcomes in healthy
young adults, with the results revealing that fish oil supplementation may improve
performance on tasks requiring attention and some aspects of mood, though the
data were rather inadequately analysed making firm conclusions about the efficacy
of the treatment difficult to draw (Fontani et al., 2005). To this end, Chapter 3
explored the associations between peripheral PUFAs and cognitive performance
and mood in healthy young adults, and Chapter 4 went on to evaluate the effects of
dietary supplementation with DHA-rich and EPA-rich FO in a similar sample.
Examination of the literature also revealed that very little attention had been given to
investigating the effects of n-3 PUFAs on brain function in humans. In order to
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address this gap in the knowledge, Chapter 5 explored the effects of DHA-rich and
EPA-rich FO on cerebral hemodynamics, and Chapter 6 extended these findings by
evaluating dose-response effects of DHA-rich FO on these parameters and
cognitive measures in parallel.
7.2 The relationship between dietary n-3 PUFAs and cognitive function and
mood
7.2.1 Children
The results described in Chapter 2 do not favour the use of either 400 mg or 1000
mg DHA for cognitive or mood enhancement in school-aged children. There was no
evidence of an effect of either treatment following 8 weeks dietary supplementation
on any of the cognitive measures that were employed, and a single treatment effect
on the mood questionnaire item ‘alert’, although further analysis revealed that
neither treatment group differed significantly compared to placebo on this measure
on Day 56. The failure of the intervention to produce any interpretable effects of
DHA supplementation on cognitive and mood outcomes cannot readily be attributed
to the sophisticated cognitive testing employed, given that the measures utilised in
this study have previously been shown to be sensitive to dietary manipulations in
similar samples of healthy children (Haskell et al., 2008, Ingwersen et al., 2007).
Instead, it is possible that a number of methodological factors contributed to the null
findings of this study, including the length of the treatment intervention, the
treatment formulation, being a predominantly DHA supplement, and the nature of
the study sample itself, being drawn from a healthy, cognitively intact population.
Reference to subsequent intervention studies in healthy children allows more light to
be shed on these potential issues. As regards the issue of the length of the
intervention, the results of Ryan and Nelson (2008) suggest that 400 mg DHA, even
when administered for a longer period of 4 months, is not effective in modulating
cognitive function in 4 year old children, suggesting that the nature of the
supplement might be more important than treatment duration. Results from other
studies carried out in children with ADHD (Hamazaki and Hirayama, 2004, Voigt et
al., 2001) that have administered DHA in isolation have also been ineffective at
modulating behavioural outcomes, indicating perhaps that effectual n-3 PUFA
formulations must include both DHA and EPA, reflecting more naturally occurring
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ratios, to produce measurable behavioural effects. On the other hand, the two
studies that have administered both DHA and EPA do not provide sufficient
evidence to conclusively assert that administration of DHA in isolation is the reason
why no effect of treatment was detected in Chapter 2. Osendarp et al. (2007) found
no effect of 12 months n-3 PUFA supplementation (88 mg DHA + 22 mg EPA) on
measures of general intelligence, learning and attention compared to placebo.
Although the quantity of n-3 PUFAs was lowest in this study compared to the others
conducted in the area, compared to placebo the peripheral n-3 PUFA status of
children receiving the active treatment was significantly greater. In contrast, the
study described by Dalton et al. (2009) administered a higher dose of n-3 PUFAs,
though less than the study described in Chapter 2 (192 mg DHA + 82 mg EPA,
equivalent to 2 portions of medium fat fish per week), in the form of a fish flour
spread for 6 months in 7-9 year olds. A beneficial effect of treatment on measures of
learning, memory and spelling was reported. However, considering that this study is
the only one out of the four studies conducted in this particular area (Osendarp et
al., 2007, Ryan and Nelson, 2008, Chapter 2) to show a benefit of n-3 PUFAs over
placebo on cognitive measures does not in itself provide adequate evidence to
support n-3 PUFA supplementation in children for cognitive enhancement. Taking
the results of all the studies together, along with the results reported in Chapter 2,
one interpretation of the available data is that n-3 PUFA supplementation does not
have any measurable effects on behavioural outcomes in healthy, normally
developing children. This conclusion goes against the popularly held, but currently
unsupported notion that n-3 PUFAs and fish oils will enhance children’s
performance. This belief—evidenced by the number of widely publicised ‘band-
wagon’ trials (e.g. “Fish oil study’s GCSE successes” 2006; “Pupils test fish brain
food pills” 2006) that followed the publication of the ‘Oxford-Durham Trial’
(Richardson and Montgomery, 2005)—may in part have been bolstered by over-
interpretation of the results of the study, and the subsequent promotion of n-3
PUFAs by n-3 PUFA manufacturers (e.g. Equazen) and food companies (e.g. St.
Ivel) alike, claiming that their products can enhance children’s learning and
concentration (ASA, 2007, Oatts, 2006), claims which have had to be subsequently
withdrawn following complaints to the Advertising Standards Agency (e.g. ASA,
2006, ASA, 2007). This is not to say that research in this area should not be
pursued further. One interesting aspect of the study published by Dalton et al.
(2009) is that the children in this study were from low socioeconomic backgrounds
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and according to the authors ate virtually no fish, lean or fatty. One possibility could
therefore be that n-3 PUFA supplementation may only enhance performance in
children not following a healthy balanced diet that includes fish meals. The findings
reported by a recent epidemiological study from Sweden would certainly support the
hypothesis that a diet incorporating fish meals on a regular basis is associated with
better cognitive performance, which they found to be the case in adolescents (18
years) regardless of socioeconomic background (Aberg et al., 2009), suggesting a
unique role for dietary fish intake in optimal cognitive function. Overall the results
presented in Chapter 2 do not support short-term use of a DHA supplement in
school-aged children for cognitive or mood enhancement. Longitudinal intervention
trials may be more fruitful in advancing our knowledge regarding the relationship
between dietary n-3 PUFAs and cognitive function in children.
7.2.2 Adults (18-35 years)
7.2.2.1 Cognitive function
Two clear patterns of results emerged from the data presented in Chapter 3, in
which the relationship between peripheral PUFA status and cognitive function and
mood was evaluated. Firstly, the data revealed that serum concentrations of total n-
3 PUFAs and EPA were associated with better performance on a cluster of episodic
memory tasks (see Table 3.2 for details). The second pattern revealed that the ratio
of serum concentrations of AA:EPA was associated with worse performance across
several cognitive domains (see Table 3.2 for details). Both of these findings are
novel. As regards the former, previous studies that have utilised episodic memory
tasks to investigate the relationship between n-3 PUFAs and cognitive function in
elderly adults do not report any associations between concentrations of any n-3
PUFAs and performance on these tasks (Dullemeijer et al., 2007, Beydoun et al.,
2007, Kalmijn et al., 2004a). However, Dalton et al. (2009) do report significant
associations between DHA, total n-3 PUFAs and the ratio of n-6:n-3 PUFAs and
performance on a memory task in 7-9 year-olds following a 6-month dietary
intervention. The finding that serum concentrations of AA:EPA were inversely
associated with performance on a number tasks requiring working memory, episodic
memory and attention is, to the author’s knowledge, the first report of an association
between the ratio of AA:EPA and specific cognitive functions. Previous literature
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implicates the balance of these two fatty acids in a range of health and behaviour
outcomes including, for example, depression (Adams et al., 1996), reading ability in
dyslexics (Cyhlarova et al., 2007) and inflammatory disease (reviewed in Calder,
2006a). This finding suggests that the AA:EPA ratio may potentially be an important
consideration as regards cognitive function, though this would need to be confirmed
in future studies. Overall the results described in Chapter 3 suggest that peripheral
fatty acid status, an index of dietary n-3 PUFA intake, may be linked to specific
cognitive functions in healthy adults. However, the results provided by the study
described in Chapter 4 do not suggest that increasing intake of n-3 PUFAs has any
effect on cognitive function in this population.
The study described in Chapter 4 utilised an identical cognitive task battery as
utilised in Chapter 3 to evaluate the effects of 12 weeks’ dietary supplementation
with either 1 g/d DHA-rich (450 mg DHA + 90 mg EPA) or EPA-rich FO (300 mg
EPA + 200 mg DHA) on cognitive performance, in a similar sample of healthy
adults. Out of the many cognitive performance outcomes that were assessed, only
two main effects of treatment were detected. Participants in the DHA-rich FO
treatment group responded faster to stimuli on the Stroop task, and participants in
both treatment groups correctly matched fewer names to faces on the Names-to-
Faces Recall task (see Section 4.3 for details). From these data it is parsimonious
to conclude that supplementation with 1 g/d DHA-rich or EPA-rich FO does not have
any interpretable effect on cognitive function in healthy adults. Taking the results of
Chapter 3 and 4 together reveals that there is little continuity between the two
studies, reflecting the findings of other studies in the field that have shown
significant associations between dietary n-3 PUFA intake or n-3 status and cognitive
function, yet supplementation studies have failed to produce consistent results. For
example, Aberg et al. (2009) reported a positive association between regular fish
meals and overall cognitive performance in healthy adolescents (18 years), and in
older adults plasma n-3 PUFA concentrations are inversely associated with decline
information processing speed (Dullemeijer et al., 2007, Beydoun et al., 2007) and
verbal fluency (Kalmijn et al., 2004a). However, only one (Fontani et al., 2005) out
of four (Hamazaki et al., 1996, Rogers et al., 2008, Antypa et al., 2009) published
studies in healthy adults has shown a benefit of the intervention upon cognitive
outcomes. It is possible that the dissimilarity between the correlational and causal
evidence provided by the literature in the area may be due to either the
methodological variation between intervention studies which has differed in terms of
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outcome measures, treatment dose and formulation, and duration of the
intervention. On the other hand, it is also possible that the effects of n-3 PUFA
supplements on behaviour, should they exist, are very subtle, and that a longer
period of intervention is required if these effects are to be observed. A number of
longitudinal intervention studies investigating the effects of n-3 PUFAs on cognitive
function are currently being conducted in older adults (Dangour et al., 2006, Gillette,
2009, Martek, 2006), the results of which may be able to further elucidate this issue.
As regards the current thesis, a limitation of the study described in Chapter 4 is that
although there was a significant within group increase in serum concentrations of
EPA at Week 12 compared to Baseline in the EPA-rich FO group, at Week 12 there
was no evidence of a significant difference between serum concentrations of EPA in
this group compared to placebo (see Section 4.3.1), which may be a contributing
factor to the null results that were reported. However, given that the overall results
are in keeping with other studies in the area, it is more likely that short-term (i.e. 12
weeks) dietary supplementation with n-3 PUFAs does not impact upon cognitive
function in healthy adults.
Results from the cognitive performance outcomes assessed in the study described
in Chapter 6 revealed that participants in both treatment groups (1 g and 2 g/d DHA-
rich FO) were faster than placebo on the Choice Reaction Time task and those in
the 2 g group were faster on the RVIP task following 12 weeks daily
supplementation. Taken as a single investigation, these results again do not provide
strong evidence to support the use of n-3 PUFA supplements for cognitive
enhancement in healthy adults. However, taking the results of Chapters 4 and 6
together, a similarity in the results of both studies is that, compared to placebo,
participants administered the DHA-rich FO (the same treatment formulation was
administered in both studies), responded faster to stimuli on attention tasks. What is
more, if these results are considered along with the available data from published
studies that have also assessed the effects of n-3 PUFAs on cognitive outcomes, a
pattern in the results can be identified. To illustrate, data from fish oil
supplementation studies in other adult samples suggests that impulsivity (Rogers et
al., 2008) and tasks requiring response inhibition and sustained attention (Fontani et
al., 2005) may be modulated by n-3 PUFAs. It is also interesting that children
diagnosed with ADHD, a developmental disorder characterised by impulsivity and
inattention (Pary et al., 2002), have lower tissue concentrations of n-3 PUFAs (DHA
and EPA) (Burgess et al., 2000, Stevens et al., 1995), and there is some evidence
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to suggest that symptoms of ADHD are ameliorated following dietary
supplementation with n-3 PUFAs (Stevens et al., 2003, Richardson and
Montgomery, 2005, Belanger et al., 2009, Richardson and Puri, 2002). What all the
available research may collectively be beginning to indicate is that dietary n-3
PUFAs, and from the studies described in this thesis DHA in particular, may
modulate mechanisms that impact upon performance on attention tasks in healthy
adults and break down in the case of neurodevelopmental disorders. This being
said, it is noteworthy that serum concentrations of DHA were not associated with
attention task outcomes in the study described in Chapter 3. Even so, the evidence
provided by Chapters 4 and 6 does merit further investigation. To better understand
the role of n-3 PUFAs in cognitive function, a future study could compare the effects
of DHA-rich FO supplementation on a small number of attention/impulsivity tasks
(e.g. CRT, Stroop, RVIP, digit vigilance, go/no go etc.). In addition, given that animal
evidence indicates the possibility of a ‘threshold’ of intake/tissue incorporation,
below which deficits are observed and can be subsequently modulated via
supplementation (Jensen et al., 1996), an informative, albeit costly feature of such a
study would recruit participants on the basis of low peripheral fatty acid
concentrations.
It is beyond the scope of the evidence provided by this thesis to conclusively assert
specific mechanisms to which these observed effects on behavioural outcomes
could be ascribed, especially given the many known actions of DHA in the brain
(see Chapter 1.4). One plausible candidate may be modulation of
neurotransmission pathways; studies conducted in animals have demonstrated that
alterations in various neurotransmitter pathways including cholinergic, serotonergic
and dopaminergic transmission occurs when n-3 PUFAs are absent from the diet
(Zimmer et al., 2000b, Zimmer et al., 2000a) and subsequently replenished (Chalon
et al., 2001, Delion et al., 1996, Kodas et al., 2004), and is reflected in task
performance. For example, cholinergic transmission is associated with sustained
attention task performance in rats (Himmelheber et al., 2000), which has been
shown to be modulated by dietary n-3 PUFAs (Tsukada et al., 1997). Alterations in
serotonergic transmission could be another candidate given that fish oil
supplementation in n-3 PUFA deficient rats results in increased levels of serotonin
in the frontal cortex (Chalon et al., 1998), and serotonin has been shown to be
directly involved in sustained attention tasks in humans (Wingen et al., 2008).
Further, chronic n-3 PUFA deficiency in rodents has been shown to lead to reduced
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levels of dopamine and binding at D2 receptors in the brain and was accompanied
by attentional dysfunctions in behaviour, not dissimilar to symptoms displayed by
children with ADHD (Zimmer et al., 2002). Of course, only other types of imaging
techniques (e.g. PET, fMRI) would be able to identify modulation of specific
pathways by dietary intake of fish oil, and presents an interesting avenue for future
research in the area.
Overall, the results presented in this thesis suggest that the relationship between
dietary n-3 PUFAs and cognitive function in healthy adults is complex, and has yet
to be fully explored. The results from the intervention studies potentially indicate a
role for DHA in attention task performance, however cautious interpretation of these
sparse cognitive performance results should be exercised considering that both
intervention studies analysed the effects of the interventions on a large number of
performance outcomes.
7.2.2.2 Mood
The results of the intervention study described in Chapter 4 did not reveal a
significant effect of either EPA-rich or DHA-rich FO on any of the assessed mood
outcome measures (Bond-Lader, DASS). Previous intervention studies that have
evaluated the effects of n-3 PUFAs on mood in healthy adults have revealed
inconsistent results. Both Fontani et al. (2005) and Antypa et al. (2009) used the
Profile of Mood States to assess mood. While the former reported within-group
differences regarding increased vigour along with reduced anger, fatigue, confusion,
anxiety and depression, the latter only reported an effect of treatment on subjective
ratings of fatigue, compared to placebo. In addition, Rogers et al. (2008) found no
effect of treatment on any of the subscales of the DASS, and no significant
associations between baseline plasma PUFA concentrations and these outcomes at
baseline. Depression in particular has received a great deal of attention in the
literature, and whilst fish consumption (Hibbeln, 1998, Tanskanen et al., 2001,
Silvers and Scott, 2002) and peripheral n-3 PUFA concentrations (Peet et al.,
1998b, Edwards et al., 1998, Adams et al., 1996) are associated with measures of
depression, the evidence provided by intervention studies is less than conclusive
(reviewed in Appleton et al., 2008, Freeman et al., 2006b). This pattern of findings
echoes the observations presented in the previous section in that
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epidemiological/cross-sectional and intervention study data do not yield consistent
results, and also that there is little consistency within the results provided by
intervention studies. A further example of this theme is provided by the finding that
the ratio of AA:EPA was positively associated with the Anxiety scale of the DASS in
Chapter 3, but this was not modulated by either intervention in Chapter 4, despite
the fact that the serum ratio of AA:EPA was significantly higher in the placebo
treatment group compared to both the active treatment groups (see Table 3.2 and
Section 4.3.1 for details). Again, reasons for this may be down to methodology or
simply that the effects of n-3 PUFAs are not manifested in observable behavioural
changes.
Having said this, an interesting finding across Chapters 3 and 4 is the relationship
with and effect of EPA-rich FO on subjective ratings of during thirty minutes of
cognitively demanding tasks (Cognitive Demand Battery - CDB). Chapter 3
demonstrated that the ratio of serum concentrations of AA:EPA was positively
associated with mental fatigue on the CDB. Similarly, in Chapter 4 participants
assigned to the EPA-rich FO treatment reported less average mental fatigue during
the CDB than placebo following 12 weeks daily supplementation, a finding that was
not observed in the DHA-rich FO group. Analysis of the serum fatty acids levels of
participants in Chapter 4 interestingly revealed that serum levels of EPA at Week 12
did not differ between those taking the EPA-rich FO and placebo. However,
reference to the serum data regarding the AA:EPA ratio however revealed that this
measure was significantly lower in the EPA-rich FO condition, compared to placebo,
although this difference is more likely due to the observed increase in this ratio at
Week 12 compared to Baseline in the placebo group (Table 4.2). Taken together,
the results of these two studies suggest that in healthy young adults, the
endogenous balance of AA and EPA may play an important role in subjective
mental fatigue. In addition, dietary supplementation with 1 g/d EPA-rich FO (EPA
3:2 DHA) may be effective at reducing subjective mental fatigue under cognitively
demanding conditions. Further, this finding is readily translated into dietary advice
and is roughly equivalent to consuming one portion of oily fish per week; herring and
some species of salmon in particular have a similar EPA:DHA ratio to the
experimental treatment. Given that the current UK advisory already recommends
consumption of one portion of oily fish a week (SACN/COT, 2004), it might be
predicted based on the findings presented in Chapter 4 that individuals following
these guidelines would suffer from less subjective mental fatigue, particularly when
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cognitive resources are in high demand. In light of the findings presented by Fontani
et al. (2005) and Antypa et al. (2009) who also reported reduced mental fatigue on
the POMS following fish oil supplementation, it might also be predicted that regular
intake of oily fish may reduce mental fatigue as a general mood state, though this
would need to be empirically confirmed.
Although these studies do not provide adequate evidence to irrefutably identify an
underlying mechanism, given the serum fatty acid data presented in Chapters 3 and
4, one hypothesis is that the reduced subjective mental fatigue reported by the
participants administered the EPA-rich FO could be attributed to modulation of
inflammatory lipid mediators by this intervention. There is evidence to suggest an
association between fatigue and elevated cytokines, such as in the case of chronic
fatigue syndrome (reviewed in Patarca, 2001), as well as evidence demonstrating
that plasma n-3 PUFAs are associated with lower levels of pro-inflammatory
cytokines, in part due to the inhibitory effect EPA-derived prostaglandins have on
the production of certain cytokines (Bagga et al., 2003, Miles et al., 2002). It is also
known that increased intake of dietary EPA leads to increased incorporation of
these molecules into membrane phospholipids, in a dose response manner and at
the expense of membrane incorporation of AA, resulting in a shift away from a pro-
inflammatory phenotype to an anti-inflammatory one (Calder, 2007). Based on this
evidence, one possibility is that administration of EPA-rich FO attenuated a further
elevation in the ratio of AA:EPA (given the serum fatty acid data), which in turn may
have modulated participant’s immunological response to laboratory-induced mental
fatigue, resulting in the significant effect of the EPA-rich FO on the subjective visual
analogues scale. Considering the ratio of AA:EPA was also lower than placebo in
participants administered the DHA-rich FO, it is also possible that the administration
of a higher amount of EPA (300 mg as opposed to 200 mg) in the EPA-rich FO
treatment group may be the basis for this effect. Naturally these hypotheses would
have to be verified in future investigations, and could be achieved by including a
variety of immunoassays.
In summary, the evidence from this thesis does not suggest that dietary
supplementation with n-3 PUFAs modulates subjective ratings of alertness,
calmness, contentedness or depression, stress and anxiety in healthy young adults.
On the other hand, the data provided by Chapters 3 and 4 suggest that subjective
ratings of mental fatigue during cognitively demanding tasks may be sensitive to
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dietary n-3 PUFAs; supplementation with EPA-rich FO appears to reduce subjective
mental fatigue, and may be linked to an endogenous balance of AA and EPA,
though this requires further investigation.
7.3 Cerebral hemodynamics
The studies presented in Chapters 5 and 6 of this thesis used Near Infrared
Spectroscopy (NIRS) to assess the effects of n-3 PUFAs on cerebral
hemodynamics during cognitive task performance following 12 weeks dietary
supplementation in healthy young adults. Overall the results revealed that cerebral
blood flow (CBF) is increased in the prefrontal cortex during tasks that activate this
brain region in participants administered DHA-rich FO compared to placebo, as
evidenced by the increased task-related concentration changes in oxygenated
haemoglobin (O2Hb) and total haemoglobin (THb). These findings provide the first
evidence of modulation of cerebral hemodynamics by n-3 PUFAs in human
participants.
The results of the pilot study described in Chapter 5 revealed that cerebral
hemodynamic response to tasks was different from placebo only in the DHA-rich FO
treatment group, and not in the EPA-rich FO treatment group. More specifically,
concentration changes in O2Hb and THb were higher in the DHA-rich FO group
compared to placebo. Given these findings were not also observed in the EPA-rich
FO treatment group, suggests that cerebral hemodynamic response to tasks is
modulated by DHA and not EPA. This may be due to the minimal amount of EPA
contained in the brain (McNamara and Carlson, 2006), despite the fact that EPA is
known to have beneficial effects elsewhere in the cardiovascular system (e.g.
endothelial cell function - Hashimoto et al., 1999, Matsumoto et al., 2009). Of course
it is possible that at very high doses of EPA, retro-conversion to DHA could occur
and in this way indirectly beneficially impact upon these parameters, although this
would need to be investigated further. Overall this small pilot trial established the
possibility of a link between n-3 PUFAs and physiological brain function in humans,
which has, to date, received little attention.
The findings revealed in Chapter 6 confirmed the results of the pilot study in that
compared to placebo, participants’ cerebral hemodynamic response to tasks was
modulated following dietary supplementation with DHA-rich FO with an increase in
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rCBF being observed. In addition, this study identified that the task-related
concentration changes in O2HB and THb occurred in a dose-response pattern.
Taking the results from both studies together, the evidence suggests that in both
consumers (Chapter 5) and non consumers (Chapter 6) of oily fish, administration of
DHA-rich FO is associated with increases in concentrations of both THb and O2Hb
in response to cognitive tasks, compared to placebo. Both O2Hb and THb (the sum
of O2Hb and HHb) have been proposed as indices for rCBF; Hoshi et al. (2001)
revealed that in rat brain perfusion models O2Hb was the most sensitive indicator of
rCBF however Steinbrink et al. (2005) demonstrated that concentrations of THb
always correspond to cerebral blood volume, which closely follows the same pattern
as CBF. Given that DHA-rich FO modulated both these parameters in the same
direction it could be concluded from these data that DHA-rich FO modulates the
rCBF response to local brain activity.
In humans, the relationship between n-3 PUFAs and physiological brain function
has only been addressed, to the author’s knowledge, by two studies, the results of
which also support a link between n-3 PUFAs and brain function. For example,
Hirashima et al. (2004) reported evidence of a dose-response effect of n-3 PUFA
supplementation on whole-brain T2 relaxation times (indicative of increased
activation following treatment) in patients with bipolar disorder, although any effects
of the treatment on this measure in normal control subjects were not assessed. In
addition, in an attempt to identify which areas of the brain might be more susceptible
to n-3 PUFA deficiency, Sublette et al. (2009) established that peripheral
concentrations of DHA (and AA) but not EPA were associated with regional glucose
metabolism (as measured by PET) in depressed patients. Both of these studies
suggest that dietary n-3 PUFAs may be associated with aspects of brain function,
though the nature of this relationship has yet to be fully explored. In relation to the
studies described in Chapters 5 and 6, it is a study conducted in rhesus monkeys
that is the most relevant. In this study, aged monkeys (mean age 18 years) were
administered either 150 mg/kg/d DHA for 4 weeks or a soybean milk placebo
(Tsukada et al., 2000a). Following the intervention it was discovered that animals
administered the active treatment had an increased rCBF response to tactile
stimulation (as measured by PET), compared to placebo. The magnitude of this
response was 133% of the rest condition, compared to 116% in the placebo group.
What is more, a previous study by the same group established that this rCBF
response was reduced in aged animals compared to young ones (116% of rest
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condition compared to 144%, respectively), suggesting that the DHA
supplementation was able to restore age-related decreases in rCBF response
(Tsukada et al., 2000b). Given these findings in aged monkeys, along with the
results presented in Chapters 5 and 6, an exciting avenue of research to pursue
could evaluate the effects of DHA-rich FO on cerebral hemodynamics in elderly
human participants. Cerebrovascular insufficiency is associated with a number of
neurodegenerative conditions including vascular dementia and Alzheimer’s disease,
but is also a feature of normal ageing (Farkas and Luiten, 2001). At the
epidemiological level, increased consumption of fish and/or higher plasma levels of
n-3 PUFAs is associated with reduced risk for cognitive decline (Kalmijn et al.,
1997a, Kalmijn et al., 2004b, Dullemeijer et al., 2007, Heude et al., 2003), dementia
(Kalmijn et al., 1997b, Cherubini et al., 2007) and Alzheimer’s disease (Conquer et
al., 2000, Morris et al., 2003), and dietary supplements containing n-3 PUFAs are
currently being trialled in several longitudinal studies as a treatment for preventing
cognitive decline and dementia in the elderly (Dangour et al., 2006, Gillette, 2009,
Martek, 2006, Quinn, 2007). To date, results from previous intervention studies
have not been successful (Terano et al., 1998, van de Rest et al., 2008, Freund-
Levi et al., 2008), but it is hoped that data from the these on-going large-scale
longitudinal trials may reveal more promising results, given the methodological
variation between the previous studies that has rendered interpretation of findings in
the field as a whole somewhat challenging (Fotuhi et al., 2009). It is interesting that
research conducted in 2VO (a model of cerebral hypoperfusion, de Wilde et al.,
2002) and hypertensive rats (de Wilde et al., 2003) has demonstrated that while n-3
PUFA administration is effective at improving vascular parameters, these
physiological benefits are not reflected in behavioural outcomes, where task
performance is similar between intervention and control animals. A similar finding
was observed in Chapter 6, where there is evidence of an effect of DHA-rich FO on
brain function (rCBF response to tasks), without consistent effects on behaviour. It
appears that the observed effects of n-3 PUFA supplementation on cerebral
hemodynamics are too subtle to affect behaviour in healthy young adults. However,
given the evidence from epidemiological studies linking fish consumption/n-3 PUFA
status with reduced cognitive decline and incidence of dementia in the elderly
suggests perhaps that the cerebral hemodynamic effects of n-3 PUFAs reported in
this thesis, if present over the course of a lifetime, may indeed impact behavioural
outcomes, and that long-term intake of n-3 PUFAs are required for these effects to
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be observed. Of course, this suggestion would require further exploration, and the
investigation of the cerebral hemodynamic effects of n-3 PUFAs in an elderly adult
sample could comprise a valuable avenue of future research.
7.4 Dietary advice on n-3 PUFA intake
At present, a dietary reference value (DRV) for DHA and EPA has not been
established. Efforts to do so have been faced with a number of challenges
concerning the nature of n-3 PUFAs themselves, along with the type and quality of
research that has been conducted to inform such decisions (Harris et al., 2009). The
focus of the advice given by all international recommendations concerns the
prevention of cardiovascular disease, with no mention of required intake in relation
to cognitive function past infancy (Harris, 2007). The current advisory in the UK is
that children and adults should aim to eat 2 portions of fish a week, one of which
should be oily, to meet a minimum intake of 450 mg/d (SACN/COT, 2004). Based
on this, the intervention studies described in Chapters 4, 5 and 6 administered
doses of fish oil which are roughly equivalent to this dietary recommendation so that
any results could be translated into meaningful dietary advice. The results
presented in Chapter 4 suggest that, in low consumers of oily fish (mean intake 1.46
portions/month), the addition of another portion of oily fish per week, or 1 g/d fish oil
supplement, is not likely to confer an appreciable benefit on cognitive performance
or mood, although the results presented in Chapters 5 and 6 suggest that this dose
may have an effect on physiological brain function (cerebral hemodynamic response
to tasks). This latter finding particularly suggests that even in the absence of any
observed behavioural effects, increased intake of dietary n-3 PUFAs does appear to
impact brain function. Given that epidemiological studies indicate that long-term
consumption of fish (and presumably n-3 PUFAs), is associated with reduced risk
for cerebral insufficiency-related conditions including cognitive decline and dementia
(e.g. Morris et al., 2005, Dullemeijer et al., 2007, Barberger-Gateau et al., 2007), it
is possible that the increased rCBF response to tasks observed in the current thesis
may be a beneficial effect of n-3 PUFAs. If so, the dose-response pattern observed
in Chapter 6 regarding the cerebral hemodynamic effects of DHA-rich FO suggests
that whilst current recommendations are likely to meet requirements for optimal
cognitive function in healthy individuals, dietary intake of n-3 PUFAs for optimal
cerebrovascular function has yet to be established.
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On a related note, the wider issue regarding the sustainability of the increased fish
intake promoted by dietary guidelines needs to be addressed. The marine
environment is already under immense pressure, and health policies that
recommend that we eat more fish directly collide with the environmental issue of
depleted fish stocks due to overfishing the world over (Brunner et al., 2009). It is
hoped that advances in plant biotechnology will be able to offer a solution to these
issues. Production of DHA from various algal species including Schizochytrium sp
has proved to be very successful and DHA produced in this way is used in
numerous supplements and infant formulas (Ward and Singh, 2005). Production of
EPA from algae is presently less fruitful, and consequently vegetarian sources of
EPA contain limited amounts of this n-3 PUFA, however research is still on-going to
increase algal production of EPA (reviewed in Ward and Singh, 2005). These forms
of algal DHA and EPA are safe and well-tolerated (Innis and Hansen, 1996,
Arterburn et al., 2000), and in the future could potentially be used to help meet
human dietary requirements for long-chain n-3 PUFAs.
In relation to this, a number of ‘smart’ or ‘functional’ foods containing added omega-
3 are currently being sold in the UK. Products include milk (e.g. St Ivel Fresh Milk
with Omega-3), yogurt (e.g. Muller Vitality Pro-biotic drinks), bread (e.g. Kingsmill
50/50 with Omega-3) and spreads (e.g. Flora Omega-3 Plus). UK consumer group
Which? warns consumers to be wary when purchasing such projects, as the
quantity of n-3 PUFAs contained within is often minimal, and large quantities of
these foods would need to be consumed on a daily basis to meet the current
guidelines (Which, 2007). Dietary decisions made by consumers to increase their
intake of n-3 PUFAs via these novel sources are unfortunately not being facilitated
by European Commission legislation. Recent laws regarding food and beverage
label claims could be potentially misleading given that a product can now state that
it is a ‘source of’ or ‘high in’ n-3 PUFAs regardless of whether the n-3 PUFAs are
derived from plant (ALA) or marine (DHA or EPA) sources, although this distinction
would have to be made elsewhere on the label [Commission Regulation (EU) No
116/2010]. Given that the conversion rate of ALA to DHA and EPA is low (Burdge et
al., 2003), and that DHA and EPA are more biologically relevant to fundamental
cellular processes, disease prevention and overall health (see Sections 1.4 and
1.5.2), it would seem that product label claims require further qualification. Further
to this, the European Food Safety Authority recently published a Scientific Opinion
document proposing a labelling reference intake value of 250 mg/d for DHA+EPA
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(ESFA, 2009), that directly conflicts with the advice of the UK government’s
(SACN/COT, 2004) and other international scientific committee guidelines (e.g.
ISSFAL, 2004). A public consultation on this document is currently on-going, and it
is hoped that these issues will be adequately addressed. Overall, it is evident that
more work is required in order to produce more detailed, accurate and helpful
advice on recommended dietary intake of n-3 PUFAs.
7.5 Limitations
Although the studies that make up this thesis present novel data regarding the
relationship between dietary n-3 PUFAs and behaviour in healthy individuals, it is
also essential to consider some potential methodological limitations, some of which
have only been briefly mentioned in previous chapters.
One potential issue arises from the large number of outcome measures that were
employed in Chapters 2, 3 and 4, and the inevitable increased risk of detecting
significant effects by chance. For the study described in Chapter 2, a
comprehensive battery of cognitive tasks was employed on the premise that no
research had previously been conducted investigating the effects of n-3 PUFAs on
cognitive function and mood in healthy children, from which educated decisions
about particular tasks to utilise could be made. Both the CDR and Internet batteries
have been shown to be sensitive to dietary manipulations in children (Haskell et al.,
2008, Ingwersen et al., 2007), so these were employed on their strength of being
able to assess performance easily and effectively across multiple cognitive
domains. This same approach was adopted in Chapters 3 and 4 in the exploration
of the relationship between n-3 PUFAs and cognitive function and mood in healthy
adults. In recognition of this potential limitation, interpretation and discussion of the
results throughout this thesis has focused on those results that fall into patterns,
rather than discussing every result at length. In relation to this, the choice of
planned comparisons for the analysis of the effects of the treatment interventions on
cognitive function in Chapters 2, 4, and 6 should also be discussed. The strictly
planned comparisons assessed a limited number of questions of true relevance i.e.
the effect of the active treatments on cognitive function/mood i.e. the effect of each
treatment versus placebo at the post-dose assessment, and is an approach that is
advocated by Keppel (1991). However, the fact that the combination of numerous
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outcome measures analysed using a powerful (i.e. least conservative) statistical
approach resulted in the detection of only a limited number of significant results
suggests that a Type II error has not been committed. Taken from this point of view,
the use of multiple outcome measures can instead be seen as a strength of the
studies described in this thesis, from which it could be concluded that the
behavioural effects of n-3 PUFA supplements on healthy, cognitively intact children
and adults, are minimal.
On a related note, the issue of correcting for multiple outcome measures should
also be addressed. For example, in Chapter 4, 30 separate dependent variables
were analysed. One approach to handling the potential increased chance of a Type
I error could be to adjust the required alpha level i.e. 0.05/30 = 0.0017. If this
method had been adopted throughout this thesis, the only significant main effect of
treatment that would have been detected is for reaction time on the RVIP task
utilised in Chapter 6. Although the findings that were significant at the 0.05 alpha
level have been discussed in context of the extant literature throughout this thesis,
the overall conclusions that have been drawn are the same as those that would be
concluded using a more conservative alpha level i.e. that fish oil supplementation in
healthy individuals has no observable effect on cognitive performance.
As mentioned above, the discussion of the significant behavioural findings has
focused on describing patterns in the data presented in this thesis, and on drawing
parallels between these patterns and the extant literature. A discussion of the
potential mechanisms has accompanied these sections. However, it must be openly
noted that it is beyond the scope of this thesis to conclusively assert that the
suggested modes of action do indeed underpin the significant results that have
been described, and have been made with reference to the extant literature. One
mechanism that was revealed in the studies described in Chapters 5 and 6 is
modulation of cerebral hemodynamic response to tasks by DHA-rich FO. However,
this effect was not consistently accompanied by behavioural modification in Chapter
6, highlighting the fact that although DHA may be impacting brain function, this
effect is not manifested in behavioural outcomes in this population. Overall, more
research into the physiological effects of dietary n-3 PUFAs, and how these are
linked to behaviour is required. It is hoped that future research will combine
techniques (e.g. imaging and behavioural measures) to further elucidate this issue.
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Another methodological consideration concerns the formulation of the fish oil
supplements administered in Chapter 4. The aim of this study was to evaluate the
effects of DHA-rich and EPA-rich fish oil on cognitive function and mood in parallel,
under the same conditions, which has previously never been carried out. It could be
argued that a more appropriate comparison would be between formulations with
opposite ratios i.e. 5:1 DHA:EPA and 1:5 DHA:EPA, given that the 3:2 EPA:DHA
ratio is closer to 1 than the DHA-rich FO. However, the ratios of 5:1 (DHA:EPA,
DHA-rich FO) and 3:2 (EPA:DHA, EPA-rich FO) were selected on the basis that
they reflect ratios that occur naturally in various oily fish, from which the findings of
the study could be readily translated into meaningful dietary advice. The results of
Chapter 4 do not favour the use of either formulation for cognitive and mood
enhancement. However, the results presented in Chapters 5 and 6 suggest that the
DHA-rich FO formulation may be impact brain function as regards cerebral
hemodynamic response to tasks.
In relation to this, another limitation of this research concerns the effectiveness of
the EPA-rich FO in increasing mean serum levels of EPA in this treatment group
significantly above that of the placebo group, although there was evidence of a
trend in this direction (see Section 4.3.1). The 1 g/d dose administered to
participants in the intervention study described in Chapter 4 was chosen on the
basis that the results could be translated into meaningful dietary advice. Therefore,
in this sample, 300 mg/d EPA was not a sufficient dose to significantly increase
peripheral concentrations. From these results it can be concluded that that the
addition of an EPA-rich FO supplement (roughly equivalent to 1 portion of oily
fish/week) to individuals consuming some oily fish meals in a month does not confer
any benefit on cognitive function. Given the serum fatty acid data, it could also be
argued that the effects of EPA supplementation on cognitive function and mood in
healthy adults have not been adequately addressed, and requires further
investigation. However, given the inconsistent behavioural results reported in
studies that have administered EPA to healthy adults at higher doses than in the
present thesis (e.g. Antypa et al., 2009, Fontani et al., 2005, Rogers et al., 2008),
does not suggest that this avenue of research will be met with more informative
findings.
Another limitation relates to the limitations of the NIRS imaging technology itself that
was utilised in Chapters 5 and 6. The results presented in these chapters suggest a
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consistent effect of DHA-rich FO on cerebral hemodynamic response to tasks, and
are among the first studies to utilise NIRS in nutritional intervention studies.
However, NIRS only provides data on the relative concentration changes in each of
the separate chromophores (O2Hb, HHb, THb) in response to tasks in the region of
interest (the prefrontal cortex in the present thesis), and does not provide any
information regarding the effects of the treatment on general cerebral blood flow. So
although the results presented in Chapters 5 and 6 are promising, the paradigm
could be improved in future interventions. Incorporating measures such as Trans-
cranial Doppler, for example, that would allow the cerebral blood flow effects of the
treatment to be quantified.
A final potential limitation concerns the cognitive tasks that were employed. One
possibility is that the tasks were not specific enough to detect any effects of
treatment. For example, a significant association between the serum AA:EPA ratio
and subjective mental fatigue during cognitively demanding tasks was detected in
Chapter 3, and in Chapter 4, ratings of metal fatigue were significantly lower in
participants following supplementation with EPA-rich FO. Given these findings, it
may be that the effects of n-3 PUFAs on cognitive performance in healthy children
and adults, if they indeed exist, may be better observed using much more difficult
tasks (e.g. increasing cognitive load using duel task paradigms etc.), than were
employed in the current thesis. Inducing mental fatigue at the start of the
assessment could comprise a second approach to this issue.
7.6 Future research
As well as addressing some of the limitations of this thesis presented above, there
are a number of novel avenues that could be pursued based on the findings
revealed by the studies described in this thesis. The first of these considerations
concerns the issue of dietary n-3 PUFAs and cognitive function in vegetarians and
vegans. Intake of total n-3 PUFAs in vegetarians is approximately 30% lower than in
fish-eaters (Welch et al., 2008) and peripheral levels of n-3 PUFAs have been
consistently found to be lower in vegetarians and vegans than in omnivores
(reviewed in Sanders, 2009). However, children raised on a vegetarian diet are
known to develop normally (Sanders and Reddy, 1994), and there is no evidence to
suggest that vegetarians are more likely to develop dementia later in life (Giem et
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al., 1993). This may be in part due to an adaptive mechanism in which conversion
from ALA to DHA is increased (Welch et al., 2008). However, the findings presented
in Chapter 6 suggest that vegetarians or indeed non-fish meat eaters comprise a
particular population which may benefit from added n-3 PUFAs. Vegetarian
supplements containing appreciable amounts of EPA are not currently available, so
this would present an issue for future supplementation studies.
The results presented in Chapters 3 and 4 reveal interesting and novel data
regarding the relationship between n-3 PUFAs and subjective mental fatigue during
cognitively demanding tasks. Although these findings require further exploration, the
results suggest that subjective mental fatigue may be associated with the balance of
endogenous AA and EPA. This balance can be manipulated via supplementation
with n-3 PUFAs, though only supplementation with EPA-rich FO had an effect on
mental fatigue, compared to placebo. Regulation of the immune response via
dietary PUFAs has been studied and reviewed in detail (e.g. De Caterina and Basta,
2001, Calder, 2006a), as has the relationship between psychological stress and the
immune response (e.g. Segerstrom and Miller, 2004), but very little attention has
been given to exploring the association between simultaneous modulation of
inflammatory parameters and behavioural outcomes. Assessing the effects of
dietary fatty acids on psychological stress would be one such opportunity for further
research. Administration of the parent fatty acids ALA and LA in a ratio of 4:1 to rats
prior to exposure to an acute stressor prevented against elevated cortisol and
cholesterol levels (Yehuda et al., 2000). Although the results presented in Chapter 4
did not reveal any evidence of modulation of subjective stress by either DHA-rich or
EPA-rich FO, whether supplementation with n-3 PUFAs attenuates physiological
and psychological stress reactivity in humans would be worthy of investigation.
Laboratory-induced stress and the inclusion of various immunoassays (e.g.
cytokines, cortisol etc.) would be key features of this work.
In addition, future research is also required to further develop the preliminary
findings presented in this thesis regarding the modulation of cerebral hemodynamic
response to tasks by the DHA-rich FO. The question of whether administration of
DHA-rich FO could similarly modulate task-related rCBF in elderly volunteers, and
possible associations with cognitive performance, remains to be demonstrated. This
research would be particularly pertinent given that a number of on-going longitudinal
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prospective intervention trials are currently evaluating the efficacy of n-3 PUFAs on
cognitive decline and dementia.
Finally, the emerging area of nutritional genomics, or nutrigenomics, may be
particularly relevant to future investigations of the effects of dietary n-3 PUFAs.
Nutrigenomics is concerned with understanding the influences of dietary factors on
the genome (the sum total of all the genetic information in an organism), and
exploiting the knowledge of these interactions to improve strategies in the
prevention and treatment of chronic disease, or indeed to maximise one’s genetic
potential (Debusk et al., 2005). Dietary PUFAs are known to influence gene
expression (see Section 1.4.3), the impact of which on health and behavioural
outcomes in humans has yet to be fully understood. For example, there are a
number of known genetic variations of the Interleukin-1 (IL-1, a cytokine) gene
cluster, some of which are associated with increased severity of inflammatory
diseases including Alzheimer’s disease (Mrak and Griffin, 2001) and rheumatoid
arthritis (Lee et al., 2004). Levels of IL-1 are suppressed following fish oil
supplementation (Endres et al., 1989), and so a greater understanding of the effects
of these particular dietary compounds in individuals with a pro-inflammatory genetic
predisposition could greatly aid the development of effective intervention strategies.
In a similar vein, the possibility that dietary interventions do not have the same
effects on all individuals must also be considered. For instance, female carriers of
the G/A allele on the APOE1 gene respond differently in terms of HDL cholesterol
levels following n-3 PUFA supplementation (Ordovas et al., 2002). Overall it seems
plausible that other, currently unknown, genetic polymorphisms or genotypes could
interact with dietary intake of n-3 PUFAs, with varied effects on behavioural
outcomes. It is hoped that the potential for future enquiry in this area to improve
quality of life at both an individual and epidemiological level is realised.
7.7 General conclusions
The commercial market for n-3 PUFA supplements includes products such as ‘Eye
q mind’ and ‘Brain Boosters’. The claims that these product labels can contain is
governed by legislation (see Section 7.4), but the names in themselves are
unambiguous. The primary aim of this thesis was therefore to empirically investigate
the relationship between dietary n-3 PUFAs and cognitive function and mood in
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healthy individuals, and specifically to evaluate their efficacy as a cognitive
enhancer. The results from the intervention study described in Chapter 2 do not
suggest a beneficial effect of either 400 mg or 1000 mg DHA on cognitive
performance or mood in healthy children. This finding is important as it goes against
the unfounded, but commonly held belief regarding the cognitive enhancing
properties of n-3 PUFAs in children. Limitations of this study include the nature of
the formulation and the duration of the intervention, however given that only one
study (Dalton et al., 2009) has reported a benefit of n-3 PUFAs on cognitive function
in children, the available evidence does not support the use of n-3 PUFA
supplements for cognitive or mood enhancement in healthy, normally developing
schoolchildren.
As regards the relationship between n-3 PUFAs and cognitive function in healthy
adults, the findings presented in Chapter 3 indicating a positive association between
serum concentrations of total n-3 PUFAs and EPA and performance on a cluster of
episodic memory tasks. However, EPA-rich FO does not appear to have any
cognitive enhancing properties. A limitation of the study described in Chapter 4, in
this respect however, is that the dose of EPA administered was not effective at
raising serum EPA levels above that of those administered the placebo treatment;
consequently the issue of EPA supplementation and cognitive function may require
further attention. Overall, the findings of the studies presented in this thesis suggest
that the cognitive enhancing effects of n-3 PUFAs in healthy adults are also
minimal. The pattern of modulation of attentional task performance following
supplementation with DHA-rich FO reported in Chapters 4 and 6 should not be
ignored, however further investigation this finding is recommended.
In both healthy children and adults, supplementation with n-3 PUFAs does not have
any measurable effect on subjective mood, however dietary n-3 PUFAs may be
associated with subjective mental fatigue under cognitively demanding conditions.
Although n-3 PUFAs have previously been shown to improve mental fatigue as a
general mood state (Antypa et al., 2009, Fontani et al., 2005), this is the first
demonstration of reduced mental fatigue induced under laboratory conditions. One
possibility is that, given the current evidence regarding the beneficial modulation of
various immune responses via increased intake of n-3 PUFAs (Calder, 2006b), an
evaluation of the parallel behavioural and immunological effects of n-3 PUFAs could
comprise an exciting avenue for future research.
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A second aim of this thesis was to assess the effects of n-3 PUFAs on cerebral
hemodynamics, given the lack of data describing the effects of n-3 PUFAs on brain
function in humans. The results presented in Chapters 5 and 6 revealed that DHA-
rich FO modulates cerebral hemodynamic response to tasks in both consumers and
non consumers of oily fish. In addition, this pattern of modulation occurs in a dose
response manner. Also, it appears that whilst DHA-rich FO has an impact on
cerebral hemodynamics, this is not manifested in behaviour modification. These
findings are the first demonstration of modulation of cerebral hemodynamics by n-3
PUFAs, and future research in this area could further elucidate the nature of the
inverse relationship between intake of n-3 PUFAs and incidence of cerebrovascular
disease and cognitive decline (e.g. Farkas and Luiten, 2001, Kalmijn, 2000).
The relationship between dietary n-3 PUFAs and behaviour is complex. Animal and
epidemiological and cross-sectional studies in humans suggest that there are
behavioural consequences of low intake of n-3 PUFAs. It has been argued that a
typical Western diet does not incorporate adequate amounts of n-3 PUFAs
(Simopoulos, 2002); this is certainly true of the UK, where the last National Diet and
Nutrition Survey revealed that 74% of the population does not eat any oily fish, a
principal source of DHA and EPA (Henderson et al., 2002). In healthy children and
adults not consuming appreciable amounts of oily fish, short-term supplementation
(8-12 weeks) with n-3 PUFAs has limited effects on behaviour. However, in the
absence of concurrent effects on behavioural measures, the findings presented in
this thesis suggest that supplementation with dietary n-3 PUFAs can influence
physiological fatty acid status and cerebral hemodynamics in healthy adults, the full
impact of which on other health and behavioural parameters has yet to be fully
addressed, and comprises several exciting possibilities for future research.
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APPENDIX I: Depression, Anxiety and Stress Scales
DASS-42
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the
statement applied to you over the past week. There are no right or wrong answers. Do
not spend too much time on any statement.
The rating scale is as follows:
0 Did not apply to me at all
1 Applied to me to some degree, or some of the time
2 Applied to me to a considerable degree, or a good part of time
3 Applied to me very much, or most of the time
1 I found myself getting upset by quite trivial things 0 1 2 3
2 I was aware of dryness of my mouth 0 1 2 3
3 I couldn't seem to experience any positive feeling at all 0 1 2 3
4 I experienced breathing difficulty (e.g., excessively
rapid breathing,
0 1 2 3
breathlessness in the absence of physical exertion)
5 I just couldn't seem to get going 0 1 2 3
6 I tended to over-react to situations 0 1 2 3
7 I had a feeling of shakiness (e.g., legs going to give
way)
0 1 2 3
8 I found it difficult to relax 0 1 2 3
9 I found myself in situations that made me so anxious I
was most
0 1 2 3
relieved when they ended
10 I felt that I had nothing to look forward to 0 1 2 3
11 I found myself getting upset rather easily 0 1 2 3
12 I felt that I was using a lot of nervous energy 0 1 2 3
13 I felt sad and depressed 0 1 2 3
14 I found myself getting impatient when I was delayed in
any way
0 1 2 3
(egg, lifts, traffic lights, being kept waiting)
15 I had a feeling of faintness 0 1 2 3
16 I felt that I had lost interest in just about everything 0 1 2 3
17 I felt I wasn't worth much as a person 0 1 2 3
18 I felt that I was rather touchy 0 1 2 3
19 I perspired noticeably (e.g., hands sweaty) in the
absence of high
0 1 2 3
temperatures or physical exertion
20 I felt scared without any good reason 0 1 2 3
21 I felt that life wasn't worthwhile 0 1 2 3
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Reminder of rating scale:
0 Did not apply to me at all
1 Applied to me to some degree, or some of the time
2 Applied to me to a considerable degree, or a good part of time
3 Applied to me very much, or most of the time
22 I found it hard to wind down 0 1 2 3
23 I had difficulty in swallowing 0 1 2 3
24 I couldn't seem to get any enjoyment out of the things I
did
0 1 2 3
25 I was aware of the action of my heart in the absence of
physical
0 1 2 3
exertion (egg, sense of heart rate increase, heart missing
a beat)
26 I felt down-hearted and blue 0 1 2 3
27 I found that I was very irritable 0 1 2 3
28 I felt I was close to panic 0 1 2 3
29 I found it hard to calm down after something upset me 0 1 2 3
30 I feared that I would be "thrown" by some trivial but 0 1 2 3
unfamiliar task
31 I was unable to become enthusiastic about anything 0 1 2 3
32 I found it difficult to tolerate interruptions to what I was
doing
0 1 2 3
33 I was in a state of nervous tension 0 1 2 3
34 I felt I was pretty worthless 0 1 2 3
35 I was intolerant of anything that kept me from getting on
with
0 1 2 3
what I was doing
36 I felt terrified 0 1 2 3
37 I could see nothing in the future to be hopeful about 0 1 2 3
38 I felt that life was meaningless 0 1 2 3
39 I found myself getting agitated 0 1 2 3
40 I was worried about situations in which I might panic and
make
0 1 2 3
a fool of myself
41 I experienced trembling (e.g., in the hands) 0 1 2 3
42 I found it difficult to work up the initiative to do things 0 1 2 3
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APPENDIX II: Health and diet questionnaire utilised in Chapter 3
Age _______ Glasses/Contacts Y/N ______
Sex _______ Handedness L/R _______
Weight _______ lbs
Height _______ ft _______ ins
1) Are you a vegetarian or vegan? No • Vegetarian • Vegan •
2) How many portions of fruit and vegetables do you eat on a typical day?
_______
(Juice only counts as 1 portion regardless is you drink multiple glasses)
3) How many portions of oily fish do you eat in a typical month? _______
(Oily fish=salmon, mackerel, sardines, trout, kippers)
4) How many portions of other (white) fish do you eat in a typical month?
_______
5) Have you purposefully changed your eating habits and diet in the past
couple of years to include more oily fish? Yes • No •
6) If yes how long ago did you start eating more oily fish? _______
7) Do you take an omega-3 supplement? Yes • No •
If yes, how often (days per week)? ______________
If yes, for how long (months, years)? ______________
If yes, which type of supplement is it?
Cod liver oil •
Fish oil •
High EPA (EPA enriched) •
High DHA (DHA enriched) •
Vegetarian (Alpha-linoleic acid) •
Not sure •
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8) Do you regularly take a vitamin supplement(s)? Yes • No •
If yes, how often (days per week)? ______________
If yes, for how long (months, years)? ______________
If yes which type of supplement(s) is it?
___________________________________________________________________
9) How many times a week do you exercise? ______________
10) Were you breastfed? Yes • No • Don’t know •
11) The next few questions are about what you eat on a typical day. Please
think about your eating habits carefully as we want to get as accurate picture
as we can of your dietary habits. Please respond honestly as the information
you provide will add to the quality of this research. Please also be as specific
as you can e.g. ‘cornflakes with semi-skimmed milk and 2 slices white toast
with jam and butter’ instead of just ‘cereal and toast’ and ‘chicken salad
sandwich on brown bread’ instead of just ‘sandwich’. If you do not usually eat
that meal, please say so.
What do you normally eat for breakfast?
___________________________________________________________________
___________________________________________________________________
What do you normally eat for lunch?
___________________________________________________________________
___________________________________________________________________
What do you normally eat for dinner?
___________________________________________________________________
___________________________________________________________________
What snacks do you have on a typical day (including through the day and
after dinner)?
___________________________________________________________________
___________________________________________________________________
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APPENDIX III: All analysed associations between serum n-3 PUFAs and
behavioural outcomes
Table III.1. Associations between serum DHA and COMPASS, mood and CDB outcome measures.
n β p 95% C.I.
Immediate Word Recall (no. correct) 217 0.12 0.892 -.087, 1.14
Delayed Word Recall (no. correct) 0.06 0.401 -0.35, 0.87
Simple RT 0.02 0.454 -9.09, 11.40
Choice RT 0.12 0.420 -12.74, 15.93
Choice RT (% accuracy) 0.07 0.344 -0.41, 1.15
4 Choice RT 0.04 0.268 -16.52, 28.20
4 Choice RT (% accuracy) -0.03 0.663 -0.45, 0.29
Stroop (RT) 212 0.06 0.370 -24.31, 65.01
Stroop (% accuracy) 0.07 0.303 -0.16, 0.50
Verbal Fluency 217 -0.06 0.367 -3.15, 1.17
Numeric Working Memory (RT) 216 0.10 0.157 -16.70, 102.83
Numeric Working Memory (% accuracy) -0.18* 0.010 -2.42, -0.34
Alphabetic Working Memory (RT) 214 -0.09 0.173 -277.99, 50.39
Alphabetic Working Memory (% accuracy) 0.03 0.646 -0.83, 1.33
Corsi Blocks Span 217 -0.09 0.185 -0.53, 0.10
3-back task (RT) 0.03 0.675 -148.09, 228.07
3-back task (% accuracy) -0.03 0.625 -4.84, 2.91
Telephone Number task (RT) 0.15* 0.030 80.61, 1588.82
Telephone Number task (% accuracy) -0.11 0.109 -11.91, 1.21
Word Recognition (RT) 0.02 0.762 -43.67, 59.57
Word Recognition (% accuracy) 0.05 0.510 -1.71, 3.43
Picture Recognition (RT) -0.01 0.923 -64.91, 58.81
Picture Recognition (% accuracy) 0.09 0.214 -1.08, 4.80
Names-to-Faces Recall (no. correct) 0.11 0.099 -0.24, 2.80
Bond-Lader alert 0.00 0.993 -3.39, 3.42
Bond-Lader calm -0.03 0.709 -3.95, 2.69
Bond-Lader content -0.06 0.377 -5.04, 1.91
DASS stress 0.08 0.244 -0.79, 3.10
DASS anxiety 0.04 0.575 -0.91, 1.63
DASS depression 0.04 0.528 -1.24, 2.41
Serial 3 Subtractions (no. correct) 213 -0.07 0.338 -5.15, 1.62
Serial 7 Subtractions (no. correct) -0.08 0.305 -3.88, 0.98
RVIP (RT) 202 -0.09 0.996 -8.76, 1.84
RVIP (% accuracy) 0.11 0.166 -22.18, 26.03
RVIP (false alarms) 0.05 0.474 -1.67, 3.27
Mental fatigue (/100) 213 -0.03 0.670 -4.53, 3.11
162
Table III.2. Associations between serum EPA and COMPASS, mood and CDB outcome measures.
n β p 95% C.I.
Immediate Word Recall (no. correct) 216 0.23** 0.001 0.49, 1.79
Delayed Word Recall (no. correct) 0.04 0.512 -0.44, 0.88
Simple RT 0.03 0.307 -9.10, 13.18
Choice RT -0.05 0.927 -20.69, 10.26
Choice RT (% accuracy) 0.06 0.372 -0.46, 1.21
4 Choice RT -0.02 0.694 -27.08, 21.51
4 Choice RT (% accuracy) 0.09 0.205 -0.14, 0.66
Stroop (RT) 211 0.00 0.962 -47.03, 49.37
Stroop (% accuracy) 0.10 0.141 -0.08, 0.58
Verbal Fluency 216 0.04 0.527 -1.61, 3.15
Numeric Working Memory (RT) 215 0.02 0.780 -54.63, 72.64
Numeric Working Memory (% accuracy) 0.03* 0.632 -0.85, 1.40
Alphabetic Working Memory (RT) 213 -0.06 0.376 -259.91, 98.68
Alphabetic Working Memory (% accuracy) 0.16 0.018 0.25, 2.57
Corsi Blocks Span 216 0.04 0.601 -0.25, 0.44
3-back task (RT) 0.11 0.110 -37.94, 369.60
3-back task (% accuracy) 0.08 0.249 -1.78, 6.84
Telephone Number task (RT) 0.05 0.425 -491.71, ,1163.36
Telephone Number task (% accuracy) 0.04 0.605 -5.25, 8.99
Word Recognition (RT) -0.11 0.122 -99.56, 11.81
Word Recognition (% accuracy) 0.03 0.646 -2.16, 3.47
Picture Recognition (RT) -0.06 0.369 -98.17, 36.59
Picture Recognition (% accuracy) 0.15* 0.027 0.41, 6.71
Names-to-Faces Recall (no. correct) 0.20** 0.003 0.83, 4.10
Bond-Lader alert 0.10 0.142 -0.93, 6.44
Bond-Lader calm 0.06 0.378 -1.99, 5.21
Bond-Lader content 0.00 0.967 -3.85, 3.70
DASS stress -0.04 0.584 -2.70, 1.52
DASS anxiety -0.13 0.062 -2.66, 0.07
DASS depression 0.00 0.970 -1.94, 2.02
Serial 3 Subtractions (no. correct) 212 0.08 0.432 -1.57, 5.83
Serial 7 Subtractions (no. correct) 0.05 0.542 -1.66, 3.66
RVIP (RT) 201 -0.04 0.109 -7.39, 4.43
RVIP (% accuracy) 0.14 0.531 -0.22, 52.85
RVIP (false alarms) -0.09 0.306 -4.40, 1.06
Mental fatigue (/100) 212 -0.06 0.332 -6.07, 2.40
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Table III.3. Associations between serum Total n-3 PUFAs (ALA+DHA+EPA) and COMPASS mood
and CDB outcome measures.
n β p 95% C.I.
Immediate Word Recall (no. correct) 218 0.17* 0.014 0.09, 0.77
Delayed Word Recall (no. correct) 0.04 0.518 -0.23, 0.45
Simple RT 0.002 0.452 -5.64, 5.83
Choice RT -0.20 0.599 -9.15, 6.89
Choice RT (% accuracy) 0.11 0.119 -0.09, 0.78
4 Choice RT 0.01 0.341 -11.39, 13.63
4 Choice RT (% accuracy) 0.06 0.377 -0.11, 0.30
Stroop (RT) 213 0.05 0.503 -16.39, 33.30
Stroop (% accuracy) 0.11 0.106 -0.03, 0.33
Verbal Fluency 218 -0.02 0.762 -1.42, 1.04
Numeric Working Memory (RT) 217 0.08 0.262 -14.17, 51.75
Numeric Working Memory (% accuracy) -0.07 0.306 -0.89, 0.28
Alphabetic Working Memory (RT) 215 -0.10 0.159 -157.95, 25.96
Alphabetic Working Memory (% accuracy) 0.10 0.143 -0.15, 1.05
Corsi Blocks Span 218 -0.04 0.585 -0.23, 0.13
3-back task (RT) 0.07 0.278 -47.25, 163.40
3-back task (% accuracy) 0.08 0.224 -0.85, 3.61
Telephone Number task (RT) 0.14* 0.043 14.82, 860.51
Telephone Number task (% accuracy) -0.07 0.304 -5.62, 1.76
Word Recognition (RT) -0.05 0.452 -39.87, 17.83
Word Recognition (% accuracy) 0.05 0.472 -0.92, 1.97
Picture Recognition (RT) -0.03 0.615 -43.63, 25.87
Picture Recognition (% accuracy) 0.16* 0.020 0.30, 3.58
Names-to-Faces Recall (no. correct) 0.14* 0.035 0.06, 1.76
Bond-Lader alert 0.07 0.322 -0.94, 2.86
Bond-Lader calm 0.03 0.639 -1.42, 2.30
Bond-Lader content -0.05 0.435 -2.72, 1.17
DASS stress 0.03 0.680 -0.86, 1.32
DASS anxiety -0.04 0.526 -0.94, 0.48
DASS depression 0.03 0.712 -0.83, 1.22
Serial 3 Subtractions (no. correct) 214 -0.01 0.908 -2.05, 1.78
Serial 7 Subtractions (no. correct) -0.03 0.799 -1.65, 1.09
RVIP (RT) -0.05 0.361 -4.05, 1.91
RVIP (% accuracy) 203 0.08 0.366 -5.81, 21.10
RVIP (false alarms) -0.04 0.727 -1.74, 1.03
Mental fatigue (/100) 214 -0.06 0.343 -3.06, 1.23
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Table III.4. Associations between serum AA and COMPASS, mood and CDB outcome measures.
n β p 95% C.I.
Immediate Word Recall (no. correct) 214 -0.24**** <0.001 -0.18, -0.05
Delayed Word Recall (no. correct) -0.10 0.148 -0.11, 0.02
Simple RT -0.09 0.187 -1.73, 0.34
Choice RT 0.01 0.869 -1.33, 1.57
Choice RT (% accuracy) -0.09 0.202 -0.13, 0.03
4 Choice RT -0.04 0.597 -2.87, 1.66
4 Choice RT (% accuracy) -0.08 0.233 -0.06, 0.02
Stroop (RT) 209 -0.03 0.641 -4.42, 2.72
Stroop (% accuracy) -0.19** 0.007 -0.08, -0.01
Verbal Fluency 215 -0.06 0.406 -0.19, 0.08
Numeric Working Memory (RT) 213 -0.08 0.241 -8.87, 2.24
Numeric Working Memory (% accuracy) -0.03 0.625 -0.14, 0.08
Alphabetic Working Memory (RT) 211 -0.05 0.455 -33.56, 15.08
Alphabetic Working Memory (% accuracy) -0.15* 0.029 -0.33, -0.02
Corsi Blocks Span 215 -0.04 0.520 -0.03, 0.01
3-back task (RT) 214 -0.09 0.196 -32.99, 6.81
3-back task (% accuracy) -0.05 0.506 -0.32, 0.16
Telephone Number task (RT) -0.07 0.315 -122.66, 39.71
Telephone Number task (% accuracy) 0.04 0.555 -0.49, 0.91
Word Recognition (RT) 0.00 0.997 -5.48, 5.46
Word Recognition (% accuracy) -0.09 0.210 -0.25, 0.06
Picture Recognition (RT) 215 0.05 0.487 -2.39, 5.00
Picture Recognition (% accuracy) 214 -0.11 0.114 -0.56, 0.06
Names-to-Faces Recall (no. correct) -0.18** 0.008 -0.38, -0.06
Bond-Lader alert -0.13 0.059 -0.71, 0.01
Bond-Lader calm 215 0.03 0.640 -0.15, 0.25
Bond-Lader content 0.12 0.087 -0.03, 0.39
DASS stress 0.04 0.561 -0.08, 0.15
DASS anxiety 0.19** 0.005 0.03, 0.18
DASS depression 0.02 0.782 -0.09, 0.12
Serial 3 Subtractions (no. correct) 210 -0.08 0.253 -0.56, 0.15
Serial 7 Subtractions (no. correct) -0.04 0.591 -0.32, 0.19
RVIP (RT) 199 0.00 0.995 -0.58, 0.58
RVIP (% accuracy) -0.31 0.659 -3.08, 1.95
RVIP (false alarms) 0.12 0.086 -0.03, 0.50
Mental fatigue (/100) 210 0.17 0.013 0.102, 0.91
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Table III.5. Associations between serum AA:EPA and COMPASS, mood and CDB outcome measures.
n β p 95% C.I.
Immediate Word Recall (no. correct) 214 -0.24**** <0.001 -0.18, -0.05
Delayed Word Recall (no. correct) -0.10 0.148 -0.11, 0.02
Simple RT -0.09 0.187 -1.73, 0.34
Choice RT 0.01 0.869 -1.33, 1.57
Choice RT (% accuracy) -0.09 0.202 -0.13, 0.03
4 Choice RT -0.04 0.597 -2.87, 1.66
4 Choice RT (% accuracy) -0.08 0.233 -0.06, 0.02
Stroop (RT) 209 -0.03 0.641 -4.42, 2.72
Stroop (% accuracy) -0.19** 0.007 -0.08, -0.01
Verbal Fluency 215 -0.06 0.406 -0.19, 0.08
Numeric Working Memory (RT) 213 -0.08 0.241 -8.87, 2.24
Numeric Working Memory (% accuracy) -0.03 0.625 -0.14, 0.08
Alphabetic Working Memory (RT) 211 -0.05 0.455 -33.56, 15.08
Alphabetic Working Memory (% accuracy) -0.15* 0.029 -0.33, -0.02
Corsi Blocks Span 215 -0.04 0.520 -0.03, 0.01
3-back task (RT) 214 -0.09 0.196 -32.99, 6.81
3-back task (% accuracy) -0.05 0.506 -0.32, 0.16
Telephone Number task (RT) -0.07 0.315 -122.66, 39.71
Telephone Number task (% accuracy) 0.04 0.555 -0.49, 0.91
Word Recognition (RT) 0.00 0.997 -5.48, 5.46
Word Recognition (% accuracy) -0.09 0.210 -0.25, 0.06
Picture Recognition (RT) 215 0.05 0.487 -2.39, 5.00
Picture Recognition (% accuracy) 214 -0.11 0.114 -0.56, 0.06
Names-to-Faces Recall (no. correct) -0.18** 0.008 -0.38, -0.06
Bond-Lader alert -0.13 0.059 -0.71, 0.01
Bond-Lader calm 215 0.03 0.640 -0.15, 0.25
Bond-Lader content 0.12 0.087 -0.03, 0.39
DASS stress 0.04 0.561 -0.08, 0.15
DASS anxiety 0.19** 0.005 0.03, 0.18
DASS depression 0.02 0.782 -0.09, 0.12
Serial 3 Subtractions (no. correct) 210 -0.08 0.253 -0.56, 0.15
Serial 7 Subtractions (no. correct) -0.04 0.591 -0.32, 0.19
RVIP (RT) 199 0.00 0.995 -0.58, 0.58
RVIP (% accuracy) -0.31 0.659 -3.08, 1.95
RVIP (false alarms) 0.12 0.086 -0.03, 0.50
Mental fatigue (/100) 210 0.17 0.013 0.102, 0.91
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APPENDIX IV: Health and diet questionnaire utilised in Chapter 4
Age _______ Glasses/Contacts Y/N ______
Sex _______ Handedness L/R _______
Height _______ cm (to be completed by researcher)
Weight _______ kgs (to be completed by researcher)
1) How many portions of fruit and vegetables do you eat on a typical day?
_______
(Juice only counts as 1 portion regardless is you drink multiple glasses)
2) How many portions of oily fish do you eat in a typical month? _______
(Oily fish=salmon, mackerel, sardines, trout, kippers)
3) How many portions of other (white) fish do you eat in a typical month?
_______
4) Do you regularly take a vitamin supplement(s)? Yes • No •
If yes, how often (days per week)? ______________
If yes, for how long (months, years)? ______________
If yes which type of supplement(s) is it?
___________________________________________________________________
___________________________________________________________________
5) How many times a week do you exercise? ______________
6) Were you breastfed? Yes • No • Don’t know •
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7) The next few questions are about what you eat on a typical day. Please
think about your eating habits carefully as we want to get as accurate picture
as we can of your dietary habits. Please respond honestly as the information
you provide will add to the quality of this research. Please also be as specific
as you can e.g. ‘cornflakes with semi-skimmed milk and 2 slices white toast
with jam and butter’ instead of just ‘cereal and toast’ and ‘chicken salad
sandwich on brown bread’ instead of just ‘sandwich’. If you do not usually eat
that meal, please say so.
What do you normally eat for breakfast?
___________________________________________________________________
___________________________________________________________________
What do you normally eat for lunch?
________________________________________________________________
What do you normally eat for dinner?
___________________________________________________________________
___________________________________________________________________
What snacks do you have on a typical day (including through the day and
after dinner)?
___________________________________________________________________
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APPENDIX V: Family background questionnaire
Please answer the following questions about your family’s socio-economic status
(SES) as accurately as you can. If your household has only one parent/guardian,
please only check the relevant box and leave the other blank. Household refers to
the home you grew up in.
1) Which of these the highest level of education your parents/guardians have
achieved?
Father Mother
16 Years  
18 Years  
Diploma level  
Degree level  
Postgraduate qualification  
2) Which of these best describes your parent’s/guardian’s occupation?
Father Mother
Professional  
Managerial/technical  
Non-manual skilled  
Partly skilled  
Unskilled  
Unemployed/unable to work  
In full-time education  
Retired  
3) What is the approximate annual income of your household?
Under £10000 
£10000-£20000 
£20000-£30000 
£30000-£40000 
£40000-£50000 
£50000-£60000 
£60000-£70000 
£70000-£80000 
£80000-£90000 
£90000-£100000 
£100000+ 
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1) Which treatment do you think you received?
Fish oil
Placebo
2) Why?
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APPENDIX VI: Average scores by group on the cognitive tasks employed in
Chapter 5
Cognitive task performance by treatment group. Means and SEM are presented.
Mean SEM
Stroop
(% accuracy)
Placebo 98.81 0.42
DHA-rich FO 98.25 0.55
EPA-rich FO 98.79 0.46
Stroop (RT)
Placebo 666.43 29.35
DHA-rich FO 674.33 36.26
EPA-rich FO 721.88 39.94
TOL
(planning time)
Placebo 2398.14 312.64
DHA-rich FO 3024.29 198.53
EPA-rich FO 3172.00 269.12
TOL
(time to complete)
Placebo 7343.29 656.66
DHA-rich FO 9046.57 763.81
EPA-rich FO 8659.88 390.49
3-back
(% accuracy)
Placebo 91.21 2.16
DHA-rich FO 89.01 5.14
EPA-rich FO 81.57 3.54
3-back (RT)
Placebo 1280.27 194.78
DHA-rich FO 1305.92 162.48
EPA-rich FO 1299.33 333.86
WCST
(% accuracy)
Placebo 80.29 3.29
DHA-rich FO 89.71 2.49
EPA-rich FO 82.87 2.02
WCST
(no. errors)
Placebo 19.71 4.65
DHA-rich FO 10.33 1.98
EPA-rich FO 15.88 3.07
WCST
(time to complete)
Placebo 1451.43 250.62
DHA-rich FO 1252.67 104.86
EPA-rich FO 1404.75 77.93
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APPENDIX VII: Resting baseline NIRS data collected in Chapter 6
Figure VII.1. Resting baseline data for O2Hb and THb, by treatment group.
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